<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/263974-novel-vanilloid-receptor-ligands-and-the-use-thereof-for-the-production-of-pharmaceuticals by HTTrack Website Copier/3.x [XR&CO'2014], Thu, 04 Apr 2024 23:02:13 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 263974:NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention relates to novel vanilloid receptor ligands, to processes for the production thereof, to pharmaceuticals containing said compounds and to the use of said compounds for the production of pharmaceuticals.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> <br><br>
Novel vanilloid receptor ligands and the use thereof for the production of<br>
pharmaceuticals<br>
The present invention relates to novel vanilloid receptor ligands, to processes for the<br>
production thereof, to pharmaceuticals containing said compounds and to the use of<br>
said compounds for the production of pharmaceuticals.<br>
The treatment of pain, particularly neuropathic pain, is of great significance in the<br>
medical field. There is a global need for effective pain therapies. The urgent need for<br>
action to provide a patient-friendly und targeted treatment of chronic and non-chronic<br>
states of pain, this being taken to mean the successful und satisfactory treatment of<br>
pain for patients, is documented by the large number of scientific papers which have<br>
recently appeared in the field of applied analgesics or in basic research concerning<br>
nociception.<br>
A suitable starting point for the treatment of pain; particularly of pain selected from<br>
the group consisting of acute pain, chronic pain, neuropathic pain, and visceral pain,<br>
particularly preferably neuropathic pain; is the vanilloid receptor of subtype 1<br>
(VR1/TRPV1), frequently also designated as the capsaicin receptor. This receptor is<br>
stimulated, inter alia, by vanilloids such as capsaicin, heat, and protons and plays a<br>
central part in the generation of pain. Furthermore, it is significant for a large number<br>
of other physiological and pathophysiological processes such as migraine; states of<br>
depression; neurodegenerative disorders; cognitive disorders; anxiety; epilepsy;<br>
coughing; diarrhea; pruritus; inflammations; disorders of the cardiovascular system;<br><br>
food intake disorders; medicine addiction; medicine abuse and, in particular, urinary<br>
incontinence.<br>
It is thus an object of the invention to provide novel compounds which are particularly<br>
suitable for use as pharmacologically active substances in pharmaceuticals,<br>
preferably in pharmaceuticals for treatment of disorders or diseases that are at least<br>
partially mediated by vanilloid receptors 1 (VR1/TRPV1 receptors).<br>
It has now been found, surprisingly, that the substituted compounds of the general<br>
formula I stated below show excellent affinity to the vanilloid receptor of subtype 1<br>
(VR1/TRPV1 receptor) and are therefore particularly suitable for the prophylaxis<br>
and/or treatment of disorders or diseases which are at least partially mediated by<br>
vanilloid receptors 1 (VR1/TRPV1). The substituted compounds of the general<br>
formula I given below also show anti-inflammatory activity.<br>
It is thus an object of the present invention to provide substituted compounds of the<br>
general formula I,<br><br>
in which<br><br>
0 stands for 0, 1,2, 3, or 4;<br>
R1 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(= O)-NH2; -S(=<br>
O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= O)-H; -S(= O)2-OH; -C(= NH)-<br>
NH2; -C(= NH)-NH-R9; -N= C(NH2)2; -N= C(NHR10)-(NHR11); -O-P(= 0)2-O-<br>
R12; -NHR13; -NR14R15; -NH-C(=O)-R13; -OR16; -SR17; -C(= O)-NHR18; -C(=<br>
O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-NR22R23; -C(= O)-OR24; -C(= O)-R25; -<br>
S(= O)-R26; or -S(= O)2-R27 or for a linear or branched, saturated or<br>
unsaturated, unsubstituted or at least monosubstituted aliphatic C1-10 radical;<br>
R2 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(= O)-NH2; -S(=<br>
O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= O)-H; -S(= O)2-OH; -C(= NH)-<br>
NH2; -C(= NH)-NH-R9; -N= C(NH2)2; -N= C(NHR10)-(NHR11); -O-P(= 0)2-O-<br>
R12; -NHR13; -NR14R15; -NH-C(= O)-R13; -OR16; -SR17; -C(= O)-NHR18; -C(=<br>
O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-NR22R23; -C(= O)-OR24; -C(= O)-R25; -<br>
S(= O)-R26; or -S(= O)2-R27 or for a linear or branched, saturated or<br>
unsaturated, unsubstituted or at least monosubstituted aliphatic C1-10 radical;<br>
R3 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(= O)-NH2; -S(=<br>
O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= 0)-H; -S(= O)2-OH; -C(= NH)-<br>
NH2; -C(= NH)-NH-R9; -N= C(NH2)2; -N= C(NHR10)-(NHR11); -O-P(= O)2-O-<br>
R12; -NHR13; -NR14R15; -NH-C(= O)-R13; -OR16; -SR17; -C(= O)-NHR18; -C(=<br>
O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-NR22R23; -C(= O)-OR24; -C(= O)-R25; -<br>
S(= O)-R26; or -S(= O)2-R27 or for a linear or branched, saturated or<br>
unsaturated, unsubstituted or at least monosubstituted aliphatic C1-10 radical;<br><br>
R4 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(= O)-NH2; -S(=<br>
O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= O)-H; -S(= O)2-OH; -C(= NH)-<br>
NH2; -C(= NH)-NH-R9; -N= C(NH2)2; -N= C(NHR10)-(NHR11); -O-P(= O)2-O-<br>
R12; -NHR13; -NR14R15; -NH-C(= 0)-R13; -OR16; -SR17; -C(= O)-NHR18; -C(=<br>
O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-NR22R23; -C(= O)-OR24; -C(= O)-R25; -<br>
S(= O)-R26; or -S(= O)2-R27 or for a linear or branched, saturated or<br>
unsaturated, unsubstituted or at least monosubstituted aliphatic C1-10 radical;<br>
R5 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(= O)-NH2; -S(=<br>
O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= O)-H; -S(= O)2-OH; -C(= NH)-<br>
NH2; -C(= NH)-NH-R9; -N= C(NH2)2; -N= C(NHR10)-(NHR11); -O-P(= O)2-O-<br>
R12; -NHR13; -NR14R15; -NH-C(= O)-R13; -OR16; -SR17; -C(= O)-NHR18; -C(=<br>
O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-NR22R23; -C(= O)-OR24; -C(= O)-R25; -<br>
S(= O)-R26; or -S(= O)2-R27 or for a linear or branched, saturated or<br>
unsaturated, unsubstituted or at least monosubstituted aliphatic C1-10 radical;<br>
R6 stands in each case for hydrogen or for a linear or branched, saturated or<br>
unsaturated, unsubstituted or at least monosubstituted aliphatic C1-10 radical;<br>
R7 stands for hydrogen or -OH;<br>
or R6 and R7 form, together with the interconnecting carbon atom as ring member,<br>
a saturated or unsaturated, unsubstituted or at least monosubstituted three-<br>
membered, four-membered, five-membered, or six-membered cycloaliphatic<br>
radical;<br><br>
R8 stands for -SF5; -O-CF3; -CF3; -O-CFH2; -O-CF2 H; -CFH2; -CF2 H; or for an<br>
unsubstituted or at least monosubstituted tert-butyl radical;<br>
T stands for C-R35 and U stands for C-R36 and V stands for N and W stands for C-R38<br>
Or<br>
T stands for C-R35 and U stands for N and V stands for C-R37 and W stands for C-R38<br>
Or<br>
T stands for N and U stands for C-R36 and V stands for C-R37 and W stands for C-R38<br>
Or<br>
T stands for N and U stands for N and V stands for C-R37 and W stands for C-R38<br>
Or<br>
T stands for N and U stands for C-R36 and V stands for N and W stands for C-R38<br>
Or<br>
T stands for C-R35 and U stands for N and V stands for N and W stands for C-R38<br>
Or<br>
T stands for C-R35 and U stands for C-R36 and V stands for C-R37 and W stands for<br>
C-R38;<br>
R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26 and<br>
R27 each independently<br>
stand for a linear or branched, saturated or unsaturated, unsubstituted or at<br>
least monosubstituted aliphatic C1-10 radical;<br><br>
for an unsaturated or saturated, unsubstituted or at least monosubstituted,<br>
three-membered, four-membered, five-membered, six-membered, seven-<br>
membered, eight-membered, or nine-membered cycloaliphatic radical<br>
optionally containing at least one heteroatom as ring member, which can be<br>
condensed with a saturated or unsaturated, unsubstituted or at least<br>
monosubstituted monocyclic or polycyclic ring system and/or can be bonded<br>
via a linear or branched, unsubstituted or at least monosubstituted C1-6<br>
alkylene group or two to six-membered heteroalkylene group;<br>
or for an unsubstituted or at least monosubstituted five-membered to fourteen-<br>
membered aryl radical or heteroaryl radical, which can be condensed with a<br>
saturated or unsaturated, unsubstituted or at least monosubstituted<br>
monocyclic or polycyclic ring system and/or can be bonded via a linear or<br>
branched, unsubstituted or at least monosubstituted C1-6 alkylene group or two<br>
to six-membered heteroalkylene group;<br>
R35, R36, and R37 each independently stand for H; F; CI; Br; I; -SF5; -NO2; -CF3; -CN; -<br>
NH2; -OH; -SH; -C(= O)-NH2; -S(= O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= <br>
O)-H; -S(= O)2-OH; -NHR13; -NR14R15; -NH-C(= O)-R13; -OR16; -SR17; -C(= O)-<br>
NHR18; -C(= O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-NR22R23; -C(= O)-OR24; -<br>
C(= O)-R25; -S(= O)-R26; -S(= O)2R27<br>
for a linear or branched, saturated or unsaturated, unsubstituted or at least<br>
monosubstituted aliphatic C1-10 radical;<br><br>
or for an unsubstituted or at least monosubstituted five-membered to fourteen-<br>
membered aryl radical or heteroaryl radical, which can be condensed with a<br>
saturated or unsaturated, unsubstituted or at least monosubstituted<br>
monocyclic or polycyclic ring system and/or can be bonded via a linear or<br>
branched, unsubstituted or at least monosubstituted C1-6 alkylene group or C2-6<br>
alkenylene group or C2-6-alkynylene group;<br>
R38 stands for F; CI; Br; I; -SF5; -NO2; -CF3; -CF2 CI; -CN; -NH2; -OH; -SH; -C(= O)-<br>
NH2; -S(= O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= O)-H; -S(= O)2-OH; -<br>
NHR39; -NR40R41; -OR42; -SR43; -C(= O)-NHR44; -C(= O)-NR45R46; -S(= O)2-<br>
NHR47; -S(= O)2-NR48R49; -C(= O)-OR50; -C(= O)-R51; -S(= O)-R52; -S(= O)2-<br>
R53; -C(= NH)-NH2; -C(= NH)-NH-R54; -N= C(NH2)2; -N= C(NHR55)-(NHR56);<br>
for a linear or branched, saturated or unsaturated, unsubstituted or at least<br>
monosubstituted aliphatic C1-10 radical;<br>
for an unsaturated or saturated, unsubstituted or at least monosubstituted<br>
three-membered, four-membered, five-membered, six-membered, seven-<br>
membered, eight-membered, or nine-membered cycloaliphatic radical<br>
optionally exhibiting at least one heteroatom as ring member, each of which is<br>
bonded to the parent structure over a carbon atom in the ring of the<br>
cycloaliphatic radical and is condensed with a saturated or unsaturated,<br>
unsubstituted or at least monosubstituted monocyclic or polycyclic ring system<br>
and/or can be bonded via a linear or branched, unsubstituted or at least<br>
monosubstituted C1-6 alkylene group or C2-6 alkenylene group or C2-6<br>
alkynylene group;<br><br>
or for an unsubstituted or at least monosubstituted five-membered to fourteen-<br>
membered aryl radical or heteroaryl radical, which can be condensed with a<br>
saturated or unsaturated, unsubstituted or at least monosubstituted<br>
monocyclic or polycyclic ring system and/or can be bonded via a linear or<br>
branched, unsubstituted or at least monosubstituted C1-6 alkylene group or C2-6<br>
alkenylene group or C2-6-alkynylene group;<br>
R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, and R56<br>
each independently<br>
stand for a linear or branched, saturated or unsaturated, unsubstituted or at<br>
least monosubstituted aliphatic C1-10 radical;<br>
for an unsaturated or saturated, unsubstituted or at least monosubstituted,<br>
three-membered, four-membered, five-membered, six-membered, seven-<br>
membered, eight-membered, or nine-membered cycloaliphatic radical<br>
optionally containing at least one heteroatom as ring member, which can be<br>
condensed with a saturated or unsaturated, unsubstituted or at least<br>
monosubstituted monocyclic or polycyclic ring system and/or can be bonded<br>
via a linear or branched, unsubstituted or at least monosubstituted C1-6<br>
alkylene group or two to six-membered heteroalkylene group;<br>
or for an unsubstituted or at least monosubstituted five-membered to fourteen-<br>
membered aryl radical or heteroaryl radical, which can be condensed with a<br>
saturated or unsaturated, unsubstituted or at least monosubstituted<br><br>
monocyclic or polycyclic ring system and/or can be bonded via a linear or<br>
branched, unsubstituted or at least monosubstituted C1-6 alkylene group or two<br>
to six-membered heteroalkylene group;<br>
or<br>
R40 and R41 form, together with the interconnecting nitrogen atom as ring member,<br>
a saturated or unsaturated four-membered, five-membered, six-membered,<br>
seven-membered, eight-membered, or nine-membered heterocycloaliphatic<br>
radical, which is unsubstituted or substituted by 1, 2, 3, 4, or 5 radicals R57 and<br>
optionally exhibits at least one further heteroatom as ring member, and which<br>
can be condensed with a saturated or unsaturated, unsubstituted or at least<br>
monosubstituted monocyclic or polycyclic ring system;<br>
R57 stands for -NHR58, -NR59R60, or for a linear or branched, saturated or<br>
unsaturated, unsubstituted or at least monosubstituted aliphatic C1-10 radical;<br>
R58, R59, and R60 each independently stand for -C(= O)-R61; for a linear or branched,<br>
saturated or unsaturated, unsubstituted or at least monosubstituted aliphatic<br>
C1-10 radical<br>
or for an unsubstituted or at least monosubstituted five-membered to fourteen-<br>
membered aryl radical or heteroaryl radical, which can be condensed with a<br>
saturated or unsaturated, unsubstituted or at least monosubstituted<br>
monocyclic or polycyclic ring system and/or can be bonded via a linear or<br><br>
branched, unsubstituted or at least monosubstituted C1-6 alkylene group or C2-6<br>
alkenylene group or C2-6 alkynylene group;<br>
and R61 stands for a linear or branched, saturated or unsaturated, unsubstituted<br>
or at least monosubstituted aliphatic C1-10 radical;<br>
each optionally in the form of one of the pure stereoisomers thereof, particularly<br>
enantiomers or diastereoisomers thereof, the racemates thereof or in the form of a<br>
mixture of stereoisomers, particularly the enantiomers and/or diastereoisomers, in an<br>
arbitrary mixing ratio, or each in the form of corresponding salts, or each in the form<br>
of corresponding solvates;<br>
wherein<br>
the aforementioned aliphatic C1-10 radicals and tert-butyl radicals can each be<br>
optionally substituted by 1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents independently selected<br>
from the group consisting of F, CI, Br, I, -CN, -NO2, -OH, -NH2, -SH, -O(C1-5 alkyl), -<br>
S(C1-5 alkyl), -NH(C1-5 alkyl), -N(C1-5 alkyl)-(C1-5 alkyl), -C(= O)-O-(C1-5 alkyl), -O-C(=<br>
O)-(C1-5 alkyl), -O-phenyl, phenyl, -OCF3, and -SCF3;<br>
the aforementioned two to six-membered heteroalkylene groups, C1-6 alkylene<br>
groups, and C2-6 alkenylene groups and C2-6 alkynylene groups can each be<br>
optionally substituted by 1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents independently selected<br>
from the group consisting of F, CI, Br, I, -CN, -NO2, -OH, -NH2, -SH, -O(C1-5 alkyl), -<br>
S(C1-5 alkyl), -NH(C1-5 alkyl), -N(C1-5 alkyl)-(C1-5 alkyl), -OCF3, and -SCF3;<br><br>
the aforementioned heteroalkylene groups each optionally exhibit 1, 2, or 3<br>
heteroatom(s) independently selected from the group consisting of oxygen, sulfur,<br>
and nitrogen (NH) as link(s);<br>
the aforementioned (hetero)cycloaliphatic radicals are optionally each substituted by<br>
1,2,3, 4, or 5 substituents independently selected from the group consisting of -(C1-6<br>
alkylene)-OH, = CH2, -O-(C1-5 alkylene)oxetanyl, -(C1-5 alkylene)-O-(C1-5<br>
alkylene)oxetanyl, -CH2-NH-(C1-5 alkyl), -CH2-N(C1-5 alkyl)2, -N[C(= O)-(C1-5<br>
alkyl)]phenyl, -CH2-O-(C1-5 alkyl), oxo (= O), thioxo (= S), F, CI, Br, I, -CN, -CF3, -SF5,<br>
-OH, -O-(C1-5 alkyl), -O-C(= O)-(C1-5 alkyl), -NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-(C1-5<br>
alkyl), -(C1-5 alkyl), -C(= O)-(C1-5 alkyl), -C(= O)-OH, -C(= O)-O-(C1-5 alkyl), -NH-(C1-5<br>
alkyl), -N(C1-5 alkyl)2, -NH-phenyl, -N(C1-5 alkyl)phenyl, cyclohexyl, cyclopentyl, (4,5)-<br>
dihydroisoxazolyl, thiazolyl, (1,2,5)-thiadiazolyl, thiophenyl, phenethyl, piperidinyl,<br>
pyrrolidinyl, -(CH2)-pyridinyl, pyridinyl, -O-phenyl, -O-benzyl, phenyl, and benzyl, and<br>
the cyclic moiety of the radicals oxetanyl, (4,5)-dihydroisoxazolyl, thiazolyl, (1,2,5)-<br>
thiadiazolyl, thiophenyl, phenethyl, -N[C(= O)-(C1-5 alkyl)]phenyl, -NH-phenyl, -N(C1-5<br>
alkyl)phenyl, -(CH2)-pyridinyl, pyridinyl, -O-phenyl, -O-benzyl, phenyl, and benzyl can<br>
each be substituted by 1, 2, 3, 4, or 5 substituents independently selected from the<br>
group consisting of F, CI, Br, -OH, -CF3, -SF5, -CN, -NO2, -C1-5-alkyl, -O-C1-5 alkyl, -<br>
O-CF3, -S-CF3, phenyl, and -O-benzyl,<br>
and, unless otherwise stated, the aforementioned (hetero)cycloaliphatic radicals can<br>
each optionally exhibit 1, 2, or 3 (further) heteroatom(s) independently selected from<br>
the group consisting of oxygen, nitrogen, and sulfur;<br><br>
the rings of the aforementioned monocyclic or polycyclic ring systems can each be<br>
optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from the<br>
group consisting of oxo (= O), thioxo (= S), F, CI, Br, I, -CN, -CF3, -SF5, -OH, -O-(C1-5<br>
alkyl), -NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-(C1-5 alkyl), -(C1-5 alkyl), -C(= O)-(C1-5<br>
alkyl), -C(= O)-OH, -C(= O)-O-(C1-5 alkyl), -NH-(C1-5 alkyl), -N(C1-5 alkyl)2, -O-phenyl,<br>
-O-benzyl, phenyl, and benzyl, and the cyclic moiety of the radicals -O-phenyl, -O-<br>
benzyl, phenyl, and benzyl can each be substituted by 1, 2, 3, 4, or 5 substituents<br>
independently selected from the group consisting of F, CI, Br, -OH, -CF3, -SF5, -CN, -<br>
NO2, -C1-5-alkyl, -O-C1-5-alkyl, -O-CF3, -S-CF3, phenyl, and -O-benzyl,<br>
and the rings of the aforementioned monocyclic or polycyclic ring systems are each<br>
five-membered, six-membered, or seven-membered and can each optionally exhibit<br>
1, 2, 3, 4, or 5 heteroatom(s) as ring member(s), which are independently selected<br>
from the group consisting of oxygen, nitrogen, and sulfur;<br>
and the aforementioned aryl radicals or heteroaryl radicals can each be optionally<br>
substituted by 1, 2, 3, 4, or 5 substituents independently selected from the group<br>
consisting of F, CI, Br, I, -CN, -CF3, -SF5, -OH, -O-C1-5-alkyl, -NH2, -NO2, -O-CF3, -S-<br>
CF3, -SH, -S-C1-5-alkyl, -C1-5 alkyl, -C(= O)-OH, -C(= O)-O-C1-5-alkyl, -NH-C1-5-alkyl, -<br>
N(C1-5-alky)2, -NH-S(= O)2-C1-5 alkyl, -NH-C(= O)-O-C1-5 alkyl, -C(= O)-H, -C(= O)-C1-<br>
5-alkyl, -C(= O)-NH2, -C(= O)-NH-C1-5-alkyl, -C(= O)-N-(C1-5-alkyl)2, -O-phenyl, -O-<br>
benzyl, phenyl, and benzyl, and the cyclic moiety of the radicals -O-phenyl, -O-<br>
benzyl, phenyl, and benzyl can each be substituted by 1, 2, 3, 4, or 5 substituents<br>
independently selected from the group consisting of F, CI, Br, -OH, -CF3, -SF5, -CN, -<br>
NO2, -C1-5-alkyl, -O-C1-5-alkyl, -O-CF3, -S-CF3, phenyl, and -O-benzyl,<br><br>
and<br>
the aforementioned heteroaryl radicals can each optionally exhibit 1, 2, 3, 4, or 5<br>
heteroatom(s) independently selected from the group consisting of oxygen, nitrogen,<br>
and sulfur as ring member(s).<br>
The term "heteroalkylene" designates an alkylene chain in which one or more C-<br>
atoms have each been replaced by a heteroatom independently selected from the<br>
group consisting of oxygen, sulfur and nitrogen (NH). Heteroalkylene groups can<br>
preferably contain 1, 2, or 3 heteroatom(s) and more preferably one heteroatom,<br>
independently selected from the group consisting of oxygen, sulfur and nitrogen<br>
(NH), as link(s). Heteroalkylene groups can preferably be two to six-membered and<br>
more preferably two or three-membered.<br>
Mention may be made, for example, of heteroalkylene groups such as -CH2-CH2-O-<br>
CH2-, -CH2-CH(CH3)-O-CH2-, -(CH2)-O-, -(CH2)2-O-, -(CH2)3-O-, -(CH2)4-O -, -O-<br>
(CH2)-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -C(C2H5)-(H)-O-, -O-C(C2H5)-(H)-, -CH2-O-<br>
CH2-, -CH2-S-CH2-, -CH2-NH-CH2-, -CH2-NH-, and -CH2-CH2-NH-CH2-CH2.<br>
If one or more of the aforementioned substituents exhibit a linear or branched C1-6-<br>
alkylene group, these can be preferably selected from the group consisting of -(CH2)-<br>
, -(CH2)2-, -C(H)-(CH3)-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -C(H)-(C(H)-(CH3)2)-, and -<br>
C(C2H5)-(H)-.<br>
Saturated or unsaturated C1-10 aliphatic radicals can stand for a C1-10-alkyl, C2-10-<br>
alkenyl, or C2-10-alkynyl radical. C2-10-alkenyl radicals have at least one and<br><br>
preferably 1, 2, 3, or 4 C-C-double bonds and C2-10-alkynyl radicals at least one and<br>
preferably 1, 2, 3, or 4 C-C-triple bonds.<br>
Preference is given to C1-10-alkyl radicals selected from the group consisting of<br>
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-<br>
methylbut-1-yl, 2-pentyl, 3-pentyl, sec-pentyl, neopentyl, 4-methylpent-1-yl, (3,3)-<br>
dimethylbut-1-yl, n-hexyl, n-heptyl, 2-heptyi, 3-heptyl, 4-heptyl, n-octyl, n-nonyl, 2-<br>
nonyl, 3-nonyl, 4-nonyl, 5-nonyl, and (2,6)-dimethylhept-4-yl, which can be optionally<br>
substituted by 1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents independently selected from the<br>
group consisting of -O-phenyl, -O-C(= O)-CH3, -O-C(= O)-C2H5, -O-C(= O)-CH(CH3)2,<br>
-O-C(= O)-C(CH3)3, -C(= O)-O-CH3, -C(= O)-O-C2H5, -C(= O)-O-CH(CH3)2, -C(= O)-<br>
O-C(CH3)3, F, CI, Br, I, -CN, -NO2, -OH, -NH2, -SH, -O-CH3, -O-C2H5, -O-CH(CH3)2, -<br>
O-C(CH3)3) -S-CH3, -S-C2H5, -S-CH(CH3)2, -S-C(CH3)3, -NH-CH3, -NH-C2H5, -NH-<br>
C(CH3)3, -N(CH3)2, -N(C2H5)2, -N(CH3)-(C2H5), -OCF3, and -SCF3.<br>
In another preferred embodiment, C2-10 alkenyl radicals are selected from the group<br>
consisting of vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-<br>
propene-1-yl, 3-methyl-but-2-en-1-yl, (3,3)-dimethyl-but-1-enyl, 2-methyl-butene-2-yl,<br>
1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 1-heptenyl, and 1-octenyl,<br>
which can be optionally substituted by 1, 2, or 3 substituents independently selected<br>
from the group consisting of F, CI, Br, I, -CN, -NO2, -OH, -NH2, -SH, -O-CH3, -O-<br>
C2H5, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH(CH3)2, -S-C(CH3)3, -NH-<br>
CH3, -NH-C2H5, -NH-C(CH3)3, -N(CH3)2, -N(C2H5)2, -N(CH3)-(C2H5), -OCF3, and -<br>
SCF3.<br><br>
Preference is also given to C2-10 alkynyl radicals selected from the group consisting<br>
of (3,3)-dimethyl-but-1-ynyl, 4-methyl-pent-1-ynyl, 1-hexynyl, ethynyl, 1-propynyl, 2-<br>
propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, and 4-<br>
pentynyl, which can be optionally substituted by 1, 2, or 3 substituents independently<br>
selected from the group consisting of F, CI, Br, I, -CN, -NO2, -OH, -NH2, -SH, -O-CH3,<br>
-O-C2H5, -O-CH(CH3)2, -O-C(CH3)3, -S-CH3, -S-C2H5, -S-CH(CH3)2, -S-C(CH3)3, -NH-<br>
CH3, -NH-C2H5, -NH-C(CH3)3, -N(CH3)2, -N(C2H5)2, -N(CH3)(C2H5), -OCF3, and -<br>
SCF3.<br>
Particularly preferred optionally substituted C1-10 aliphatic radicals are selected from<br>
the group consisting of methyl, -CF3, -CHF2, -CH2F, -CF2CI, -CCI2F, -CCI3, -CBr3, -<br>
CH2-CN, -CH2-O-CH3, -CH2-O-CF3, -CH2-SF3, -CH2-NH2, -CH2-OH, -CH2-SH, -CH2-<br>
NH-CH3, -CH2-N(CH3)2, -CH2-N(C2H5)2, -CH2-N(CH3)-(C2H5), ethyl, -CF2-CH3, -CHF-<br>
CF2CI, -CF2-CFCI2, -CFCI-CF2CI, -CFCI-CFCI2, -CH2-CH2-NH2, -CH2-CH2-OH, -CH2-<br>
CH2-SH, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)2, -CH2-CH2-N(C2H5)2, -CH2-CH2-<br>
N(CH3)-(C2H5), -CH2-CF3, -C2F5, -CH2-CCI3, -CH2-CBr3, -CH2-CH2-CN, n-propyl, -<br>
CH2-CH2-CH2-OH, -CH2-CH2-CH2-SH, -CH2-CH2-CH2-NH2, -CH2-CH2-CH2-NH-CH3, -<br>
CH2-CH2-CH2-N(CH3)2, -CH2-CH2-CH2-N(C2H5)2, -CH2-CH2-CH2-N(CH3)-(C2H5), -<br>
CH2-CH2-O-CH3, -CF2-CF2-CF3, -CF(CF3)2, isopropyl, -CH2-CH2-CH2-CN, -CH2-O-<br>
CH2-CH3, -CH2-CH2-SF3, -CH2-CH2-OCF3, -CH(CH3)-(O-CH3), -CH(CH3)-(S-CH3), n-<br>
butyl, -CF2-CF2-CF2-CF3, -CH2-CH2-CH2-CH2-CN, -CH2-CH2-CH2-CF3, -CH2-CH2-<br>
CH2-CH2-CF3, -CH2-O-C(= O)-CH3, -CH2-O-C(= O)-C2H5, -CH2-O-C(= O)-CH(CH3)2, -<br>
CH2-O-C(= O)-C(CH3)3, -CH2-C(= O)-O-CH3, -CH2-C(= O)-O-C2H5, -CH2-C(= O)-O-<br>
C(CH3)3, -CH2-CH2-O-CH3, -CH2-CH2-O-C2H5l -CH2-CH2-O-phenyl, -CH2-CH2-CH2-<br>
O-CH3, sec-butyl, isobutyl, tert-butyl, n-pentyl, sec-pentyl, neo-pentyl, n-hexyl, vinyl,<br>
1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-butene-2-yl, (1,1,2)-<br><br>
trifluoro-1 -butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, -CF= CF2, -CCI=<br>
CCI2, -CH2-CF= CF2, -CH2-CCI= CCI2, -C=C-I, -OC-, and -C=C-CI.<br>
If one or more of the aforementioned substituents stand for a (hetero)cycloaliphatic<br>
radical, which can be optionally condensed with a saturated or unsaturated,<br>
unsubstituted or at least monosubstituted monocyclic or polycyclic ring system, this<br>
can preferably be selected from the group consisting of cyclopropyl, cyclobutyl,<br>
cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cycloheptenyl,<br>
imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl,<br>
morpholinyl, piperazinyl, thiomorpholinyl, tetrahydropyranyl, oxetanyl, (1,2,3,6)-<br>
tetrahydropyridinyl, azepanyl, azocanyl, diazepanyl, dithiolanyl, (1,3,4,5)-<br>
tetrahydropyrido[4.3-b]indolyl, (3,4)-dihydro-1 H-isoquinolinyl, (1,3,4,9)-<br>
tetrahydro[b]carbolinyl, and (1,3)-thiazolidinyl.<br>
As examples of suitable (hetero)cycloaliphatic radicals, which can be unsubstituted<br>
or monosubstituted or polysubstituted and are condensed with a monocyclic or<br>
bicyclic ring system, there may be mentioned (4,5,6,7)-tetrahydroisoxazolo[5.4-<br>
c]pyridinyl, (2,3)-dihydro-1H-indenyl, 3-aza-bicyclo[3.1.1]heptyl, 3-aza-<br>
bicyclo[3.2.1]octyl, 6-aza-bicyclo[3.3.1]heptyl, 8-aza-bicyclo[3.2.1]octyl, isoindolyl,<br>
indolyl, (1,2,3,4)-tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, (2,3)-dihydro-<br>
1 H-isoindolyl, (1,2,3,4)-tetrahydronaphthyl, (2,3)-dihydro-benzo[1.4]dioxinyl,<br>
benzo[1.3]dioxolyl, (1,4)-benzodioxanyl, (2,3)-dihydrothieno[3.4-b][1.4]dioxinyl, (3,4)-<br>
dihydro-2H-benzo[1.4]oxazinyl, octahydro-1 H-isoindolyl, and octahydro-pyrrolo[3.4-<br>
c]pyrrolyl.<br><br>
(Hetero)cycloaliphatic radicals can form, within the scope of the present invention, a<br>
spirocyclic radical with another (hetero)cycloaliphatic radical via a carbon atom<br>
common to both rings.<br>
As examples of suitable spirocyclic radicals there may be mentioned a 6-aza-<br>
spiro[2.5]octyl radical, 8-aza-spiro[4.5]decyl radical and a 1-oxa-2,8-diaza-<br>
spiro[4.5]dec-2-enyl radical.<br>
More preferably the (hetero)cycloaliphatic radicals can each be optionally substituted<br>
by 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of<br>
oxo (= O), thioxo (= S), F, CI, Br, I, -CN, -CF3, -SF5, -OH, -O-CH3, -O-C2H5, -O-<br>
CH(CH3)2, -O-C(CH3)3, -NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, -S-<br>
CH(CH3)2, -S-C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, n-pentyl, -C(= O)-CH3, -C(= O)-C2H5, -C(= O)-CH(CH3)2, -C(= O)-C(CH3)3, -<br>
C(= O)-0H, -C(= O)-O-CH3, -C(= O)-O-C2H5, -C(= O)-O-CH(CH3)2, -C(= O)-O-<br>
C(CH3)3, -NH-CH3, -NH-C2H5, -NH-C(CH3)3, -N(CH3)2, -N(C2H5)2, -N(CH3)-(C2H5), -<br>
CH2-OH, -CH2-CH2-OH, = CH2, -CH2-O-CH2-oxetanyl, -O-CH2-oxetanyl, -CH2-<br>
N(CH3)2, -CH2-N(C2H5)2, -CH2-NH-CH3, -CH2-NH-C2H5, -N-[C(= O)-C2H5]-phenyl, -N-<br>
[C(= O)-CH3]-phenyl, -CH2-O-CH3, -CH2-O-CH2-CH3, -NH-phenyl, -N(CH3)phenyl, -<br>
N(C2H5)phenyl, -N(C2H5)phenyl, -O-CH2-CH2-CH2-CH3, (4,5)-dihydroisoxazolyl,<br>
thiazolyl, (1,2,5)-thiadiazolyl, thiophenyl, phenethyl, cyclohexyl, cyclopentyl,<br>
piperidinyl, pyrrolidinyl, -O-C(= O)-CH3, -O-C(= O)-C2H5, -O-C(= O)-C(CH3)3, -<br>
(CH2)pyridinyl, pyridinyl, -O-phenyl, -O-benzyl, phenyl, and benzyl, and the cyclic<br>
moiety of the radicals oxetanyl, (4,5)-dihydroisoxazolyl, thiazolyl, (1,2,5)-thiadiazolyl,<br>
thiophenyl, phenethyl, -N-[C(= O)-C2H5]phenyl, -N-[C(= O)-CH3]phenyl, -NH-phenyl, -<br>
N(CH3)phenyl, -N(C2H5)phenyl, -(CH2)pyridinyl, pyridinyl, -O-phenyl, -O-benzyl,<br><br>
phenyl, and benzyl can each be substituted by 1, 2, 3, 4, or 5 substituents<br>
independently selected from the group consisting of F, CI, Br, -OH, -CF3, -SF5, -CN, -<br>
NO2, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -O-CH3,<br>
-O-C2H5, -O-CH(CH3)2, -O-C(CH3)3, -O-CF3, -S-CF3, phenyl, and -O-benzyl.<br>
If one or more of the aforementioned substituents stand for an aryl radical, this can<br>
preferably be selected from the group consisting of phenyl and naphthyl (1-naphthyl<br>
and 2-naphthyl).<br>
If one or more of the aforementioned substituents stand for a heteroaryl radical, this<br>
can preferably be selected from the group consisting of tetrazolyl, thiophenyl, furanyl,<br>
pyrrolyl, pyrazolyl, pyrazinyl, pyranyl, triazolyl, pyridinyl, imidazolyl, indolyl, isoindolyl,<br>
benzo[b]furanyl, benzo[b]thiophenyl, benzoxazolyl, benzisoxazolyl, thiazolyl,<br>
oxazolyl, isoxazolyl, pyridazinyl, pyrazinyl, pyrimidinyl, indazolyl, quinoxalinyl,<br>
quinolinyl, and isoquinolinyl.<br>
As examples of suitable aryl and heteroaryl radicals, which can be unsubstituted or<br>
monosubstituted or polysubstituted and are condensed with a monocyclic or bicyclic<br>
ring system, there may be mentioned isoindolyl, indolyl, (1,2,3,4)-<br>
tetrahydroquinolinyl, (1,2,3,4)-tetrahydroisoquinolinyl, (2,3)-dihydro-1 H-isoindolyl,<br>
(1,2,3,4)-tetrahydronaphthyl, (2,3)-dihydrobenzo[1.4]dioxinyl, (2,3)-dihydrothieno[3.4-<br>
b][1.4]dioxinyl, benzo[1.3]dioxolyl, and (1,4)-benzodioxanyl.<br>
More preferably, the aryl radicals or heteroaryl radicals can each be optionally<br>
substituted by 1, 2, 3, 4, or 5 substituents independently selected from the group<br>
consisting of F, CI, Br, I, -CN, -CF3, -SF5, -OH, -O-CH3, -O-C2H5, -O-CH(CH3)2, -O-<br><br>
C(CH3)3, -NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, -S-CH(CH3)2, -S-<br>
C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-<br>
pentyl, -C(= O)-OH, -C(= O)-O-CH3, -C(= O)-O-C2H5l -C(= O)-O-CH(CH3)2, -C(= O)-<br>
O-C(CH3)3, -NH-CH3, -NH-C2H5, -NH-C(CH3)3, -N(CH3)2, -N(C2H5)2, -N(CH3)-(C2H5), -<br>
NH-S(= O)2-CH3, -NH-S(= 02)-C2H5, -NH-S(= O)2-CH(CH3)2, -NH-C(= O)-O-CH3, -<br>
NH-C(= O)-O-C2H5, -NH-C(= O)-O-C(CH3)3, -C(= O)-H, -C(= O)-CH3, -C(= O)-C2H5, -<br>
C(= O)-CH(CH3)2, -C(= O)-C(CH3)3, -C(= O)-NH2, -C(= O)-NH-CH3, -C(= O)-NH-<br>
C2H5, -C(= O)-N(CH3)2, -C(= O)-N(C2H5)2, -O-phenyl, -O-benzyl, phenyl, and benzyl,<br>
and the cyclic moiety of the radicals -O-phenyl, -O-benzyl, phenyl, and benzyl can<br>
each be substituted by 1, 2, 3, 4, or 5 substituents independently selected from the<br>
group consisting of F, CI, Br, -OH, -CF3, -SF5, -CN, -NO2, methyl, ethyl, n-propyl,<br>
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, -O-CH3, -O-C2H5, -O-CH(CH3)2, -O-<br>
C(CH3)3, -O-CF3, -S-CF3, phenyl, and -O-benzyl.<br>
If a polycyclic ring system such as a bicyclic ring system is present, the different rings<br>
can independently exhibit a different degree of saturation, i.e. be saturated or<br>
unsaturated. A polycyclic ring system is preferably a bicyclic ring system.<br>
As examples of aryl radicals condensed with a monocyclic or polycyclic ring system<br>
mention may be made of (1,3)-benzodioxolyl and (1,4)-benzodioxanyl.<br>
If one or more of the aforementioned substituents have a monocyclic or polycyclic<br>
ring system, this can preferably be substituted by 1, 2, 3, 4, or 5 substituents<br>
independently selected from the group consisting of oxo (= O), thioxo (= S), F, CI, Br,<br>
I, -CN, -CF3, -SF5, -OH, -O-CH3, -O-C2H5, -O-CH(CH3)2, -O-C(CH3)3, -NH2, -NO2, -O-<br>
CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, -S-CH(CH3)2, -S-C(CH3)3, methyl, ethyl, n-propyl,<br><br>
isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, -C(= O)-OH, -C(= O)-O-<br>
CH3, -C(= O)-O-C2H5, -C(= O)-O-CH(CH3)2l -C(= O)-O-C(CH3)3, -NH-CH3, -NH-C2H5,<br>
-NH-C(CH3)3, -N(CH3)2, -N(C2H5)2, -N(CH3HC2H5), -NH-C(= O)-O-CH3, -NH-C(= O)-<br>
O-C2H5, -NH-C(= O)-O-C(CH3)3, -C(= O)-H, -C(= O)-CH3, -C(= O)-C2H5, -C(= O)-<br>
CH(CH3)2, -C(= O)-C(CH3)3, -C(= O)-NH2, -C(= O)-NH-CH3, -C(= O)-nH-C2H5, -C(=<br>
 O)-N(CH3)2, -C(= O)-N(C2H5)2, -O-phenyl, -O-benzyl, phenyl, and benzyl, and the<br>
cyclic moiety of the radicals -O-phenyl, -O-benzyl, phenyl, and benzyl can each be<br>
substituted by 1, 2, 3, 4, or 5 substituents independently selected from the group<br>
consisting of F, CI, Br, -OH, -CF3, -SF5, -CN, -NO2, methyl, ethyl, n-propyl, isopropyl,<br>
n-butyl, sec-butyl, isobutyl, tert-butyl, -O-CH3, -O-C2H5, -O-CH(CH3)2, -O-C(CH3)3, -<br>
O-CF3l -S-CF3, phenyl, and -O-benzyl.<br>
If the radicals R41 and R42, together with the interconnecting nitrogen atom as ring<br>
member, form a heterocycloaliphatic radical which is substituted by 1, 2, 3, 4 or 5<br>
radicals R57, these radicals R57 each have, independently of one another, one of the<br>
indicated meanings.<br>
Preference is given to compounds of the general formula la,<br><br>
in which<br><br>
D stands for N or CH;<br>
R1 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23; -S(=O)2-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl,<br>
sec-butyl, isobutyl, and tert-butyl;<br>
R2 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23; -S(=O)2-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl,<br>
sec-butyl, isobutyl, and tert-butyl;<br>
R3 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23; -S(=O)2-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl,<br>
sec-butyl, isobutyl, and tert-butyl;<br>
R4 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23; -S(=O)2-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl,<br>
sec-butyl, isobutyl, and tert-butyl;<br>
R5 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23; -S(=O)2-R27 or for a radical selected from the group<br><br>
consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl,<br>
sec-butyl, isobutyl, and tert-butyl;<br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl; or -C(CH3)2(CH2OH);<br>
R13, R16, R17, R22, R23 and R27 each independently stand for a radical selected from<br>
the group consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, -CF2-CH3, -CH2-CF3, -<br>
C2F5, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-<br>
heptyl, 4-heptyl, n-octyl, n-nonyl, 5-nonyl, (2,6)-dimethyl-hept-4-yl, 3-methyl-butyl, n-<br>
hexyl, (3,3)-dimethylbutyl and ethenyl;<br>
R42 stands for a radical selected from the group consisting of methyl, -CH2-O-CH3,<br>
ethyl, n-propyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-hexyl, (3,3)-<br>
dimethylbutyl, -CH2-CH2-O-CH3, -CH2-CH2-O-C2H5l and -CH2-CH2-CH2-O-CH3;<br>
or for a radical selected from the group consisting of 2,3-dihydro-1H-indenyl,<br>
cyclopropyl, oxetanyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolidinyl,<br>
tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, morpholinyl,<br>
piperazinyl, azepanyl, diazepanyl, azocanyl, and thiomorpholinyl, each of which can<br>
be optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from<br>
the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, and n-pentyl;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in the form<br>
of a mixture of stereoisomers, particularly the enantiomers and/or diastereoisomers,<br><br>
in an arbitrary mixing ratio, or in each case in the form of corresponding salts, or in<br>
each case in the form of corresponding solvates.<br>
Special preference is given to compounds of the general formula la,<br><br>
in which<br>
D stands for N or CH;<br>
R1 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(=O)-R13; -<br>
OR16; SR17, -S(=O)2-NR22R23 or -(S=O)-R27;<br>
R2 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(=O)-R13; -<br>
OR16; SR17, -S(=O)2-NR22R23 or-(S=O)-R27;<br>
R3 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(=O)-R13; -<br>
OR16; SR17, -S(=O)2-NR22R23 or-(S=O)-R27;<br>
R4 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(=O)-R13; -<br>
OR16; SR17, -S(=O)2-NR22R23 or-(S=O)-R27;<br><br>
R5 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(=O)-R13; -<br>
OR16; SR17, -S(=O)2-NR22R23 or-(S=O)-R27;<br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl; or -C(CH3)2(CH2OH);<br>
R13, R16, R17, R22, R23 and R27 each independently stand for a radical selected from<br>
the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, n-pentyl and ethenyl;<br>
R42 stands for a radical selected from the group consisting of methyl, ethyl, n-<br>
propyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-hexyl, and<br>
(3,3)-dimethylbutyl;<br>
or for a radical selected from the group consisting of cyclopropyl, cyclobutyl,<br>
cyclopentyl, cyclohexyl, and cycloheptyl, each of which can be optionally substituted<br>
by 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of<br>
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and n-pentyl;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in the form<br>
of a mixture of stereoisomers, particularly the enantiomers and/or diastereoisomers,<br>
in an arbitrary mixing ratio, or in each case in the form of corresponding salts, or in<br>
each case in the form of corresponding solvates.<br>
Very particular preference is given to compounds of the general formula la,<br><br><br>
in which<br>
D stands for N or CH;<br>
R1 stands for H; F; CI; Br; or I;<br>
R2 stands for H; F; CI; Br; I; methyl; -OH; -NH2 or -OR16;<br>
R3 stands for H; F; CI; Br; I; -NO2; -OH; -NH2; -NH-C(= O)-R13, -OR16; SR17, -<br>
S(=O)2-NR22R23 or-(S=O)-R27;<br>
R4 stands for H; F; CI; Br; I; methyl, -OH; -NH2; or -OR16;<br>
R5 stands for H; F; CI; Br; or I;<br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl; or -C(CH3)2(CH2OH);<br>
R13, R16, R17, R22, R23 and R27 each independently stand for a radical selected from<br>
the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, n-pentyl and ethenyl;<br><br>
R42 stands for a radical selected from the group consisting of methyl, ethyl, n-<br>
propyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-hexyl, and (3,3)-<br>
dimethylbutyl;<br>
or for a radical selected from the group consisting of cyclopropyl, cyclobutyl,<br>
cyclopentyl, cyclohexyl, and cycloheptyl, each of which can be optionally substituted<br>
by 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of<br>
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and n-pentyl;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, the racemates thereof or in the form of<br>
a mixture of stereoisomers, particularly the enantiomers and/or diastereoisomers, in<br>
an arbitrary mixing ratio, or in each case in the form of corresponding salts, or in<br>
each case in the form of corresponding solvates.<br>
Preference is given to compounds of the general formula lb,<br><br>
in which<br>
D stands for N or CH;<br><br>
R1 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23; -(S=O)-R27 or for a radical selected from the group consisting<br>
of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
and tert-butyl;<br>
R2 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23; -(S=O)-R27 or for a radical selected from the group consisting<br>
of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
and tert-butyl;<br>
R3 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23; -(S=O)-R27 or for a radical selected from the group consisting<br>
of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
and tert-butyl;<br>
R4 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23; -(S=O)-R27 or for a radical selected from the group consisting<br>
of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
and tert-butyl;<br>
R5 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23; -(S=O)-R27 or for a radical selected from the group consisting<br>
of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
and tert-butyl;<br><br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl; or -C(CH3)2(CH2OH);<br>
R13, R16, R17, R22, R23 and R27 each independently stand for a radical selected from<br>
the group consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, -CF2-CH3, -CH2-CF3, -<br>
C2F5, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-<br>
heptyl, 4-heptyl, n-octyl, n-nonyl, 5-nonyl, (2,6)-dimethyl-hept-4-yl, 3-methyl-butyl, n-<br>
hexyl, (3,3)-dimethylbutyl and ethenyl;<br>
R43 stands for a radical selected from the group consisting of methyl, -CH2-O-CH3,<br>
ethyl, n-propyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-hexyl, (3,3)-<br>
dimethylbutyl, -CH2-CH2-O-CH3, -CH2-CH2-O-C2H5, and -CH2-CH2-CH2-O-CH3;<br>
or for a radical selected from the group consisting of 2,3-dihydro-1 H-indenyl,<br>
cyclopropyl, oxetanyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolidinyl,<br>
tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, morpholinyl,<br>
piperazinyl, azepanyl, diazepanyl, azocanyl, and thiomorpholinyl, each of which can<br>
be optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from<br>
the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, and n-pentyl;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in the form<br>
of a mixture of stereoisomers, particularly the enantiomers and/or diastereoisomers,<br>
in an arbitrary mixing ratio, or in each case in the form of corresponding salts, or in<br>
each case in the form of corresponding solvates.<br><br>
Special preference is given to compounds of the general formula lb,<br><br>
in which<br>
D stands for N or CH;<br>
R1 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(= O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23 or-(S=O)-R27;<br>
R2 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(= O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23 or -(S=O)-R27;<br>
R3 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(= O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23 or -(S=O)-R27;<br>
R4 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(= O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23 or-(S=O)-R27;<br>
R5 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(= O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23 or -(S=O)-R27;<br><br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl; or -C(CH3)2(CH2OH);<br>
R13, R16, R17, R22, R23 and R27 each independently stand for a radical selected from<br>
the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, n-pentyl and ethenyl;<br>
R43 stands for a radical selected from the group consisting of methyl, ethyl, n-<br>
propyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-hexyl, and (3,3)-<br>
dimethylbutyl;<br>
or for a radical selected from the group consisting of cyclopropyl, cyclobutyl,<br>
cyclopentyl, cyclohexyl, and cycloheptyl, each of which can be optionally substituted<br>
by 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of<br>
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and n-pentyl;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in the form<br>
of a mixture of stereoisomers, particularly the enantiomers and/or diastereoisomers,<br>
in an arbitrary mixing ratio, or in each case in the form of corresponding salts, or in<br>
each case in the form of corresponding solvates.<br>
Very particular preference is given to compounds of the general formula lb,<br><br><br>
in which<br>
D stands for N or CH;<br>
R1 stands for H; F; CI; Br; or I;<br>
R2 stands for H; F; CI; Br; I; methyl; -OH; -NH2; or -OR16;<br>
R3 stands for H; F; CI; Br; I; -NO2; -OH; -NH2; -NH-C(= O)-R13, -OR16; SR17; -<br>
S(=O)2-NR22R23 or -(S=O)-R27;<br>
R4 stands for H; F; CI; Br; I; methyl; -OH; -NH2; or -OR16;<br>
R5 stands for H; F; CI; Br; or I;<br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl; or -C(CH3)2(CH2OH);<br>
R13, R16, R17, R22, R23 and R27 each independently stand for a radical selected from<br>
the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, n-pentyl and ethenyl;<br><br>
R43 stands for a radical selected from the group consisting of methyl, ethyl, n-<br>
propyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-hexyl, and (3,3)-<br>
dimethylbutyl;<br>
or for a radical selected from the group consisting of cyclopropyl, cyclobutyl,<br>
cyclopentyl, cyclohexyl, and cycloheptyl, each of which can be optionally substituted<br>
by 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of<br>
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and n-pentyl;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in the form<br>
of a mixture of stereoisomers, particularly the enantiomers and/or diastereoisomers,<br>
in an arbitrary mixing ratio, or in each case in the form of corresponding salts, or in<br>
each case in the form of corresponding solvates.<br>
Preference is given to compounds of the general formula Ic,<br><br>
in which<br><br>
D stands for N or CH;<br>
R1 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23 or -(S=O)-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,<br>
isobutyl, and tert-butyl;<br>
R2 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23 or -(S=O)-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,<br>
isobutyl, and tert-butyl;<br>
R3 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23 or -(S=O)-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,<br>
isobutyl, and tert-butyl;<br>
R4 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23 or -(S=O)-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,<br>
isobutyl, and tert-butyl;<br>
R5 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(= O)-R13; -OR16; -<br>
SR17; -S(=O)2-NR22R23 or -(S=O)-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,<br>
isobutyl, and tert-butyl;<br><br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl; or -C(CH3)2(CH2OH);<br>
R13, R16, R17, R22, R23 and R27 each independently stand for a radical selected from<br>
the group consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, -CF2-CH3, -CH2-CF3, -<br>
C2F5, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-<br>
heptyl, 4-heptyl, n-octyl, n-nonyl, 5-nonyl, (2,6)-dimethyl-hept-4-yl, 3-methyl-butyl, n-<br>
hexyl, (3,3)-dimethylbutyl and ethenyl;<br>
R40 and R41 each independently stand for a radical selected from the group<br>
consisting of methyl, -CH2-O-CH3, ethyl, n-propyl, n-butyl, sec-butyl, isobutyl, tert-<br>
butyl, n-pentyl, 3-pentyl, n-hexyl, (3,3)-dimethylbutyl, -CH2-CH2-O-CH3, -CH2-CH2-O-<br>
C2H5, and -CH2-CH2-CH2-O-CH3;<br>
for a radical selected from the group consisting of 2,3-dihydro-1H-indenyl,<br>
cyclopropyl, oxetanyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolidinyl,<br>
tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, morpholinyl,<br>
piperazinyl, azepanyl, diazepanyl, azocanyl, and thiomorpholinyl, each of which can<br>
be optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from<br>
the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, and n-pentyl;<br>
or<br>
R40 and R41 form, together with the interconnecting nitrogen atom as ring member, a<br>
radical selected from the group consisting of 3-aza-bicyclo[3.1.1]heptyl, 6-aza-<br><br>
spiro[2.5]octyl, 3-aza-bicyclo[3.2.1]octyl, 6-aza-bicyclo[3.3.1]heptyl, 8-aza-<br>
bicyclo[3.2.1]octyl, 1-oxa-2,8-diaza-spiro[4.5]dec-2-enyl, azocanyl, isoindolyl, indolyl,<br>
(1,2,3,6)-tetrahydropyridinyl, (4,5,6,7)-tetrahydroisoxazolo[5.4-c]pyridinyl, pyrrolidinyl,<br>
piperidinyl, piperazinyl, morpholinyl, azepanyl, diazepanyl, and thiomorpholinyl, of<br>
which the heterocycloaliphatic moiety can in each case be unsubstituted or<br>
substituted by 1, 2, 3, 4, or 5 radicals R57;<br>
R57 stands for -NHR58, -NR59R60, or for an alkyl radical selected from the group<br>
consisting of-CF3, -CH2-CF3, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl,<br>
sec-butyl, and isobutyl;<br>
R58, R59, and R60 each independently stand for -C(= O)-R61;<br>
for an alkyl radical selected from the group consisting of-CF3, -CH2-CF3, methyl,<br>
ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, sec-butyl, and isobutyl;<br>
or for a radical selected from the group consisting of phenyl and naphthyl, and each<br>
radical can be bonded via a -(CH2)-, -(CH2)2- or -(CH2)3 group and/or can each be<br>
unsubstituted or optionally substituted by 1, 2, 3, 4, or 5 substituents independently<br>
selected from the group consisting of F, CI, Br, I, -CN, -CF3, -O-CH3, -O-C2H5, -O-<br>
CH(CH3)2, -O-C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, and n-pentyl;<br>
and R61	stands for an alkyl radical selected from the group consisting of -CF3, -<br>
CH2-CF3, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, sec-butyl, and isobutyl;<br><br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in the form<br>
of a mixture of stereoisomers, particularly the enantiomers and/or diastereoisomers,<br>
in an arbitrary mixing ratio, or in each case in the form of corresponding salts, or in<br>
each case in the form of corresponding solvates.<br>
Special preference is given to compounds of the general formula Ic,<br><br>
in which<br>
D stands for N or CH;<br>
R1 stands for H; F; CI; Br; I; methyl; ethyl; -NO2; -OH; -NH2; -NH-C(= O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23 or-(S=O)-R27;<br>
R2 stands for H; F; CI; Br; I; methyl; ethyl; -NO2; -OH; -NH2; -NH-C(= O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23 or -(S=O)-R27;<br>
R3 stands for H; F; CI; Br; I; methyl; ethyl; -NO2; -OH; -NH2; -NH-C(= O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23 or-(S=O)-R27;<br><br>
R4 stands for H; F; CI; Br; I; methyl; ethyl; -NO2; -OH; -NH2; -NH-C(= O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23 or -(S=O)-R27;<br>
R5 stands for H; F; CI; Br; I; methyl; ethyl; -NO2; -OH; -NH2; -NH-C(= O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23 or -(S=O)-R27;<br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl; or -C(CH3)2(CH2OH);<br>
R13, R16, R17, R22, R23 and R27 each independently stand for a radical selected from<br>
the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, n-pentyl and ethenyl;<br>
R40 and R41 form, together with the interconnecting nitrogen atom as ring member, a<br>
radical selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl,<br>
morpholinyl, and azepanyl, of which the heterocycloaliphatic moiety can in each case<br>
be unsubstituted or substituted by 1, 2, 3, 4, or 5 radicals R57;<br>
and R57 stands for an alkyl radical selected from the group consisting of methyl,<br>
ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, sec-butyl, and isobutyl;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in the form<br>
of a mixture of stereoisomers, particularly the enantiomers and/or diastereoisomers,<br>
in an arbitrary mixing ratio, or in each case in the form of corresponding salts, or in<br>
each case in the form of corresponding solvates.<br><br>
Very particular preference is given to compounds of the general formula Ic,<br><br>
in which<br>
D stands for N or CH;<br>
R1 stands for H; F; CI; Br; or I;<br>
R2 stands for H; F; CI; Br; I; -OH; -NH2; or -OR16;<br>
R3 stands for H; F; CI; Br; I; -NO2; -OH; -NH2; -NH-C(= O)-R13, -OR16; -SR17; -<br>
S(=O)2-NR22R23 or -(S=O)-R27;<br>
R4 stands for H; F; CI; Br; I; methyl; -OH; -NH2; or -OR16;<br>
R5 stands for H; F; CI; Br; or I;<br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl; or -C(CH3)2(CH2OH);<br><br>
R13, R16, R17, R22, R23 and R27 each independently stand for a radical selected from<br>
the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, n-pentyl and ethenyl;<br>
R40 and R41 form, together with the interconnecting nitrogen atom as ring member, a<br>
radical selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl,<br>
morpholinyl, and azepanyl, of which the heterocycloaliphatic moiety can in each case<br>
be unsubstituted or substituted by 1, 2, 3, 4, or 5 radicals R57;<br>
and R57 stands for an alkyl radical selected from the group consisting of methyl,<br>
ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, sec-butyl, and isobutyl;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in the form<br>
of a mixture of stereoisomers, particularly the enantiomers and/or diastereoisomers,<br>
in an arbitrary mixing ratio, or in each case in the form of corresponding salts, or in<br>
each case in the form of corresponding solvates.<br>
Even greater preference is given to compounds of the general formulas I, la, lb, and<br>
Ic selected from the group consisting of<br>
[1] 2-(4-Amino-3-fluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide;<br>
[2] 2-(3,5-Dibromophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-<br>
3-yl)methyl)acetamide;<br><br>
[3] 2-(4-Amino-3-bromo-5-methoxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide;<br>
[4] 2-(3-Fluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-<br>
yl)methyl)acetamide;<br>
[5] 2-(2,4-Difluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-<br>
3-yl)methyl)acetamide;<br>
[6] 2-(2,6-Difluorophenyl)-N-((2-(4-fnethylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-<br>
3-yl)methyl)acetamide;<br>
[7] 2-(2,5-Difluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-<br>
3-yl)methyl)acetamide;<br>
[8] 2-(4-Fluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-<br>
yl)methyl)acetamide;<br>
[9] 2-(4-Hydroxy-3-methoxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide;<br>
[10] 2-(3,5-Difluorophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-(trifluoromethyl)pyridin-<br>
3-yl)methyl)propanamide;<br>
[11] 2-(3,4-Difluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-<br>
3-yl)methyl)propanamide;<br>
[12] 2-(4-Fluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-<br>
yl)methyl)propanamide;<br>
[13] 2-(3-Fluorophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-(trifluoromethyl)pyridin-3-<br>
yl)methyl)propanamide;<br>
[14] 2-(3,4-Diaminophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-<br>
3-yl)methyl)propanamide;<br>
[15] N-(2-Butoxy-6-tert-butylpyridin-3-ylmethyl)-2-(3,4-diamino-phenyl)-<br>
propionamide;<br><br>
[16] N-((6-tert-Butyl-2-(4-methylpiperidin-1 -yl)pyridin-3-yl)methyl)-2-(3,4-<br>
diaminophenyl)propanamide;<br>
[17] N-((6-tert-Butyl-2-(cyclohexylthio)pyridin-3-yl)methyl)-2-(3,4-<br>
diaminophenyl)propanamide;<br>
[18] 2-(4-Acetamido-3-fluorophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide;<br>
[19] 2-(3,5-Dibromo-4-hydroxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide;<br>
[20] 2-(4-Amino-3,5-dibromophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide;<br>
[21] 2-(3-Bromo-4-hydroxy-5-methoxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide;<br>
[22] 2-(4-Amino-3,5-dibromophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide;<br>
[23] 2-(3,5-Dibromo-4-hydroxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide;<br>
[24] 2-(3-Amino-4-hydroxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide; and<br>
[25] 2-(3,5-Dibromophenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-<br>
[1,2']bipyridinyl-3'-ylmethyl)acetamide;<br>
[26] 2-(4-Amino-3,5-difluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[27] 2-(3-Fluoro-5-hydroxy-4-nitrophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[28] 2-(3-Chloro-4-(methylthio)phenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br><br>
[29] 2-(3-Chloro-4-(methylsulfonyl)phenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[30] 2-(3-Fluoro-4-(methylthio)phenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[31] 2-(3-Fluoro-4-(methylsulfonyl)phenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[32] 2-(4-(N,N-Dimethylsulfamoyl)-3-fluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[33] N-(2-Fluoro-4-(1-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-<br>
yl)methylamino)-1-oxopropane-2-yl)phenyl)acrylamide,<br>
[34] N-(2-Fluoro-6-iodo-4-(1-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-<br>
yl)methylamino)-1-oxopropane-2-yl)phenyl)acrylamide,<br>
[35] 2-(4-Methoxy-3,5-dimethylphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[36] 2-(3,5-Difluoro-4-methoxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[37] 2-(4-Hydroxy-3,5-dimethylphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[38] 2-(3,5-Difluoro-4-hydroxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
each optionally in the form of one of the pure stereoisomers thereof, particularly<br>
enantiomers or diastereoisomers thereof, the racemates thereof or in the form of a<br>
mixture of stereoisomers, particularly the enantiomers and/or diastereoisomers, in an<br>
arbitrary mixing ratio, or each in the form of corresponding salts, or each in the form<br>
of corresponding solvates;<br><br>
Furthermore, preference may be given to compounds according to the invention of<br>
the general formulas I, la, lb and Ic, which in the FLIPR assay using CHO-K1 cells,<br>
which have been transfected with the human VR1 gene in a concentration below<br>
2000 nM, preferably below 1000 nM, more preferably below 300 nM, even more<br>
preferably below 100 nM, still more preferably below 75 nM, \/ery preferably below<br>
50 nM and most preferably below 10 nM, cause a 50 percent displacement of<br>
capsaicin present in a concentration of 100 nM.<br>
In the FLIPR assay, the Ca2+ influx is quantified with the aid of a Ca2+-sensitive dye<br>
(type Fluo-4, Molecular Probes Europe BV, Leiden, Netherlands) in a fluorescent<br>
imaging plate reader (FLIPR, Molecular Devices, Sunnyvale, USA), as described<br>
below.<br>
The invention further relates to a process for the production of compounds of the<br>
above general formula I, according to which at least one compound of the general<br>
formula II,<br><br>
in which R8, U, T, V, and W have the aforementioned meanings, m stands for 0, 1, 2,<br>
or 3, and R stands for hydrogen or for a linear or branched C1-6-alkyl radical, in a<br>
reaction medium, in the presence of at least one reducing agent, preferably in the<br>
presence of at least one reducing agent selected from the group consisting of sodium<br><br>
hydride, sodium, potassium hydride, lithium aluminum hydride, sodium<br>
tetrahydridoborate, and di(isobutyl)aluminum hydride<br>
is converted to at least one compound of the general formula III,<br><br>
in which<br>
R8, U, T, V, and W have the meanings stated above and m stands for 0, 1, 2, or 3,<br>
and this is optionally purified and/or isolated,<br>
and at least one compound of the general formula III is converted, in a reaction<br>
medium in the presence of diphenylphosphorylazide or in the presence of HN3, to at<br>
least one compound of the general formula IV,<br><br>
in which<br>
R8, U, T, V, and W have the meanings stated above and m stands for 0,1,2, or 3,<br>
and this is optionally purified and/or isolated,<br><br>
and at least one compound of the general formula IV is converted, in a reaction<br>
medium in the presence of at least one reducing agent, preferably in the presence of<br>
at least one reducing agent selected from the group consisting of sodium hydride,<br>
potassium hydride, lithium aluminum hydride, sodium tetrahydridoborate, and<br>
di(isobutyl)aluminum hydride,<br>
or in a reaction medium in the presence of a catalyst, preferably in the presence of a<br>
catalyst based on platinum or palladium, more preferably in the presence of<br>
palladium-on-charcoal, and in the presence of hydrogen or in the presence of<br>
hydrazine,<br>
or in a reaction medium in the presence of triphenylphosphine<br>
to at least one compound of the general formula V,<br><br>
in which R8, U, T, V, and W have the meanings stated above and m stands for 0, 1,<br>
2, or 3, and this is optionally purified and/or isolated,<br>
or at least one compound of the general formula VI<br><br><br>
in which<br>
R8, U, T, V, and W have the meanings stated above and m stands for 0, 1,2, or 3, in<br>
a reaction medium is converted,<br>
in the presence of at least one catalyst, preferably in the presence of at least one<br>
catalyst based on palladium or platinum, more preferably in the presence of<br>
palladium-on-charcoal, under a blanket of hydrogen, optionally in the presence of at<br>
least one acid, preferably in the presence of hydrochloric acid,<br>
or in the presence of at least one reducing agent selected from the group consisting<br>
of BH3.S(CH3)2, lithium aluminum hydride, and sodium tetrahydridoborate, optionally<br>
in the presence of NiCl2,<br>
to form at least one compound of the general formula V, optionally in the form of a<br>
corresponding salt, preferably in the form of a corresponding hydrochloride, and this<br>
is optionally purified and/or isolated,<br>
and at least one compound of the general formula V is caused to react with at least<br>
one compound of the general formula VII,<br><br><br>
in which R1, R2, R3, R4, R5, R6, and R7 have the meanings stated above, in a reaction<br>
medium, optionally in the presence of at least one suitable coupling agent, optionally<br>
in the presence of at least one base,<br>
or with at least one compound of the general formula VIII,<br><br>
in which R1, R2, R3, R4, R5, R6, and R7 have the meanings stated above and LG<br>
stands for a leaving group, preferably for a chlorine or bromine atom, in a reaction<br>
medium, optionally in the presence of at least one base, to form at least one<br>
compound of the general formula I,<br><br><br>
in which T, U, V, W, R1, R2, R3, R4, R5, R6, R7, and R8 have the meanings stated<br>
above and n stands for 1, 2, 3, or 4, and this is optionally purified and/or isolated.<br>
The invention further relates to a process for the production of compounds of the<br>
above general formula I, according to which at least one compound of the general<br>
formula II,<br><br>
in which<br>
R8, U, T, V, and W have the meanings stated above, is caused to react with at least<br>
one compound of the general formula VII,<br><br>
in which R1, R2, R3, R4, R5, R6, and R7 have the meanings stated above, in a reaction<br>
medium, optionally in the presence of at least one suitable coupling agent, optionally<br>
in the presence of at least one base,<br>
or with at least one compound of the general formula VIII,<br><br><br>
in which R1, R2, R3, R4, R5, R6, and R7 have the meanings stated above and LG<br>
stands for a leaving group, preferably for a chlorine or bromine atom, in a reaction<br>
medium, optionally in the presence of at least one base, to form at least one<br>
compound of the general formula Im,<br><br>
in which<br>
T, U, V, W, R1, R2, R3, R4, R5, R6, R7, and R8 have the meanings stated above, and<br>
this is optionally purified and/or isolated.<br>
The reaction of compounds of the above general formulas V or X with carboxylic<br>
acids of the above general formula VII to form compounds of the above general<br>
formulas I or Im is carried out preferably in a reaction medium selected from the<br>
group consisting of diethyl ether, tetrahydrofuran, acetonitrile, methanol, ethanol,<br>
(1,2)-dichloroethane, dimethylformamide, dichloromethane and appropriate mixtures<br>
thereof, optionally in the presence of at least one coupling agent, preferably selected<br><br>
from the group consisting of 1-benzotriazolyloxy-tris(dimethylamino)phosphonium<br>
hexafluorophosphate (BOP), dicyclohexylcarbodiimide (DCC), N'-(3-<br>
dimethylaminopropyl)-N-ethylcarbodiimide (EDCI), diisoproylcarbodiimide, 1,1'-<br>
carbonyldiimidazole (CDI), N-[(dimethylamino)-1 H-1,2,3-triazolo[4.5-b]pyridino-1-<br>
ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU), O-<br>
(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU),<br>
0(benzotriazol-1-yl)-N,N,N',N-tetramethyluronium tetrafluoroborate (TBTU), N-<br>
hydroxybenzotriazole (HOBT), and 1-hydroxy-7-azabenzotriazole (HOAt), optionally<br>
in the presence of at least one organic base, preferably selected from the group<br>
consisting of triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine,<br>
and diisopropylethylamine, preferably at temperatures ranging from -70 C to 100 C.<br>
Alternatively, the reaction of compounds of the above general formulas V or X with<br>
carboxylic derivatives of the above general formula VIII, in which LG stands for a<br>
leaving group, preferably for a chlorine or bromine atom, to form compounds of the<br>
above general formulas Ih or Im is carried out in a reaction medium preferably<br>
selected from the group consisting of diethyl ether, tetrahydrofuran, acetonitrile,<br>
methanol, ethanol, dimethylformamide, dichloromethane and appropriate mixtures<br>
thereof, optionally in the presence of an organic or inorganic base, preferably<br>
selected from the group consisting of triethylamine, dimethylaminopyridine, pyridine,<br>
and diisopropylamine, at temperatures ranging from -70 C to 100 C.<br>
The compounds of the above formulas II, III, IV, V, VI, VII, X and VIII are all<br>
commercially available and can be obtained by conventional methods known to the<br>
person skilled in the art.<br><br>
The synthesis of compounds of the general formula VII is described in the paper "4-<br>
(Methylsulfonylamino)phenyl analogues as vanilloid antagonist showing excellent<br>
analgesic activity and the pharmaceutical compositions comprising the same" by J.<br>
W. Lee et al. [WO 2005/003084-A1]. The appropriate sections of this reference are<br>
hereby to be regarded as part of the disclosure.<br>
The conversions described above can each be carried out under usual conditions<br>
well-known to the person skilled in the art, for example, in respect of pressure or<br>
order of addition of the components. Optionally, the optimal procedure under the<br>
respective conditions can be determined by the person skilled in the art using simple<br>
preliminary tests. The intermediates and end products obtained by the<br>
aforementioned reactions can in each case be isolated and/or purified by<br>
conventional methods known to the person skilled in the art, if desired and/or<br>
necessary. Suitable purification techniques are, for example, extraction processes<br>
and chromatographic processes such as column chromatography or preparative<br>
chromatography. All of the process steps described above and the purification and/or<br>
isolation of intermediate or end products can be carried out partially or completely<br>
under a blanket of inert gas, preferably under a blanket of nitrogen.<br>
The substituted compounds according to the invention of the aforementioned general<br>
formulas I, la, lb and Ic, designated below simply as compounds of the general<br>
formula I, and corresponding stereoisomers can be isolated either in the form of the<br>
free bases thereof, the free acids thereof or in the form of corresponding salts,<br>
particularly physiologically compatible salts.<br><br>
The free bases of the respective substituted compounds according to the invention of<br>
the aforementioned general formula I and corresponding stereoisomers can, for<br>
example by reaction with an inorganic or organic acid, preferably with hydrochloric<br>
acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-<br>
toluenesulfonic acid, carbonic acid, formic acid, acetic acid, oxalic acid, succinic acid,<br>
tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid, or<br>
aspartic acid, be converted to the corresponding salts, preferably physiologically<br>
compatible salts. The free bases of the respective substituted compounds of the<br>
aforementioned general formula I and corresponding stereoisomers can be likewise<br>
caused to react with the free acid or a salt of a sugar substitute, such as saccharin,<br>
cyclamate, or acesulfam, to form the corresponding physiologically compatible salts.<br>
Similarly, the free acids of the substituted compounds of the aforementioned general<br>
formula I and corresponding stereoisomers can be caused to react with a suitable<br>
base to form the corresponding physiologically compatible salts. Mention may be<br>
made, for example, of the alkali-metal salts, alkaline earth metal salts, or ammonium<br>
salts [NHXR4-X]+ in which x is equal to 0, 1, 2, 3, or 4, and R stands for a linear or<br>
branched C1-4-alkyl radical.<br>
The substituted compounds according to the invention designated by the<br>
aforementioned general formula I and corresponding stereoisomers can optionally,<br>
like the corresponding acids, the corresponding bases or salts of these compounds,<br>
be obtained in the form of the solvates thereof, preferably in the form of the hydrates<br>
thereof, by conventional methods known to the person skilled in the art.<br><br>
If the substituted compounds according to the invention designated by the<br>
aforementioned general formula I are obtained, following production thereof, in the<br>
form of a mixture of the stereoisomers thereof, preferably in the form of the<br>
racemates thereof or other mixtures of the various enantiomers and/or<br>
diastereoisomers thereof, these compounds can be separated and, if desired,<br>
isolated by methods known to the person skilled in the art. Mention may be made,<br>
for example, of chromatographic separation methods, particularly liquid-<br>
chromatographic methods carried out under standard pressure or at elevated<br>
pressure, preferably MPLC and HPLC methods, and also methods of fractional<br>
crystallization. In particular, individual enantiomers can be separated from each<br>
other, e.g. diastereoisomeric salts formed by means of HPLC on chiral stationary<br>
phase or by means of crystallization with chiral acids, say, (+)-tartaric acid, (-)-tartaric<br>
acid, or (+)-10-camphorsulfonic acid.<br>
The substituted compounds according to the invention designated by the<br>
aforementioned general formula I and corresponding stereoisomers and in each case<br>
the corresponding acids, bases, salts, and solvates are toxicologically safe and are<br>
therefore suitable for use as pharmaceutically active substances in pharmaceuticals.<br>
The invention therefore further relates to a pharmaceutical containing at least one<br>
compound according to the invention of the above general formula I, each optionally<br>
in the form of one of the pure stereoisomers thereof, particularly enantiomers or<br>
diastereoisomers thereof, the racemates thereof or in the form of a mixture of<br>
stereoisomers, particularly the enantiomers and/or diastereoisomers, in an arbitrary<br>
mixing ratio, or each in the form of a corresponding salt, or each in the form of a<br><br>
corresponding solvate, and optionally one or more pharmaceutically compatible<br>
adjuvants.<br>
These pharmaceuticals according to the invention are particularly suitable for<br>
vanilloid receptor 1-(VR1/TRPV1) regulation, preferably vanilloid receptor 1-<br>
(VR1/TRPV1) inhibition and/or vanilloid receptor 1-(VR1/TRPV1) stimulation.<br>
In another preferred embodiment, the pharmaceuticals according to the invention are<br>
suitable for prophylaxis and/or treatment of disorders or diseases that are at least<br>
partially mediated by vanilloid receptors 1.<br>
Preferably, the pharmaceutical according to the invention is suitable for treatment<br>
and/or prophylaxis of one or more disorders selected from the group consisting of<br>
pain selected from the group consisting of acute pain, chronic pain, neuropathic pain<br>
and visceral pain; arthralgia; hyperalgesia; allodynia; causalgia; migraine; states of<br>
depression; nervous disorders; neurotraumas; neurodegenerative disorders,<br>
preferably selected from the group consisting of multiple sclerosis, Morbus<br>
Alzheimer, Morbus Parkinson, and Morbus Huntington; cognitive dysfunctions,<br>
preferably cognitive deficiency states, more preferably memory defects; epilepsy;<br>
respiratory tract diseases, preferably selected from the group consisting of asthma,<br>
bronchitis, and pneumonia; coughing; urinary incontinence; an overactive bladder<br>
(OAB); disorders and/or injuries of the gastrointestinal tract; duodenal ulcers; gastric<br>
ulcers; colitis syndrome; apoplectic strokes; eye irritations; cutaneous irritations;<br>
neurotic skin conditions; allergic skin diseases; psiorasis; vitiligo; Herpes simplex;<br>
inflammations, preferably inflammation of the intestine, the eyes, the bladder, the<br>
skin, or the nasal mucosa; diarrhea; pruritus; osteoporosis; arthritis; osteo-arthritis;<br><br>
rheumatic disorders; food intake disorders, preferably selected from the group<br>
consisting of bulimia, cachexia, anorexia, and obesity; medicine addiction; medicine<br>
abuse; withdrawal phenomena following medicine addiction; tolerance development<br>
to pharmaceuticals, particularly to natural or synthetic opioids; drug addiction; drug<br>
abuse; withdrawal phenomena following drug addiction; alcohol addiction; alcohol<br>
abuse and withdrawal phenomena following alcohol addiction; for diuresis; for<br>
antinatriuresis; for affection of the cardiovascular system; for vigilance enhancement;<br>
for treatment of wounds and/or burning; for treatment of severed nerves; for libido<br>
enhancement; for modulation of movement activity; for anxiolysis; for local<br>
anesthesia and/or for inhibition of undesirable side effects, preferably selected from<br>
the group consisting of hyperthermia, hypertension, and bronchial constriction, as<br>
caused by administration of vanilloid receptor 1 (VR1/TRPV1 receptor) agonists,<br>
preferably selected from the group consisting of capsaicin, resiniferatoxin, olvanil,<br>
arvanil, SDZ-249665, SDZ-249482, nuvanil, and capsavanil.<br>
The pharmaceutical according to the invention is particularly preferably suitable for<br>
treatment and/or prophylaxis of one or more disorders selected from the group<br>
consisting of pain, preferably pain selected from the group consisting of acute pain,<br>
chronic pain, neuropathic pain, and visceral pain; arthralgia; migraine; states of<br>
depression; neurodegenerative disorders, preferably selected from the group<br>
consisting of multiple sclerosis, Morbus Alzheimer, Morbus Parkinson, and Morbus<br>
Huntington; cognitive dysfunctions, preferably cognitive deficiency states, more<br>
preferably memory defects; inflammation, preferably inflammation of the intestine, the<br>
eyes, the bladder, the skin or the nasal mucosa; urinary incontinence; an overactive<br>
bladder (OAB); medicine addiction; medicine abuse; withdrawal phenomena<br>
following medicine addiction; tolerance development to pharmaceuticals, preferably<br><br>
tolerance development to natural or synthetic opioids; drug addiction; drug abuse;<br>
withdrawal phenomena following drug addiction; alcohol addiction; alcohol abuse and<br>
withdrawal phenomena following alcohol addiction.<br>
The pharmaceutical according to the invention is most preferably suitable for<br>
treatment and/or prophylaxis of pain, preferably pain selected from the group<br>
consisting of acute pain, chronic pain, neuropathic pain, and visceral pain, and/or<br>
urinary incontinence.<br>
The invention further relates to the use of at least one compound according to the<br>
invention and optionally one or more pharmaceutically compatible adjuvants for the<br>
production of a pharmaceutical for vanilloid receptor 1-(VR1/TRPV1) regulation,<br>
preferably vanilloid receptor 1-(VR1/TRPV1) inhibition and/or vanilloid receptor 1-<br>
(VR1/TRPV1) stimulation.<br>
Preference is given to the use of at least one substituted compound according to the<br>
invention and optionally one or more pharmaceutically compatible adjuvants for the<br>
production of a pharmaceutical for the prophylaxis and/or treatment of disorders or<br>
diseases which are at least partially mediated by vanilloid receptors 1.<br>
Particular preference is given to the use of at least one compound according to the<br>
invention and optionally one or more pharmaceutically compatible adjuvants for the<br>
production of a pharmaceutical for treatment and/or prophylaxis of one or more<br>
disorders selected from the group consisting of pain, preferably of pain selected from<br>
the group consisting of acute pain, chronic pain, neuropathic pain, visceral pain, and<br>
arthralgia.<br><br>
Particular preference is given to the use at least one compound according to the<br>
invention and optionally one or more pharmaceutically compatible adjuvants for the<br>
production of a pharmaceutical for treatment and/or prophylaxis of one or more<br>
disorders selected from the group consisting of hyperalgesia; allodynia; causalgia;<br>
migraine; states of depression; nervous disorders; neurotraumas; neurodegenerative<br>
disorders, preferably selected from the group consisting of multiple sclerosis, Morbus<br>
Alzheimer, Morbus Parkinson, and Morbus Huntington; cognitive dysfunctions,<br>
preferably cognitive deficiency states, more preferably memory defects; epilepsy;<br>
respiratory tract diseases, preferably selected from the group consisting of asthma,<br>
bronchitis, and pneumonia; coughing; urinary incontinence; an overactive bladder<br>
(OAB); disorders and/or injuries of the gastrointestinal tract; duodenal ulcers; gastric<br>
ulcers; colitis syndrome; apoplectic strokes; eye irritations; cutaneous irritations;<br>
neurotic skin conditions; allergic skin diseases; psiorasis; vitiligo; Herpes simplex;<br>
inflammation, preferably inflammation of the intestine, the eyes, the bladder, the skin,<br>
or the nasal mucosa; diarrhea; pruritus; osteoporosis; arthritis; osteo-arthritis;<br>
rheumatic disorders; food intake disorders, preferably selected from the group<br>
consisting of bulimia, cachexia, anorexia, and obesity; medicine addiction; medicine<br>
abuse; withdrawal phenomena following medicine addiction; tolerance development<br>
to pharmaceuticals, preferably to natural or synthetic opioids; drug addiction; drug<br>
abuse; withdrawal phenomena following drug addiction; alcohol addiction; alcohol<br>
abuse and withdrawal phenomena following alcohol addiction; for diuresis; for<br>
antinatriuresis; for affection of the cardiovascular system; for vigilance enhancement;<br>
for treatment of wounds and/or burning; for treatment of severed nerves; for libido<br>
enhancement; for modulation of movement activity; for anxiolysis; for local<br>
anesthesia and/or for inhibition of undesirable side effects, preferably selected from<br><br>
the group consisting of hyperthermia, hypertension, and bronchial constriction, as<br>
caused by administration of vanilloid receptor 1 (VR1/TRPV1 receptor) agonists,<br>
preferably selected from the group consisting of capsaicin, resiniferatoxin, olvanil,<br>
arvanil, SDZ-249665, SDZ-249482, nuvanil, and capsavanil.<br>
Very particular preference is given to the use of at least one substituted compound<br>
according to the invention and optionally one or more pharmaceutically compatible<br>
adjuvants for the production of a pharmaceutical for treatment and/or prophylaxis of<br>
one or more disorders selected from the group consisting of pain, preferably pain<br>
selected from the group consisting of acute pain, chronic pain, neuropathic pain, and<br>
visceral pain; arthralgia; migraine; states of depression; neurodegenerative disorders,<br>
preferably selected from the group consisting of multiple sclerosis, Morbus<br>
Alzheimer, Morbus Parkinson, and Morbus Huntington; cognitive dysfunctions,<br>
preferably cognitive deficiency states, more preferably memory defects;<br>
inflammation, preferably inflammation of the intestine, the eyes, the bladder, the skin,<br>
or the nasal mucosa; urinary incontinence; an overactive bladder (OAB); medicine<br>
addiction; medicine abuse; withdrawal phenomena following medicine addiction;<br>
tolerance development to pharmaceuticals, preferably tolerance development to<br>
natural or synthetic opioids, drug addiction; drug abuse; withdrawal phenomena<br>
following drug addiction; alcohol addiction; alcohol abuse and withdrawal phenomena<br>
following alcohol addiction.<br>
Even more preference is given to the use of at least one substituted compound<br>
according to the invention and optionally one or more pharmaceutically compatible<br>
adjuvants for the production of a pharmaceutical for treatment and/or prophylaxis of<br><br>
pain, preferably selected from the group consisting of acute pain, chronic pain,<br>
neuropathic pain, and visceral pain, and/or urinary incontinence.<br>
The pharmaceutical according to the invention is suitable for administration to adults<br>
and children including infants and babies.<br>
The pharmaceutical according to the invention can exist as a liquid, semisolid, or<br>
solid pharmaceutical dosage form, for example, in the form of injection fluids, drops,<br>
juices, syrups, sprays, suspensions, tablets, patches, capsules, plasters,<br>
suppositories, ointments, creams, lotions, gels, emulsions, or aerosols, or in a<br>
multiparticular form, for example, in the form of pellets or granules, optionally<br>
compressed to tablets, filled into in capsules, or suspended in a liquid, and can be<br>
administered as such.<br>
In addition to at least one substituted compound of the above general formula I,<br>
optionally in the form of a pure stereoisomer thereof, particularly an enantiomer or<br>
diastereoisomer, the racemate thereof or in the form of mixtures of the<br>
stereoisomers, particularly the enantiomers or diastereoisomers, in an arbitrary<br>
mixing ratio, or optionally in the form of a corresponding salt or each in the form of a<br>
corresponding solvate, the pharmaceutical according to the invention usually<br>
contains further physiologically compatible pharmaceutical adjuvants, which, for<br>
example, can be selected from the group consisting of vehicles, fillers, solvents,<br>
diluents, surfactants, dyes, preservatives, blasting agents, slip agents, lubricants,<br>
flavors, and binding agents.<br><br>
The selection of the physiologically compatible adjuvants and the amount thereof to<br>
be used depends on whether the pharmaceutical is to be applied orally,<br>
subcutaneously, parenterally, intravenously, intraperitoneally, intradermally,<br>
intramuscularly, intranasally, buccally, rectally or locally, e.g. to infected parts of the<br>
skin, the mucous membrane, or the eyes. Preparations suitable for oral<br>
administration are preferably in the form of tablets, dragees, capsules, granules,<br>
pellets, drops, juices, and syrups, and preparations suitable for parenteral, topical<br>
and inhalative administration are solutions, suspensions, readily reconstitutable dry<br>
preparations, and sprays. The substituted compounds according to the invention<br>
used in the pharmaceutical according to the invention in a depot in dissolved form or<br>
in a plaster, optionally with the addition of skin penetration-enhancing agents, are<br>
suitable percutaneous administration forms. Formulations for oral or percutaneous<br>
application may be such as to effect delayed release of the respective substituted<br>
compound according to the invention.<br>
The production of the pharmaceutical according to the invention is effected by<br>
conventional means, devices, methods, and processes, as are known in the prior art,<br>
such as are described, for example, in "Remington's Pharmaceutical Sciences",<br>
Editor A.R. Gennaro, 17th Edition, Mack Publishing Company, Easton, Pa, 1985,<br>
particularly in Section 8, Chapters 76 to 93. The corresponding description is<br>
incorporated herein by reference and is to be regarded as part of the disclosure. The<br>
amount of the respective substituted compounds according to the invention of the<br>
above general formula I to be administered to the patients can vary and is<br>
dependent, for example, on the weight or age of the patient and also on the method<br>
of administration, the indication, and the severity of the disorder. Usually from 0.001<br>
to 100 mg/kg, preferably from 0.05 to 75 mg/kg and more preferably from 0.05 to 50<br><br>
mg/kg, of body weight of the patient of at least one such compound according to the<br>
invention are administered.<br><br>
Pharmacological methods:<br>
I. Functional investigation on the vanilloid receptor 1 (VRI/TRPV1 receptor)<br>
The agonistic or antagonistic action of the substances to be investigated on the<br>
vanilloid receptor 1 (VR1/TRPV1) of the species rat can be determined using the<br>
following assay. According to this assay, the Ca2+ influx through the receptor<br>
channel is quantified with the aid of a Ca2+-sensitive dye (Type Fluo-4, Molecular<br>
Probes Europe BV, Leiden Netherlands) in a fluorescent imaging plate reader<br>
(FLIPR, Molecular Devices, Sunnyvale, USA).<br>
Method:<br>
Complete medium: 50 mL of HAMS F12 Nutrient Mixture (Gibco Invitrogen GmbH,<br>
Karlsruhe, Germany) with<br>
10% by volume of FCS (fetal calf serum, Gibco Invitrogen GmbH, Karlsruhe,<br>
Germany, heat-inactivated);<br>
2mM of L-glutamine (Sigma, Munich, Germany);<br>
1% by weight of AA solution (antibiotics/antimycotics solution, PAA, Pasching,<br>
Austria)<br>
and 25 ng/mL of Medium NGF (2.5 S, Gibco Invitrogen GmbH, Karlsruhe, Germany)<br>
Cell culture plate: Poly-D-lysine-coated, black 96-well plates with a clear bottom (96-<br>
well black/clear plate, BD Biosciences, Heidelberg, Germany) are additionally coated<br>
with laminin (Gibco Invitrogen GmbH, Karlsruhe, Germany) by diluting laminin to a<br>
concentration of 100 g/mL with PBS (Ca-Mg-free PBS, Gibco Invitrogen GmbH,<br><br>
Karlsruhe, Germany). Aliquots having a concentration of 100 g/mL of laminin are<br>
taken and stored at -20 C. The aliquots are diluted with PBS in the ratio 1:10 to<br>
10 g/mL of laminin and in each case 50 uL of the solution is pipeted into a well of<br>
the cell culture plate. The cell culture plates are incubated at 37 C for at least two<br>
hours, the supernatant solution is aspirated and the wells are in each case washed<br>
twice with PBS. The coated cell culture plates are stored with supernatant PBS and<br>
this is removed only directly before the addition of the cells.<br>
Preparation of the cells:<br>
The vertebral column is removed from decapitated rats and this is laid directly in a<br>
cold, i.e. ice bath-surrounded, HBSS buffer (Hank's buffered saline solution, Gibco<br>
Invitrogen GmbH, Karlsruhe, Germany) and 1% by volume of an AA solution<br>
(antibiotics/antimycotics solution, PAA, Pasching, Austria) is added. The vertebral<br>
column is cut in two, longitudinally, and the vertebral canal is removed together with<br>
fascias. Subsequently, the dorsal root ganglia (DRGs) are removed and in turn<br>
stored in cold HBSS buffer to which 1% by volume of an AA solution has been<br>
added. The DRGs completely freed from blood residues and spinal nerves are in<br>
each case transferred to 500 L of cold collagenase Type 2 (PAA, Pasching, Austria)<br>
and incubated at 37 C for 35 minutes. After the addition of 2.5% by volume of trypsin<br>
(PAA, Pasching, Austria), the preparation is incubated at 37 C for a further 10<br>
minutes. On completion of incubation, the enzyme solution is carefully pipeted off<br>
and 500 uL of complete medium are added to the DRGs in each case. The DRGs are<br>
in each case repeatedly suspended, drawn through No. 1, No. 12, and No. 16<br>
needles by means of a syringe and transferred to 50 mL Falcon tubes and these are<br><br>
filled to 15 mL with complete medium. The contents of each Falcon tube are in each<br>
case filtered through a 70 m Falcon filter insert and centrifuged at 1200 rpm and RT<br>
for 10 minutes. The resulting pellet is in each case taken up in 250 L of complete<br>
medium and the cell count is determined.<br>
The number of cells in the suspension is adjusted to 3 x 105 per mL and in each case<br>
150 L of this suspension are added to a well of the cell culture plates coated as<br>
described above. The plates are allowed to stand at 37 C, 5% by volume of CO2 and<br>
95% relative humidity for two to three days in an incubator.<br>
Subsequently, the cells are loaded with 2 M of Fluo-4 and 0.01% by volume of<br>
Pluronic F127 (Molecular Probes Europe BV, Leiden Netherlands) in HBSS buffer<br>
(Hank's buffered saline solution, Gibco Invitrogen GmbH, Karlsruhe, Germany) at<br>
37C for 30 min, washed 3 times with HBSS buffer and, after a further incubation of<br>
15 minutes at RT, employed in the FLIPR assay for Ca2+ measurement. The Ca2+-<br>
dependent fluorescence is measured before and after addition of substances (ex =<br>
488 nm, em = 540 nm). Quantification is carried out by measuring the highest<br>
fluorescence intensity (FC, fluorescence counts) over time.<br>
FLIPR assay:<br>
The FLIPR protocol consists of two substance additions. Initially, the compounds to<br>
be tested (10 M) are pipeted onto the cells and the Ca2+ influx is compared with the<br>
control (capsaicin 10 M). Information is gained therefrom in percentage activation<br>
relative to the Ca2+ signal after addition of 10 M of capsaicin (CP). After incubation<br>
for 5 minutes, 100 nM of capsaicin are applied and the influx of Ca2+ is likewise<br><br>
determined.<br>
Desensitizing agonists and antagonists lead to suppression of the Ca2+ influx. The<br>
percentage inhibition is calculated in comparison with the maximum inhibition<br>
achieved with 10 M of capsaicin.<br>
Triple determinations (n=3) are carried out and these are repeated in at least 3<br>
independent experiments (N=4).<br>
Based on the percentage displacement effected by different concentrations of the<br>
compounds of the general formula I to be tested, IC50 inhibition concentrations that<br>
cause 50 percent displacement of capsaicin are calculated. Conversion using the<br>
Cheng Prusoff equation gave Ki values for the test substances (Cheng, Prusoff;<br>
Bioch. Pharmacol. 22, 3099-3108, 1973).<br>
II. Functional investigations on the vanilloid receptor (VR1)<br>
The agonistic or antagonistic action of the substances to be examined on the<br>
vanilloid receptor (VR1) can also be determined by the following assay. According to<br>
this assay, the Ca2+ influx through the canal is quantified with the aid of a Ca2+-<br>
sensitive dye (type Fluo-4, Molecular Probes, Europe BV, Leiden, Netherlands) in a<br>
fluorescent imaging plate reader (FLIPR, Molecular Devices, Sunnyvale, USA).<br>
Method:<br>
Chinese hamster ovary cells (CHO-K1 cells, European Collection of Cell Cultures<br>
(ECACC) UK) are stably transfected with the VR1 gene. For carrying out functional<br>
investigations, these cells are plated on poly-D-lysine-coated, black 96-well plates<br><br>
with a clear bottom (BD Biosciences, Heidelberg, Germany) in a density of 25,000<br>
cells/well. The cells are incubated overnight at 37 C and 5% CO2 in a culture<br>
medium (Nutrient Mixture 'am's F12, 10% by volume of FCS (fetal calf serum),<br>
18 g/mL of L-proline). On the following day the cells are incubated with Fluo-4 (Fluo-<br>
4 2 M, Pluronic F127 0.01 by volume, Molecular Probes in HBSS (Hank's buffered<br>
saline solution), Gibco Invitrogen GmbH, Karlsruhe, Germany) for 30 minutes at<br>
37 C. The plates are then washed 3 times with HBSS buffer and, after another<br>
incubation over a period of 15 minutes at RT, are used in the FLIPR for Ca2+<br>
measurement. The Ca2+-dependent fluorescence is measured prior to and following<br>
the addition of the substances being examined (wavelength ex = 488 nm, em = 540<br>
nm). Quantification is carried out by measuring the highest fluorescence intensity<br>
(FC, fluorescence counts) over time.<br>
FLIPR assay:<br>
The FLIPR protocol consists of two substance additions. First of all, the substances<br>
to be tested (10 M) are pipeted onto the cells and the Ca2+ influx is compared with<br>
the control (capsaicin 10 M) (percentage activation based on the Ca2+ signal<br>
following addition of 10 M of capsaicin). Following incubation over a period of 5<br>
minutes 100 nM of capsaicin are applied and the influx of Ca2+ is likewise<br>
determined.<br>
Desensitizing agonists and antagonists led to a suppression of the Ca2+ influx. The<br>
percentage inhibition compared with the maximum inhibition achieved with 10 M of<br>
capsaicin is calculated.<br><br>
Based on the percentage displacement effected by different concentrations of the<br>
compounds of the general formula I to be tested, IC50 inhibition concentrations that<br>
cause 50 percent displacement of capsaicin are calculated. Conversion using the<br>
Cheng Prusoff equation gave Ki values for the test substances (Cheng, Prusoff;<br>
Bioch. Pharmacol. 22, 3099-3108, 1973).<br>
III. Formalin test on mice<br>
The investigation for the determination of the antinociceptive action of the<br>
compounds according to the invention is carried out in the formalin test on male mice<br>
(NMRI, of 20 to 30 g body weight, Iffa, Credo, Belgium).<br>
In the formalin test, the first (early) phase (0 to 15 minutes after the formalin injection)<br>
and the second (late) phase (15 to 60 minutes after the formalin injection) are<br>
distinguished according to D. Dubuisson et al., Pain 1977, 4, 161-174. The early<br>
phase, as a direct reaction to the formalin injection, is a model of acute pain, whereas<br>
the late phase is regarded as a model of persistent (chronic) pain (T.J. Coderre et al.,<br>
Pain 1993, 52, 259-285). The appropriate literature references are incorporated<br>
herein by reference and are to be regarded as part of the disclosure.<br>
The compounds according to the invention are examined in the second phase of the<br>
formalin test, in order to obtain information concerning a substance's action on<br>
chronic/inflammatory pain.<br>
The point in time of administration of the compounds according to the invention<br>
before the formalin injection is selected according to the method of administration of<br><br>
the compounds according to the invention. Intravenous administration of 10 mg/kg of<br>
body weight of the test substances is carried out 5 minutes before the formalin<br>
injection. This is carried out by a single subcutaneous formalin injection (20 L, 1%<br>
strength aqueous solution) into the dorsal side of the right hind paw so that in the<br>
case of free-moving experimental animals a nociceptive reaction is induced which is<br>
manifested by marked licking and biting of the relevant paw.<br>
The nociceptive behavior is then continuously registered during an investigation<br>
period of three minutes in the second (late) phase of the formalin test (21 to 24<br>
minutes after the formalin injection) by observation of the animals. Quantification of<br>
the pain behavior is carried out by summating the seconds during which the animals<br>
exhibit licking and biting of the relevant paw during the investigation period.<br>
In each case, comparison is carried out with control animals, which receive, instead<br>
of the compounds according to the invention, a vehicle (0.9% strength aqueous<br>
sodium chloride solution) prior to formalin administration. Based on the quantification<br>
of the pain behavior, the substance's action in the formalin test is determined as the<br>
degree of change compared with the corresponding control in percent.<br>
Following injection of the substances having an antinociceptive action in the formalin<br>
test, the aforementioned behavioral patterns of the animals, i.e. licking and biting,<br>
decrease or cease.<br>
IV. Test for analgesic effectiveness in the writhing test<br><br>
Investigation of the compounds of the general formula I according to the invention for<br>
analgetic effectiveness was carried out based on phenylquinone-induced writhing in<br>
mice, modified in accordance with I.e. Hendershot and J. Forsaith (1959) J.<br>
Pharmacol. Exp. Ther. 125, 237-240. The corresponding literature reference is<br>
incorporated herein by reference and is to be regarded as part of the disclosure.<br>
For this purpose, male NMRI mice having a weight of from 25 to 30 g were used.<br>
Groups of 10 animals per dose of the test compound received by intraperitoneal<br>
administration, 10 minutes after intravenous administration of the compounds to be<br>
tested, 0.3 mL/mouse of a 0.02% strength aqueous solution of phenylquinone<br>
(phenylbenzoquinone, Sigma, Deisenhofen, Germany and produced by adding to the<br>
solution 5% by weight of ethanol and storing it in a water bath at 45 C). The animals<br>
were placed individually in observation cages. With the aid of a pushbutton counter,<br>
the number of pain-induced stretching movements (so-called writhing reactions -<br>
straightening of the body with stretching of the rear extremities) was counted over a<br>
period of from 5 to 20 minutes following the administration of the phenylquinone. The<br>
control was provided by animals receiving only physiological saline. All of the<br>
compounds were tested using the standard dosage of 10 mg/kg.<br>
V. Hypothermia assay in mice<br>
Description of the method:<br>
The hypothermia assay was carried out on male NMRI mice (weight 25-35 gram,<br>
breeder IFFA CREDO, Brussels, Belgium). The animals were kept under<br>
standardized conditions: light/dark rhythm (from 6:00 to 18:00 hours light phase; from<br>
18:00 to 6:00 hours dark phase), RT 19-22 C, relative air humidity 35-70 %, 15 air<br><br>
changes per hour, air movement 
(ssniff R/M-Haltung, ssniff Spezialdiaeten GmbH, Soest, Germany) and tap water.<br>
Water and feed were withdrawn during the experiment. All animals were used only<br>
once during the experiment. The animals had an acclimatization period of at least 5<br>
days.<br>
Acute administration of capsaicin (VR-1 agonist) leads to a drop in the core<br>
temperature of the body in rats and mice due to stimulation of heat sensors. Only<br>
specifically effective VR-1 receptor antagonists can antagonize the capsaicin-induced<br>
hypothermia. By contrast, hypothermia induced by morphine is not antagonized by<br>
VR-1 antagonists. This model is therefore suitable for identifying substances with VR-<br>
1 antagonistic properties via their effect on body temperature.<br>
Measurement of the core temperature is carried out using a digital thermometer<br>
(Thermalert TH-5, physitemp, Clifton NJ, USA). The sensing element is inserted into<br>
the rectum of the animals.<br>
To give an individual basic value for each animal, the body temperature is measured<br>
twice at an interval of approximately half an hour. One group of animals (n = 6 to 10)<br>
then receives an intraperitoneal (i.p.) application of capsaicin 3 mg/kg and vehicle<br>
(control group). Another group of animals receives the substance to be tested (i.v. or<br>
p.o.) and additionally capsaicin (3 mg/kg) i.p. The administration of the test<br>
substance is carried out i.v. 10 min, or p.o 15 minutes, prior to capsaicin. The body<br>
temperature is then measured 7.5/15 and 30 min following capsaicin (i.v. + i.p.) or<br>
15/30/60/90/120 min (p.o. + i.p.) following capsaicin. In addition, one group of<br>
animals is treated with the test substance only and one group with vehicle only. The<br><br>
evaluation or representation of the measured values as mean +/- SEM of the<br>
absolute values is presented as a graphical representation. The antagonistic action is<br>
calculated as the percentage reduction of the capsaicin-induced hypothermia.<br>
VI. Neuropathic pain in mice<br>
The investigation on effectiveness on neuropathic pain was examined using the<br>
Bennett Model (chronic constriction injury; Bennett und Xie, 1988, Pain 33:87-107).<br>
Three loose ligatures are tied around the right ischiadic nerve of Ketavet/Rompun-<br>
anesthetized NMRI mice weighing 16-18 g. The animals develop hypersensitivity of<br>
the nervate paw caused by the damaged nerve, which hypersensitivity is quantified,<br>
following a recovery phase of one week, over a period of approximately three weeks<br>
by means of a cold metal plate (temperature 4 C) (cold allodynia). The animals are<br>
observed on this plate over a period of 2 min, and the withdrawal reactions of the<br>
damaged paw are counted. Based on the pre-value prior to administration of<br>
substance, the substance's action over a certain period of time is determined at<br>
various points in time (e.g., 15, 30, 45, or 60 min following administration) and the<br>
resultant area under the curve (AUC) and/or the inhibition of cold allodynia at the<br>
individual measuring points was/were expressed as percentage action relative to the<br>
vehicle control (AUC) or to the starting value (individual measuring points). The group<br>
size is n= 10, the significance of an anti-allodynic action (*= p 
with the aid of an analysis of variance with repeated measurement and Bonferroni<br>
post hoc analysis.<br><br>
The invention is described below with reference to some examples. These<br>
explanations are by way of example only and do not restrict the general inventive<br>
concept.<br><br>
Examples:<br>
The yields of the compounds produced were not optimized.<br>
All temperatures are uncorrected.<br>
The statement "equivalents" denotes mol equivalents, "RT" room temperature, "M"<br>
and "N" are concentrations in mol/L, "aq." aqueous, "sat." saturated, "soln." solution,<br>
Further abbreviations:<br>
AcOH	acetic acid<br>
DCM	dichloromethane<br>
DMF	N,N-dimethylformamide<br>
EDCI	N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride<br>
EA	ethyl acetate<br>
H2O	water<br>
HOBt	N-hydroxybenzotriazole<br>
MeOH	methanol<br>
THF	tetrahydrofuran<br>
The chemicals and solvents used were obtained commercially from the usual<br>
suppliers (Acros, Avocado, Aldrich, Bachem, Fluka, Lancaster, Maybridge, Merck,<br>
Sigma, TCI, Oakwood etc.) or synthesized by usual methods known to the person<br>
skilled in the art.<br><br>
The stationary phase used for column chromatography was silica gel 60 (0.0-0 -<br>
0.063 mm) supplied by E. Merck, Darmstadt.<br>
The thin-layer chromatographic analyses were carried out using preformed HPTLC<br>
plates, Silica Gel 60 F 254, supplied by E. Merck, Darmstadt.<br>
The mixing ratios of solvents, mobile solvents, or for chromatographic analyses are<br>
always stated in vol/vo!.<br>
Analysis was carried out by mass spectroscopy and NMR.<br>
1. General instructions for the preparation of amines of the general formula V-<br>
A.<br>
Preparation of amines of the general formula V-A is carried out as illustrated by the<br>
following scheme 1.<br><br>
Stage 1: Preparation of nitriles of the general formula Vl-B<br>
Method A:<br><br>
Compounds of the general formula Vl-A (1 equivalent), in which R8, U, T, and V have<br>
the meanings stated above and m stands for 0,1,2, or 3, are stirred with an amine of<br>
the general formula HNR40R41 (6 equivalents) over a period of 48 hours at RT. To the<br>
reaction mixture there is added 1N hydrochloric acid, and the mixture is extracted<br>
with EA a number of times. The aqueous phase is saturated with NaCI and then<br>
again extracted with EA. The combined organic phases are washed with 1N<br>
hydrochloric acid and with sat. aq. NaCI soln., dried over MgSO4, and the solvent is<br>
removed in vacuo.<br>
The following compound was obtained by method A:<br>
6'-tert-Butyl-4-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carbonitrile<br><br>
1H-NMR(CDCI3)  7.65 (d, 1H, J = 7.9 Hz, Ar), 6.70 (d, 1H, J = 8.0 Hz, Ar), 4.45 (m,<br>
2H, piperidine), 2.98 (m, 2H, piperidine), 1.75-1.24 (m, 5H, piperidine), 1.29 (s, 9H,<br>
C(CH3)3), 0.98 (d, 3H, J = 5.9 Hz, CHCH3)<br>
IR 2956, 2213, 1583, 1550, 1452, 1230, 965 crrT1<br>
Method B:<br>
Compounds of the general formula Vl-A (1 equivalent), in which R8, U, T, and V have<br>
the meanings stated above and m stands for 0,1,2, or 3, are stirred with an amine of<br><br>
the general formula HNR40R41 (2 equivalents) and DBU [1.8-diaza-<br>
bicyclo[5.4.0]undec-7-ene] (2 equivalents) in acetonitrile (7 mL per mmol of the<br>
compound of formula Vl-A) over a period of 12 hours at RT. The reaction mixture is<br>
extracted with EA a number of times. The combined organic phases are washed with<br>
sat. aq. NaCI solution, dried over MgSO4, and the solvent is removed in vacuo. The<br>
residue is purified in each case by column chromatography (SiO2, various mixtures of<br>
hexane/EA).<br>
The following compound was produced by method B.<br>
6-(Trifluoromethyl)-2-(4-methylpiperidin-1-yl)pyridine-3-carbonitrile<br><br>
1H NMR (300 M Hz, CDCI3)  7.87 (d, 1 h, J = 7.8 Hz), 6.95 (d, 1 h, J = 7.8 Hz), 4.53<br>
(m, 2 H), 3.05 (m, 2 H), 1.78 (m, 2 H), 1.64 (m, 1 H), 1.29 (m, 2 H), 1.00 (d, 3 H, J =<br>
6.6 Hz); IR (PUR) 2926, 2852, 2218, 1590, 1497, 1456, 1324, 1237, 1186, 1147,<br>
1082, of 963 cm-1; MS (FAB) m/z 270 (M+H)<br>
Step 2:<br>
Method 1<br>
Compounds of the general formula Vl-B (5 mmol), in which R8, R40, R41, U, T, and V<br>
have the meanings stated above and m stands for 0, 1, 2, or 3, palladium-on-<br>
charcoal (10%, 500 mg) and conc, hydrochloric acid (3 mL) are dissolved in MeOH<br><br>
(30 mL) and exposed to a hydrogen atmosphere over a period of 6 hours at RT. The<br>
reaction mixture is filtered over Celite and the filtrate is concentrated in vacuo. The<br>
residue is purified by means of flash chromatography (SiO2, EA).<br>
Method 2:<br>
Compounds of the general formula Vl-B (2 mmol), in which R8, R40, R41, U, T, and V<br>
have the meanings stated above and m stands for 0, 1, 2, or 3, are dissolved in THF<br>
(10 mL, 10 mL), and BH3'S(CH3)2 [2.0 M in THF, 3 mL, 3 equivalents] is added. The<br>
reaction mixture is heated under reflux over a period of 8 hours, aq. HCI (2N) is<br>
added and the reaction mixture is again heated under reflux for 30 minutes. Aq.<br>
sodium hydroxide solution (2N) is added to the reaction mixture, and the mixture is<br>
washed with EA. The combined organic phases are washed with sat. aq. NaCI<br>
solution and dried over magnesium sulfate. The solvent is removed in vacuo and the<br>
residue purified by column chromatography (SiO2, various mixtures of<br>
dichloromethane and MeOH as mobile solvent).<br>
The following compounds were obtained by method 2.<br>
(6-(Trifluoromethyl)-2-(4-methylpiperidin-1-yl)pyridin-3-yl)methanamine<br><br><br>
1H NMR (300 M Hz, CDCI3)  7.89 (d, 1 H, J = 7.8 Hz), 7.33 (d, 1H, J = 7.8 Hz), 3.88<br>
(s, 2H), 3.39 (m, 2 H), 2.83 (m, 2 H), 1.75 (m, 2 H), 1.55 (m, 1 H), 1.38 (m, 2 H), 1.00<br>
(d, 3 H, J = 6.6 Hz); MS (FAB) m/z 274(M+H)<br>
C-(6'-tert-Butyl-4-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-yl)-<br>
methylamine<br><br>
1H-NMR (CDCI3)  7.48 (d, 1H, J = 7.7 Hz, Ar), 6.90 (d, 1H, J = 7.7 Hz, Ar), 3.82 (s,<br>
2H, CH2NH2), 3.38 (m, 2H, piperidine), 2.81 (m, 2H, piperidine), 1.73-1.28 (m, 5H,<br>
piperidine), 1.31 (s, 9H, C(CH3)3), 0.98 (d, 3H, J = 6.4 Hz, CHCH3)<br>
IR 3363, 2954, 1571, 1451, 1400, 1372, 1234, 960 cm"1<br>
2. General instructions for the preparation of amines of the general formula V-E<br>
The preparation of amines of the general formula V-E is carried out as illustrated in<br>
the following scheme 2.<br><br>
Scheme 2.<br><br>
Step 1:<br>
Synthesis of 2-(cyclohexylthio)-6-(trifluoromethyl)nicotinonitrile<br><br>
1.3 Equivalents of NaH (4.9 g, 0.124 mol) were dissolved in 50 mL of DMF under a<br>
blanket of nitrogen. Following the addition of 1.2 equivalents of cyclohexanethiol<br>
(14.2 mL, 0.116 mol), the mixture was stirred at RT over a period of 1.5 h. The<br>
resulting suspension was cooled to 10 C and added dropwise to 1 equivalent of 2-<br>
chloro-6-(trifluoromethyl)nicotinonitrile (20 g, 0.096 mol) in 50 mL of DMF and stirred<br>
over a period of 2 h at RT. To the reaction mixture there was added sat. aq. NH4CI<br>
soln. and the mixture was diluted with 1 L of water and extracted with EA (3 x 200<br>
mL) a number of times. The combined organic phases were washed with sat. aq.<br>
NaCI solution, dried over MgSO4 and concentrated in vacuo. Column<br>
chromatographic purification (silica gel 100-200 mesh, eluant: 2% EA in hexane)<br>
yielded 26 g (93.8%) of product.<br>
1H NMR (300 M Hz, CDCI3)  7.94 (d ,1 H, J = 7.9 Hz), 7.34 (d, 1 H, J = 7.9 Hz), 4.00<br>
(m, 1 H),1.90-2.14 (m, 2 H), 1.42-1.88 (m, 8 H)<br>
IR (neat) 2930, 2854, 2232, 1643, 1573, 1447, 1334, 1245, 1186, 1149, 1107, 851<br>
cm"1<br>
MS (FAB) m/z 287 (M+H)<br>
Step 2:<br>
Synthesis of (2-(cyclohexylthio)-6-(trifluoromethyl)-pyridin-3-yl)methanamine<br>
dihydrochloride<br><br>
The nitrile (26 g, 0.091 mol) was dissolved in 600 mL of THF under a blanket of<br>
nitrogen and cooled to 5 C. BH3-dimethyl sulfide (13.78 g, 0.182 mol) was added<br>
dropwise and the mixture was boiled under reflux over a period of 20 h. After cooling<br>
to 5 C, 100 mL of MeOH were added to the reaction batch and the mixture was<br>
stirred at RT over a period of 15 minutes. Di-tert-butyldicarbonate (29.7 g, 0.136 mol)<br>
was then added and the mixture was stirred at RT for 30 min. Following the removal<br>
of the solvent in vacuo, the crude product was purified by column chromatography<br>
(silica gel 100-200 mesh, eluant: 10% EA in hexane) and 23.4 g (66%) of product<br>
were obtained.<br>
The crude product was dissolved in 120 mL of sat. HCI/dioxane soln., and the<br>
solution was stirred at RT over a period of 6 h. Following the removal of the solvent in<br>
vacuo, the solid matter was washed with 10% EA in hexane (2 x 100 mL) and<br>
isolated by filtration.<br>
Yield: 17 g (88.8%)<br>
1H NMR (DMSO-d6, 400 M Hz):  8.8 (s,2H), 8.05(d,1H), 7.76 (d,1H), 4.01 (s, 1H),<br>
3.86-3.93 (m,1H), 2.02-2.08 (m,2H), 1.71-1.74 (m,2H), 1.40-1.60 (m,6H).<br>
3. General instructions for the preparation of amines of the general formula V-B<br>
The preparation of amines of the general formula V-B is carried out as illustrated in<br>
the following scheme 3.<br><br><br>
Step 1: Preparation of nitriles of the general formula Vl-C<br>
Compounds of the general formula Vl-A (1 equivalent), in which R8, U, T, and V have<br>
the meanings stated above and m stands for 0,1,2, or 3, are stirred with an alcohol<br>
of the general formula HO-R42 (3.5 equivalents) and DBU [1,8-diaza-<br>
bicyclo[5.4.0]undec-7-ene] (3,5 equivalents) in acetonitrile (7 mL per mmol of the<br>
compound of formula Vl-A) over a period of 12 hours at RT. The reaction mixture is<br>
extracted with EA a number of times. The combined organic phases are washed with<br>
sat. aq. NaCI soln. and dried over MgSO4, and the solvent is removed in vacuo. The<br>
residue is purified in each case by column chromatography (SiO2, various mixtures of<br>
hexane/EA).<br>
Method 2:<br>
Compounds of the general formula Vl-C (2 mmol), in which R8, R42, U, T, and V have<br>
the meanings stated above and m stands for 0, 1,2, or 3, are dissolved in THF<br>
(10 mL, 10 mL) and BH3'S(CH3)2 [2.0 M in THF, 3 mL, 3 equivalent] is added. The<br>
reaction mixture is heated under reflux over a period of 8 hours, aq. HCI (2N) is<br>
added and the reaction mixture is again heated under reflux for 30 minutes. Aq.<br>
sodium hydroxide solution (2N) is added to the reaction mixture, and the mixture is<br>
washed with EA. The combined organic phases are washed with sat. aq. NaCI<br>
solution and dried over magnesium sulfate. The solvent is removed in vacuo and the<br><br>
residue is purified by column chromatography (SiO2, various mixtures of<br>
dichloromethane and methanol as mobile solvent).<br>
Method 3:<br>
Compounds of the general formula Vl-C (1,5 mmol), in which R8, R42, U, T, and V<br>
have the meanings stated above and m stands for 0,1,2, or 3, are dissolved in<br>
diethyl ether (3 mL) and a suspension of lithium aluminum hydride (3 mmol) in ether<br>
(5 mL) is slowly added dropwise at 0 C. The reaction mixture is heated under reflux<br>
over a period of 4 hours and methanol followed by 1N aq. NaOH solution are slowly<br>
added dropwise at 0 C. The reaction mixture is diluted with methanol and filtered<br>
over Celite. The solvent is removed in vacuo and the residue is purified by column<br>
chromatography (SiO2, various mixtures of dichloromethane and methanol as mobile<br>
solvent).<br>
4. General instructions for the preparation of amines of the general formula V-C<br>
The preparation of amines of the general formula V-C is carried out as illustrated in<br>
the following scheme 4.<br><br><br>
Step 1:<br>
Preparation of nitriles of the general formula Vl-D<br>
Compounds of the general formula Vl-A (1 equivalent), in which R8, U, T, and V have<br>
the meanings stated above and m stands for 0,1,2, or 3, are dissolved together with<br>
bis(triphenylphosphine)palladium dichloride (7 mol%) and copper(l) iodide (14 mol%)<br>
in 1-methyl-2-pyrrolidinone (7 mL per mmol of the compound of the general formula<br>
Vl-A). Following a period of 10 minutes the alkyne of the general formula HC=C-R38<br>
(3,5 equivalents) and N,N-diisopropylethylamine (2 equivalents) are added, and the<br>
reaction mixture is stirred over a period of 12 h at a temperature between 90 and<br>
110 C. The reaction mixture is filtered over Celite and extracted with EA a number of<br>
times. The combined organic phases are washed with sat. aq. NaCI solution, dried<br>
over MgSO4, and the solvent is removed in vacuo. The residue is purified in each<br>
case by column chromatography (SiO2, various mixtures of hexane/EA).<br>
5. General instructions for the preparation of amines of the general formula V-D<br>
The preparation of amines of the general formula V-D is carried out as illustrated in<br>
the following scheme 5.<br><br><br>
Step 1: Preparation of nitriles of the general formula Vl-E<br>
Compounds of the general formula Vl-A (1 equivalent), in which R8, U, T, and V have<br>
the aforementioned meanings and m stands for 0, 1, 2, or 3, are stirred with<br>
palladium dichloride (5 mol%) and a compound of the general formula R38-B(OH)2 (2<br>
equivalents), in which R38 stands for aryl, heteroaryl, or cycloalkenyl, in a solvent<br>
mixture of toluene/dioxane/2N aq. sodium carbonate solution (20 mL per 1 mmol of<br>
compounds of the general formula Vl-A). The reaction mixture is heated under reflux<br>
over a period of 12 h and filtered over Celite. The combined organic phases are dried<br>
over magnesium sulfate, and the solvent is removed in vacuo. The residue is purified<br>
by column chromatography (SiO2, various solvent mixtures of hexane and EA).<br>
Step 2:<br>
Method 1:<br>
Compounds of the general formula Vl-E (5 mmol), in which R8, R38, U, T, and V have<br>
the meanings stated above and m stands for 0, 1,2, or 3, palladium-on-charcoal<br>
(10%, 500 mg) and concentrated hydrochloric acid (3 mL) are dissolved in MeOH (30<br>
mL) and exposed to a hydrogen atmosphere over a period of 6 hours at RT. The<br>
reaction mixture is filtered over Celite and the filtrate is concentrated in vacuo. The<br>
residue is purified by means of flash chromatography (SiO2, EA).<br>
Method 2:<br>
Compounds of the general formula Vl-E (2 mmol), in which R8, R38, U, T, and V have<br>
the meanings stated above and m stands for 0,1,2, or 3, are dissolved in THF<br>
(10 mL, 10 mL), and BH3'S(CH3)2 [2.0 M in THF, 3 mL, 3 equivalent] is added. The<br>
reaction mixture is heated under reflux over a period of 8 hours, aq. HCI (2N) is<br>
added and the reaction mixture is again heated under reflux for 30 minutes. Aq.<br><br>
sodium hydroxide solution (2N) is added to the reaction mixture, and the mixture is<br>
washed with EA. The combined organic phases are washed with sat. aq. NaCI<br>
solution and dried over magnesium sulfate. The solvent is removed in vacuo and the<br>
residue is purified by column chromatography (SiO2, various mixtures of<br>
dichloromethane and methanol as mobile solvent).<br>
6. Preparation of specific acids<br>
Preparation of 2-(3-halogenated-4-(methylthio)phenyl)propanoic acids<br>
(cf. Examples 28, 29)<br><br>
Substituted methylthiophenylpropanoic acids can be prepared as described in<br>
US2003/225283. For this purpose, a solution of AICI3 (54.9 g, 412 mmol) in<br>
chloroform (180 mL) is cooled under an argon atmosphere to 0 C and a solution of<br>
methyl-2-chloro-2-oxoacetate (24.3 mL, 264 mmol) in chloroform (180 mL) is added<br>
in drops. After this reaction mixture has been stirred for 30 min at 0 C, a solution of<br>
2-chlorothioanisol (39.4 g, 247 mmol) in chloroform (180 mL) is added in drops. The<br>
red-coloured reaction mixture is slowly heated to room temperature and stirred for a<br><br>
further 4 h. The reaction mixture is then slowly stirred in ice water (700 mL) and the<br>
obtained yellow mixture is stirred for 15 min and filtered to remove the aluminium<br>
salts. The filtrate is extracted with dichloromethane (3 x 50 mL) and the combined<br>
organic phases are washed with sat. aq. sodium bicarbonate solution (1 x 50 mL).<br>
After drying of the organic phase over MgSO4 and removal of the solvent in vacuo,<br>
the (3-chloro-4-methylsulfanyl-phenyl)-oxo-methyl acetate as oil (36.4 g, 60%) is<br>
obtained (a).<br>
A solution of this ester (61.7 g, 252 mmol) in toluol (120 mL) is heated to 50 C.<br>
While ensuring that the temperature of the reaction mixture does not exceed 60 C, a<br>
3 M NaOH solution (105 mL, 313 mmol) is now added in drops and subsequently<br>
stirred for 1.5 h at 50 C. After removal of the heat source, cone. HCI (10.6 mL, 290<br>
mmol) is added to the warm solution in drops and once the mixture is cooled to room<br>
temperature, it is let to stir for a further 16 h. The resultant precipitate is filtered off,<br>
washed with water (50 mL) and toluol (50 mL) and dried. The (3-chloro-4-<br>
methylsulfanyl-phenyl)-oxo-acetic acid accumulates as a white solid (57.2 g, 98%)<br>
(b).<br>
Hydrazine-hydrate (8.5 mL, 273 mmol) is provided in a reaction flask with a<br>
mechanical stirrer. After cooling to -50 C, in one portion, the oxo-acetic acid (12.6 g,<br>
54.6 mmol) is added, which leads to an increase in temperature. The resultant milky<br>
mixture is heated to 80 C and, after removal of the heat source, KOH (2.09 g, 31.7<br>
mmol) is added in one portion. This leads to an exothermal reaction. After cooling to<br>
80 C, a further portion of KOH (2.09 g, 31.7 mmol) is added and in turn cooled to 80<br>
C. This procedure is now repeated two further times. After addition of the fourth<br>
portion of KOH, the reaction mixture is boiled for 16 h at 100 C. After cooling of the<br>
homogeneous reaction mixture to room temperature, it is diluted with water (12 mL)<br>
and, following transfer to a separating funnel, further water (12 mL) and diethylether<br><br>
(40 mL) are added. After phase separation, the organic phase is extracted with water<br>
(2x15 mL). Heptane (20 mL) is added to the combined aqueous phases and the<br>
mixture is vigorously stirred. While keeping the temperature below 50 C by means of<br>
an ice bath, cone. HCI (26 mL) is added in drops over a period of 30 min and the<br>
resultant suspension is stirred for 3 h at room temperature. The resultant precipitate<br>
is filtered off and consecutively washed with 1 N aq. HCI solution (2x6 mL), heptane<br>
(1x12 mL) and heptane/diethyl ether (15 mL, 4:1). After drying, the (3-chloro-4-<br>
methylsulfanyl-phenyl)-acetic acid (10.48 g, 89%) is obtained as a cream-coloured<br>
solid (c).<br>
This (3-chloro-4-methylsulfanyl-phenyl)-acetic acid is now alkylated in alpha position<br>
in an analogous manner to Vazquez et al. Eur. J. Med. Chem. Chim. Ther. (1997),<br>
32, 6, 529-53. A solution of the aryl acetic acid (1.05 mmol) in dry THF (3 mL) is<br>
cooled to -78 C and stirred under an argon atmosphere . For this purpose, a 2 M<br>
solution of LDA in hexane (1.6 mL, 3.2 mmol) and TMEDA (0.3 mL, 1.9 mmol) is<br>
added in drops over a period of 15 min. After 3 hours of slow stirring at -78 C,<br>
methyl iodide (0.17 mL, 2.7 mmol) is added slowly while stirring. After 16 hours of<br>
stirring at room temperature, the reaction mixture is neutralized with sat. aq. NH4CI<br>
solution (10 mL) and stirred for 1 h at room temperature. After separation of the<br>
organic phase, the aqueous, alkaline phase is acidified with 5 N HCI and the product<br>
extracted with ether (3 x 20 mL). The combined organic phases are dried over<br>
Na2SO4 and the solvent is removed in vacuo. Purification by means of column<br>
chromatography (hexane/ethyl acetate 8:2) produces the desired<br>
methylthiophenylpropanoic acid (d).<br><br>
Preparation of 2-(3-halogenated-4-(methylsulfonyl)phenyl)propanoic acids<br>
(cf. Examples 29, 31)<br><br>
In an analogous manner to the method described in US2003/225283, the<br>
methylthiophenylpropanoic acids are reacted to yield the corresponding<br>
methylsulfonylphenylpropanoic acids. In this process, a solution of<br>
methylthiophenylpropanoic acid (0.16 mmol) is dissolved in formic acid (0.19 mL, 4.8<br>
mmol) and cooled to 0 C. After addition of 30% strength aq. hydrogen peroxide<br>
solution (0.10 mL, 0.8 mmol), stirring is performed at 0 C for 30 min and the reaction<br>
is then quenched with 10% strength aq. sodium bisulphite solution. The reaction<br>
mixture is diluted with water (5 mL) and extracted ethyl acetate (2x5 mL). The<br>
combined organic phases are dried over Mg2SO4 and the solvent is removed in<br>
vacuo. The residue obtained is dissolved in methanol (1 mL) and a solution of<br>
KMNO4 (0.028 g, 0.176 mmol) in water (0.5 mL) is added by drops. The dark brown<br>
solution is now stirred for 30 min at room temperature and then diluted with methanol<br>
(10 mL). After filtration of the solution, the filtrate is concentrated in vacuo and<br>
purified by column chromatography (hexane/ethyl acetate 1:4) (a).<br><br>
Preparation of 2-(4-(N-substituted sulfamoyl)-3-fluorophenyl)propanoic acids<br>
(cf. Ex. 32)<br><br>
In an analogous manner to Greig, IR et al. J. Med. Chem. (2006), 49, 4787-7492, the<br>
bromo-fluorobenzyl-sulfonylchloride (5 mmol) is dissolved with dimethylamine (5<br>
mmol) in dichloromethane (15 mL). Pyridine (5 mmol) is added to this mixture and<br>
the mixture is stirred for 2 h at room temperature. After addition of water (15 mL), the<br>
organic phase is separated and the aqueous phase extracted with ethyl acetate (15<br>
mL). The combined organic phases are dried over Na2SO4, the solvent is removed in<br>
vacuo and the residue is purified by column chromatography (a).<br>
As described in Durandetti M. et al., Tetrahedron (2007), 63, 1146-1153, the<br>
sulfamoyl-aryl bromide is converted with ethylchloropropionate into sulfamoyl-<br>
arylpropanoic acid ester. Together with ethylchloropropionate (1.6 mL ,13 mmol),<br>
sulfamoyl-aryl bromide (10 mmol) is stirred under an argon atmosphere at room<br>
temperature in 15 ml DMF. For the purpose of activation, (1.1 g, 20 mmol) Mn,<br>
followed by 2,2'-bipyridine)nickel-(ll)-dibromide (0.26 g, 0.7 mmol) and TFA (20 mL)<br>
are then added. The reaction mixture is stirred for 1.5 h at 50 C.<br><br>
After cooling of the reaction mixture, hydrolysis is performed with 25 mL 1 N HCI, the<br>
mixture is extracted 3 x with 25 mL diethyl ether, the combined organic phases are<br>
washed with 25 mL water and 25 mL sat. NaCI solution, dried over MgSO4 and<br>
concentrated in vacuo. The resultant precipitate is removed by suction, washed with<br>
diethyl ether and purified by means of column chromatography (b).<br>
The propionate (0.81 mmol) is then dissolved in a mixture of THF (1.6 mL, 20 mmol)<br>
and water (0.8 mL, 45 mmol). After addition of LiOH (0.058 g, 2.43 mmol), the<br>
reaction mixture is refluxed overnight. For the purpose of processing, 25 mL water<br>
and 25 mL diethyl ether are added to the mixture and the resultant phases are<br>
separated. The aqueous phase is acidified with HCI and extracted 3x with in each<br>
case 25 mL dichloromethane. After combination of the organic phases, drying over<br>
MgSO4 and concentration in vacuo, the N-substituted sulfamoyl-<br>
fluorophenylpropanoic acid can be obtained.<br><br>
Preparation of 2-(4-methoxy- and hydroxy-3,5-dimethylphenyl)propanoic acids<br>
(cf. Examples 35-38)<br><br>
In an analogous manner to the method described in WO2006/078834, on the basis of<br>
aryl bromides, phenylpropanoic acids can be obtained by reaction with<br>
diethylmalonate. For this purpose, in the first step, NaH (60%, 1.45 g, 36.2 mmol) is<br>
added to a solution of aryl bromide (16.5 mmol), CuBr (4.72 g, 32.9 mmol) and<br>
diethyl malonate (5 mL, 32.9 mmol) in 1,4-dioxane (20 mL) at room temperature<br>
while stirring slowly and stirred for 16 h at 100 C. After filtration, the filtrate is<br>
concentrated in vacuo and purified by means of column chromatography<br>
(hexane/ethyl acetate 4:1) (a).<br>
The obtained phenylmalonic acid diethyl ester (21 mmol) is now dissolved in 2 N<br>
NaOH /THF:H20 (1:1) (20 mL) and refluxed for 3 h. After acidification of the reaction<br>
mixture to pH 1 with cone HCI, stirring is carried out for a further hour at room<br>
temperature. The solution is then adjusted with 1 N NaOH to pH 13 and extracted<br>
with diethyl ether. The aqueous phase is adjusted with 1 N HCI to pH 5 and extracted<br><br>
with ethyl acetate (3 x). The combined organic phases are washed with sat. NaCI<br>
solution, dried over Na2SO4 and, after filtration, the solvent is removed in vacuo (b).<br>
This phenylacetic acid is now alkylated in an analogous manner to Vazquez et al.<br>
Eur. J. Med. Chem. Chim. Ther. (1997), 32, 6, 529-53 in alpha position. A solution of<br>
arylacetic acid (1.05 mmol) in dry THF (3 mL) is cooled under an argon atmosphere<br>
to -78 C and stirred. For this purpose, a 2 M solution of LDA in hexane (1.6 mL, 3.2<br>
mmol) and TMEDA (0.3 mL, 1.9 mmol) is added in drops over a period of 15 min.<br>
After 3 hours of slow stirring at -78 C, methyl iodide (0.17 mL, 2.7 mmol) is added<br>
slowly while stirring. After 16 hours of stirring at room temperature, the reaction<br>
mixture is neutralized with sat. aq. NH4CI solution (10 mL) and stirred for 1 h at room<br>
temperature. After separation of the organic phase, the aqueous, alkaline phase is<br>
acidified with 5 N HCI and the product is extracted with ether (3 x 20 mL). The<br>
combined organic phases are dried over Na2SO4 and the solvent is removed in<br>
vacuo. Purification by means of column chromatography (hexane/ethyl acetate 8:2)<br>
produces the desired substituted phenylmethoxy-propanoic acid (c).<br>
According to a method known to the person skilled in the art, the methoxy ether is<br>
split by means of HBr in glacial acetic acid and the corresponding phenylhydroxy-<br>
propanoic acid is obtained (d).<br>
Preparation of 2-(4-amino-3,5-difluorophenyl)propanoic acid<br>
(cf. Ex. 26)<br><br><br>
KOtBu (3.57 g, 31.85 mmol) was dissolved in DMF (30 mL) and cooled to -45 C. A<br>
mixture of ethyl-2-chloropropionate (2 mL, 15.9 mmol) and 2,6-difluoronitrobenzene<br>
(2.5 g, 15.7 mmol) were added slowly in drops to the solution kept at -40 C and<br>
stirred for 1 h after addition. For the purpose of processing, the reaction mixture was<br>
adjusted with 16% strength HCI to pH 4 and diluted with water (150 mL). The mixture<br>
was extracted with ethyl acetate (3 x 50 mL), the combined organic phases washed<br>
with water (50 mL) and sat. NaCI solution (2 x 50 mL) and dried over MgSO4. After<br>
removal of the solvent in vacuo, the product was obtained as an oil (4.12 g, 99%) (a).<br>
The difluoronitropropanoate (2.59 g, 10 mmol) was dissolved in EtOH/acetic acid<br>
ester (200 mL, 1 : 1) and hydrated in the H cube (1 bar, 25 C, 1 mL/min, 0.25 mol/L).<br>
After removal of the solvent in vacuo, the difluoroaminopropionate could be obtained<br>
as an oil (2.27 g, 99%) (b).<br>
The raw product of the hydrogenation (1 g, 4.36 mmol) was dissolved in THF/water<br>
(10 mL, 2 :1), LiOH (0.312 g, 13.1 mmol) added and refluxed for 16 h.<br>
Water (50 mL) and diethyl ether (25 mL) were added to the reaction mixture. After<br>
phase separation, the aqueous phase was acidified with HCI to pH 2 and extracted<br>
with dichloromethane (3 x 50 mL). The combined organic phases were dried over<br><br>
MgSO4 and the solvent removed in vacuo. The product was obtained as a white solid<br>
(0.72 g, 81%) (c).<br>
7. General instructions for the reaction of amines of the general formulas V or<br>
X with carboxylic acids of the general formula VII<br>
Method A:<br>
The acid of the general formula VII (1 equivalent), the amine of the general formulas<br>
V or X (1.2 equivalents) and EDCI (1.2 equivalents) are stirred in DMF (10 mmol of<br>
acid in 20 mL) over a period of 12 hours at RT, and water is then added. The reaction<br>
mixture is extracted with EA a number of times, the aqueous phase is saturated with<br>
NaCI and then again extracted with EA. The combined organic phases are washed<br>
with 1N hydrochloric acid and sat. aq. NaCI soln., dried over MgSO4, and the solvent<br>
is removed in vacuo. The residue is purified by means of flash chromatography<br>
(SiO2, EA/hexane 1:2).<br>
Method B:<br>
The acid of the general formula VII (1 equivalent) and the amine of the general<br>
formula V or X (1.1 equivalents) are dissolved in DCM (1 mmol acid in 6 mL), and to<br>
the solution EDCI (1.5 equivalents), HOBt (1.4 equivalents) and triethylamine (3<br>
equivalents) are added at 0 C. The reaction mixture is stirred at RT for a period of<br>
20 h and purified by column chromatography (2:1 mixture of n-hexane/AE).<br>
The following exemplary compounds were obtained in accordance with method B<br>
above.<br><br>
Exemplary Compound 3:<br>
2-(4-Amino-3-bromo-5-methoxy-phenyl)-N-(4-methyl-6,-trifluoromethyl-3,4,5,6-<br>
tetrahydro-2H-[1,2']bipyridinyl-3'-ylmethyl)acetamide<br><br>
1H-NMR (CDCl3)  7.52 (d, 1H, J = 7.5 Hz), 7.21 (d, 1H, J = 7.5 Hz), 6.93 (d, 1H, J =<br>
1.4 Hz), 6.57 (d, 1H), 6.24 (bt, NH), 4.47 (d, 2H), 4.22 (s, 2H), 3.80 (s, 3H), 3.51 (s,<br>
2H), 3.30-3.26 (m, 2H), 1.70-1.48 (m, 3H), 1.21-1.09 (m, 2H), 0.95 (d, 3H, J = 6.4 Hz)<br>
IR 3298, 2924, 1649, 1575, 1500, 1460, 1420, 1338, 1135, 1047 cm-1<br>
Mass (FAB) m/z 515 and 517 [M+H]+ (Base), 537 and 539 [M+Na]+<br>
Exemplary Compound 4:<br>
2-(3-Fluorophenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-<br>
[1,2']bipyridinyl-3'-ylmethyl)acetamide<br><br>
IR (KBr) 3272, 2923, 1648, 1592, 1552, 1455, 1421, 1374, 1337, 1246, 1138,958,<br>
835, 774 cm-1<br>
MS(FAB) m/z 410(M+H)<br>
Exemplary Compound 5:<br>
2-(2,4-Difluoro-phenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-<br>
[1,2']bipyridinyl-3'-ylmethyl)acetamide<br><br><br>
IR (KBr) 3270, 2921, 1647, 1558, 1507, 1424, 1330, 1242, 1134, 966, 851 cm-1<br>
MS (FAB) m/z 428 (M+H)<br>
Exemplary Compound 6:<br>
2-(2,6-Difluoro-phenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-<br>
[1,2']bipyridinyl-3'-ylmethyl)acetamide<br><br>
IR (KBr) 3292, 2924, 1656, 1593, 1553, 1468, 1419, 1337, 1238, 1178, 1135, 1017,<br>
945, 834, 784 cm-1<br>
MS (FAB) m/z 428 (M+H)<br>
Exemplary Compound 7:<br>
2-(2,5-Difluoro-phenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-<br>
y[1,2']bipyridinyl-3'-ylmethyl)acetamide<br><br>
IR (KBr) 3271, 2922, 1644, 1593, 1555, 1497, 1424, 1329, 1137, 960, 833, 756 cm-1<br><br>
MS (FAB) m/z 428 (M+H)<br>
Exemplary Compound 8:<br>
2-(4-Fluoro-phenyl)-N-(4-methyl-6,-trifluoromethyl-3,4,5,6-tetrahydro-2H-<br>
 [1,2']bipyridinyl-3'-ylmethyl)acetamide<br><br>
IR (KBr) 3255, 2920, 1646, 1595, 1558, 1509, 1424, 1330, 1229, 1132, 1043, 960,<br>
828, 755 cm-1<br>
MS(FAB) m/z 410 (M+H)<br>
Exemplary Compound 9:<br>
2-(4-Hydroxy-3-methoxy-phenyl)-N-methyl-6'-trifluoromethyl-3,4,5,6-<br>
tetrahydro-2H-[1,2']bipyridinyl-3'-ylmethyl)propionamide<br><br>
' 1H NMR (300 M Hz, CDCl3)  7.44 (d, 1 H, J = 7.7 Hz), 7.17 (d, 1 H, J = 7.5 Hz), 6.88<br>
(d, 1 H, J= 7.9 Hz), 6.80-6.70 (m, 2 H), 6.11 (bt, 1 H), 5.60 (s, 1 H), 4.46-4.42 (m, 2<br>
H), 3.84 (s, 3 H), 3.55 (q, 1 H, J = 7.1 Hz), 3.32-3.23 (m, 2 H), 2.83-2.73 (m, 2 H),<br>
1.71-1.66 (m, 2 H), 1.53 (d, 3 H, J= 7.1 Hz), 1.26-1.1 (m, 2 H), 0.96 (d, 3 H, J= 6.6<br>
Hz)<br>
 IR (KBr) 3301, 2925, 1650, 1516, 1458, 1421, 1373 cm"1<br>
MS (FAB) m/z 452 (M+H)<br><br>
Exemplary Compound 10:<br>
2-(3,5-Difluoro-phenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-<br>
[1,2']bipyridinyl-3'-ylmethyl)propionamide<br><br>
1H NMR (300 M Hz, CDCl3)  7.47 (d, 1 H, J- 7.5 Hz), 7.21 (d, 1 H, J- 7.7 Hz),<br>
6.85-6.82 (m, 2 H), 6.80-6.70 (m, 2 H), 6.11 (bt, 1 H), 5.60 (s, 1 H), 4.46-4.42 (m, 2<br>
H), 3.84 (s, 3 H), 3.55 (q, 1 H, J = 7.1 Hz), 3.32-3.23 (m, 2 H), 2.83-2.73 (m, 2 H),<br>
1.71-1.66 (m, 2 H), 1.53 (d, 3 H, J= 7.1 Hz), 1.26-1.1 (m, 2 H), 0.96 (d, 3 H, J = 6.6<br>
Hz)<br>
IR (KBr) 3293, 2925, 1651, 1596, 1542, 1460, 1335 cm"1<br>
MS (FAB) m/z 442 (M+H)<br>
Exemplary Compound 12:<br>
2-(4-Fluoro-phenyl)-N(4-methyl-6'-trifluoromethyl-3,5,4,6-tetrahydro-2H-<br>
[1,2']bipyridinyl-3'-ylmethyl)propionamide<br><br><br>
1H-NMR(CDCI3)  7.43(d, 1H, J = 7.5 Hz), 7.28-7.24(m, 2H), 7.18(d, 1H, J = 7.7 Hz),<br>
7.06-7.00(m, 2H), 6.16 (bs, NH), 4.45(d, 2H), 3.59(q, 1H, J = 7.0 Hz), 3.29(m, 2H),<br>
2.79(m, 2H0, 1.75-1.50(m, 3H), 1.53(d, 3H, J = 7.1 Hz), 1.26-1.10(m, 2H), 0.96(d,<br>
3H, J = 6.4 Hz)<br>
IR 3291, 2925, 1650, 1510, 1458, 1419, 1336, 1231, 1177, 1138 cm-1<br>
Mass (FAB) m/z 424 [M+H]+ (Base), 446 [M+Na]+<br>
Exemplary Compound 13:<br>
2-(3-Fluoro-phenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-<br>
[1,2']bipyridinyl-3'-ylmethyl)propionamide<br><br>
1H-NMR(CDCI3)  7.43(d, 1H, J = 7.7 Hz), 7.31 (m, 1H), 7.18(d, 1H, J = 7.7 Hz), 7.07-<br>
6.95(m, 3H), 6.23(bs, NH), 4.45(d, 2H), 3.60(q, 1H, J = 7.0 Hz), 3.29(m, 2H), 2.79(m,<br>
2H), 1.65-1.50(m, 3H), 1.54(d, 2H, J = 7.0 Hz), 1.24-1.12(m, 2H), 0.96(d, 3H, J = 6.4<br>
Hz)<br>
IR 3292, 2925, 1651, 1592, 1542, 1456, 1419, 1177, 1140 cm"1<br>
Mass (FAB) m/z 424 [M+H]+ (Base), 446 [M+Na]+<br>
Exemplary Compound 14:<br>
2-(3,4-Diamino-phenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-<br>
[1,2']bipyridinyl-3'-ylmethyl)propionamide<br><br><br>
1H-NMR(CDCI3)  7.42 (d, 1H, J = 7.5 Hz), 7.17 (d, 1H, J = 7.7 Hz), 6.67-6.57 (m,<br>
3H), 6.03 (bt, NH), 4.41 (d, 2H), 3.49 (q, 1H, J = 7.3 Hz), 3.40 (br, NH2), 3.33-3.27<br>
(m, 2H), 2.84-2.74 (m, 2H), 1.73-1.55 (m, 3H), 1.51 (d, 3H, J = 7.1 Hz), 1.30-1.18 (m,<br>
2H), 0.96 (d, 3H, J = 6.6 Hz)<br>
IR 3334, 2925, 1651, 1518, 1419, 1176, 1135, 733 cm'1<br>
Mass (FAB) m/z 436 [M+H]+<br>
Exemplary Compound 15:<br>
N-(2-Butoxy-6-tert-butyl-pyridin-3-ylmethyl)-2-(3,4-diaminophenyl)propionamide<br><br>
1H-NMR(CDCI3)  7.32 (d, 1H, J = 7.5 Hz, Ar), 6.76 (d, 1H, J = 7.3 Hz, Ar), 6.66-6.57<br>
(m, 3H, Ar), 6.00 (bt, NH), 4.27 (m, 4H, OCH2 &amp; CH2NH), 3.41 (q, 1H, J = 7.1 Hz,<br>
CHCH3), 1.64 (m, 2H, OCH2CH2), 1.45 (d, 3H, J = 7.1 Hz, CHCH3), 1.39 (m, 2H,<br>
CH2CH3), 1.29 (s, 9H, C(CH3)3), 0.95 (t, 3H, J = 7.3 Hz, CH2CH3)<br>
IR 3303, 2960, 1649, 1517, 1456, 1254 cm'1<br>
Mass (FAB) 399 m/z [M+H]+<br>
Exemplary Compound 16:<br>
N-(6'-tert-Butyl-4-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-ylmethyl)-2-<br>
(3,4-diamino-phenyl)propionamide<br><br><br>
1H-NMR(CDCI3)  7.26 (d, 1H, J = 7.9 Hz, Ar), 6.85 (d, 1H, J = 7.7 Hz, Ar), 6.66-6.58<br>
(m, 3H, Ar), 6.39 (bt, NH), 4.37 (m, 2H, CH2NH), 3.45 (q, 1H, J = 7.1 Hz, CHCH3),<br>
3.37 (bs, NH2*2), 3.23 (m, 2H, piperidine), 2.74 (m, 2H, piperidine), 1.65-1.45 (m, 3H,<br>
piperidine), 1.49 (d, 3H, J = 7.1 Hz, CHCH3), 1.29 (s, 9H, C(CH3)3), 1.28-1.16 (m, 2H,<br>
piperidine), 0.95 (d, 3H, J = 6.4 Hz, piperidine CH3)<br>
IR 3338, 2955, 1648, 1517, 1449, 1232 cm-1<br>
Mass (FAB) m/z 424[M+H]+<br>
Exemplary Compound 17:<br>
N-(6-tert-Butyl-2-cyclohexylsulfanyl-pyridin-3-ylmethyl)-2-(3,4-diamino-phenyl)-<br>
propionamide<br><br>
1H-NMR(CDCI3)  7.27 (d, 1H, Ar), 6.91 (d, 1H, J = 7.9 Hz, Ar), 6.67-6.59 (m, 3H, Ar),<br>
5.90 (bt, NH), 4.26 (m, 2H, CH2NH), 3.96 (m, 1H, SCH), 3.46 (q, 1H, J = 7.3 Hz,<br>
CHCH3), 3.37 (bs, NH2*2), 2.06 (m, 2H, cyclohexyl), 1.80-1.20 (m, 8H, cyclohexyl),<br>
1.50 (d, 3H, CHCH3), 1.31 (s, 9H, C(CH3)3)<br>
IR 3303, 2929, 2854, 1651, 1517, 1444, 1079cm-1<br>
Mass (FAB) m/z 441[M+H]+<br><br>
Exemplary Compound 19:<br>
2-(3,5-Dibromo-4-hydroxy-phenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-tetra-<br>
hydro-2H-[1,2']bipyridinyl-3'-ylmethyl)propionamide<br><br>
1H-NMR(CDCI3)  7.48 (m, 1H, Ar), 7.39 (s, 2H, Ar), 7.22 (d, 1H, J = 7.7 Hz, Ar),<br>
6.27 (bt, NH), 4.47 (m, 2H, CH2NH), 3.46 (q, 1H, J = 7.1 Hz, CHCH3), 3.31 (m, 2H,<br>
piperidine), 2.81 (m, 2H, piperidine), 2.40 (s, OH), 1.75-1.16 (m, 5H, piperidine), 1.50<br>
(d, 3H, J = 7.1 Hz, CHCH3), 0.98 (d, 3H, J = 6.4 Hz, piperidine CH3)<br>
IR 3298, 2924, 1650, 1550, 1462, 1417, 1176, 1138 cm-1<br>
Mass (FAB) m/z 580 [M+H]+<br>
Exemplary Compound 20:<br>
2-(4-Amino-3,5-dibromo-phenyl)-N-(4-methyl-6'-trlfluoromethyl-3,4,5,6-tetra-<br>
hydro-2H-[1,2']bipyridinyl-3'-ylmethyl)propionamide<br><br>
1H-NMR(CDCI3)  7.47 (d, 1H, J = 7.7 Hz, Ar), 7.31 (s, 2H, Ar), 7.21 (d, 1H, J = 7.7<br>
Hz, Ar), 6.18 (bt, NH), 4.55 (bs, NH2), 4.46 (m, 2H, CH2NH), 3.43 (q, 1H, J = 7.0 Hz,<br>
CHCH3), 3.30 (m, 2H, piperidine), 2.81 (m, 2H, piperidine), 1.75-1.15 (m, 5H,<br>
piperidine), 1.48 (d, 3H, J = 7.1 Hz, CH2CH3), 0.97 (d, 3H, J = 6.4 Hz, piperidine CH3)<br>
IR 3298, 2924, 1649, 1544, 1474, 1418, 1177, 1136 cm-1<br>
Mass (FAB) m/z 579[M+H]+<br><br>
Exemplary Compound 21:<br>
2-(3-Bromo-4-hydroxy-5-methoxy-phenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-<br>
tetrahydro-2H-[1,2']bipyridinyl-3'-ylmethyl)acetamide<br><br>
1H-NMR(CDCI3)  7.54 (d, 1H, J = 7.5 Hz, Ar), 7.22 (d, 1H, J = 7.7 Hz, Ar), 6.99 (d,<br>
1H, J = 1.5 Hz, Ar), 6.69 (d, 1H, J = 2.0 Hz, Ar), 6.27 (bt, NH), 5.91 (bs, OH), 4.48 (m,<br>
2H, CH2NH), 3.86 (s, 3H, OCH3), 3.53 (s, 2H, CH2CO), 3.28 (m, 2H, piperidine), 2.80<br>
(m, 2H, piperidine), 1.73-1.07 (m, 5H, piperidine), 0.96 (d, 3H, J = 6.4 Hz, piperidine<br>
CH3)<br>
IR 3298, 2924, 1649, 1501, 1459, 1421, 1282, 1178, 1136, 1047 cm-1<br>
Mass(FAB)m/z 517[M+H]+<br>
Exemplary Compound 22:<br>
2-(4-Amino-3,5-dibromo-phenyl)-N-(4-methyl-6,-trifluoromethyl-3,4,5,6-tetra-<br>
hydro-2H-[1,2']bipyridinyl-3'-ylmethyl)acetamide<br><br>
1H-NMR(CDCI3)  7.53 (d, 1H, J = 7.3 Hz, Ar), 7.29 (s, 2H, Ar), 7.23 (d, 1H, J = 7.7<br>
Hz, Ar), 6.26 (bt, NH), 4.57 (bs, NH2), 4.48 (m, 2H, CH2NH), 3.46 (s, 2H, CH2CO),<br>
3.30 (m, 2H, piperidine), 2.81 (m, 2H, piperidine), 1.75-1.10 (m, 5H, piperidine), 0.97<br>
(d, 3H, J = 6.4 Hz, piperidine CH3)<br><br>
IR 3288, 2923, 1649, 1544, 1478, 1418, 1337, 1177, 1135 cm-1<br>
Mass (FAB) m/z 565 [M+H]+<br>
Exemplary Compound 23:<br>
2-(3,5-Dibromo-4-hydroxy-phenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-tetra-<br>
hydro-2H-[1,2']bipyridinyl-3'-ylmethyl)acetamide<br><br>
1H-NMR(CDCI3)  7.55 (d, 1H, J = 7.7 Hz, Ar), 7.38 (s, 2H, Ar), 7.24 (d, 1H, J = 7.7<br>
Hz, Ar), 6.31 (bt, NH), 4.50 (m, 2H, CH2NH), 3.50 (s, 2H, CH2CO), 3.31 (m, 2H,<br>
piperidine), 2.82 (m, 2H, piperidine), 2.40 (s, OH), 1.77-1.10 (m, 5H, piperidine), 0.97<br>
(d, 3H, J = 6.6 Hz, piperidine CH3)<br>
IR 3297, 2924, 1650, 1546, 1473, 1419, 1337, 1177, 1137 cm-1<br>
Mass (FAB) m/z 566 [M+H]+<br>
Exemplary Compound 24:<br>
2-(3-Amino-4-hydroxy-phenyl)-N-(4-methyl-6'-trlfluoromethyl-3,4,5,6-tetrahydro-<br>
2H-[1,2']bipyridinyl-3'-ylmethyl)propionamide<br><br>
1H-NMR(CDCI3)  7.42 (d, 1H, J = 7.7 Hz, Ar), 7.17 (d, 1H, J = 7.7 Hz, Ar), 6.69-6.64<br>
(m, 2H, Ar), 6.53 (dd, 1H, J = 8.0, 1.8 Hz, Ar), 6.07 (bt, NH), 4.42 (d, 2H, J = 5.7 Hz,<br>
CH2NH), 3.69 (bs, NH2), 3.59 (q, 1H, J = 7.1 Hz, CHCH3), 3.30 (m, 2H, piperidine),<br><br>
2.79 (m, 2H, piperidine), 1.71-1.50 (m, 6H, piperidine &amp; CHCH3), 1.22 (m, 2H,<br>
piperidine), 0.96 (d, 3H, J = 6.6 Hz, CHCH3)<br>
IR 3298, 2924, 1649, 1519, 1458, 1420, 1177, 1136 cm-1<br>
Mass (FAB) m/z 437 [M+H]+, 459 [M+Na]+<br>
Exemplary Compound 25:<br>
2-(3,5-Dibromo-phenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-<br>
[1,2']bipyridinyl-3'-ylmethyl)acetamide<br><br>
1H-NMR(CDCI3)  7.61 (t, 1H, J = 1.7 Hz), 7.54 (d, 1H, J = 7.7 Hz), 7.38 (d, 1H, J =<br>
1.7 Hz), 7.24 (d, 1H, J = 7.7 Hz), 6.34 (bt, NH), 4.50 (d, 2H), 3.54 (s, 3H), 3.32 (m,<br>
2H), 2.83 (m, 2H), 1.75-1.50 (m, 3H), 1.33-1.13 (m, 2H), 0.98 (d, 3H, J = 6.4 Hz)<br>
IR 3291, 2924, 1649, 1554, 1458, 1421, 1337, 1176, 1138 cm"1<br>
Mass (FAB) m/z 550[M+H]+<br>
The following further exemplary compounds were obtained by the methods described<br>
above:<br><br><br><br>
Exemplary compounds 28-32 and 35-33 can likewise be obtained according to the<br>
methods described above.<br>
Pharmacological Data<br>
The affinity of the compounds according to the invention for the vanilloid receptor 1<br>
(VR1/TRPV1 -Receptor) was detected as described above (Pharmacological Methods<br>
I and II respectively).<br><br>
The compounds according to the invention of the above formula I exhibit excellent<br>
affinity to the VR1/TRPV1 receptor (Table 1).<br><br><br><br>
Ne denotes "no effect", i.e. no reaction was observed.<br>
The value following the symbol "@" indicates the concentration at which the inhibition (in percent) was<br>
determined.<br><br>
Claims<br>
1. Substituted compounds of the general formula I,<br><br>
in which<br>
n stands for 0, 1, 2, 3, or 4;<br>
R1 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(= O)-NH2;<br>
-S(= O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= O)-H; -S(= O)2-OH; -<br>
C(= NH)-NH2; -C(= NH)-NH-R9; -N= C(NH2)2; -N= C(NHR10)-(NHR11); -<br>
O-P(= O)2-O-R12; -NHR13; -NR14R15; -NH-C(= O)-R13; -OR16; -SR17; -C(= <br>
O)-NHR18; -C(= O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-NR22R23; -C(= <br>
O)-OR24; -C(= O)-R25; -S(= O)-R26; or -S(= O)2-R27 or for a linear or<br>
branched, saturated or unsaturated, unsubstituted or at least<br>
monosubstituted aliphatic C1-10 radical;<br>
R2 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(= O)-NH2;<br>
-S(= O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= O)-H; -S(= O)2-OH; -<br>
C(= NH)-NH2; -C(= NH)-NH-R9; -N= C(NH2)2; -N= C(NHR10)-(NHR11); -<br><br>
O-P(= O)2-O-R12; -NHR13; -NR14R15; -NH-C(= O)-R13; -OR16; -SR17; -C(= <br>
O)-NHR18; -C(= O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-NR22R23; -C(= <br>
O)-OR24; -C(= O)-R25; -S(= O)-R26; or -S(= O)2-R27 or for a linear or<br>
branched, saturated or unsaturated, unsubstituted or at least<br>
monosubstituted aliphatic C1-10 radical;<br>
R3 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(= O)-NH2;<br>
-S(= O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= O)-H; -S(= O)2-OH; -<br>
C(= NH)-NH2; -C(= NH)-NH-R9; -N= C(NH2)2; -N= C(NHR10)-(NHR11); -<br>
O-P(= O)2-O-R12; -NHR13; -NR14R15; -NH-C(= O)-R13; -OR16; -SR17, -C(= <br>
O)-NHR18; -C(= O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-NR22R23; -C(=<br>
 O)-OR24; -C(= O)-R25; -S(= O)-R26; or -S(= O)2-R27 or for a linear or<br>
branched, saturated or unsaturated, unsubstituted or at least<br>
monosubstituted aliphatic C1-10 radical;<br>
R4 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(= O)-NH2;<br>
-S(= O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= O)-H; -S(= O)2-OH; -<br>
C(= NH)-NH2; -C(= NH)-NH-R9; -N= C(NH2)2; -N= C(NHR10)-(NHR11); -<br>
O-P(= O)2-O-R12; -NHR13; -NR14R15; -NH-C(= O)-R13; -OR16; -SR17; -C(= O)-NHR18; -C(= <br>
O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-NR22R23; -C(=<br>
 O)-OR24; -C(= O)-R25; -S(= O)-R26; or -S(= O)2-R27 or for a linear or<br>
branched, saturated or unsaturated, unsubstituted or at least<br>
monosubstituted aliphatic C1-10 radical;<br>
R5 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(= O)-NH2;<br>
-S(= O)2-NH2; -C(= O)-NH-OH; -C(= O)-OH; -C(= O)-H; -S(= O)2-OH; -<br><br>
C(= NH)-NH2; -C(= NH)-NH-R9; -N= C(NH2)2; -N= C(NHR10)-(NHR11); -<br>
O-P(= O)2-O-R12; -NHR13; -NR14R15; -NH-C(= O)-R13; -OR16; -SR17; -C(= <br>
O)-NHR18; -C(= O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-NR22R23; -C(= <br>
O)-OR24; -C(= O)-R25; -S(= O)-R26; or -S(= O)2-R27 or for a linear or<br>
branched, saturated or unsaturated, unsubstituted or at least<br>
monosubstituted aliphatic C1-10 radical;<br>
R6 stands in each case for hydrogen or for a linear or branched, saturated<br>
or unsaturated, unsubstituted or at least monosubstituted aliphatic C1-10<br>
radical;<br>
R7 stands for hydrogen or -OH;<br>
or R6 and R7 each form, together with the interconnecting carbon atom<br>
as ring member, a saturated or unsaturated, unsubstituted or at least<br>
monosubstituted three-membered, four-membered, five-membered, or<br>
six-membered cycloaliphatic radical;<br>
R8 stands for -SF5; -O-CF3; -CF3; -O-CFH2; -O-CF2 H; -CFH2; -CF2 H; or for<br>
an unsubstituted or at least monosubstituted tert-butyl radical;<br>
T stands for C-R35 and U stands for C-R36 and V stands for N and W<br>
stands for C-R38<br>
or<br>
T stands for C-R35 and U stands for N and V stands for C-R37 and W<br>
stands for C-R38<br><br>
or<br>
T stands for N and U stands for C-R36 and V stands for C-R37 and W<br>
stands for C-R38<br>
or<br>
T stands for N and U stands for N and V stands for C-R37 and W stands<br>
for C-R38<br>
or<br>
T stands for N and U stands for C-R36 and V stands for N and W stands<br>
for C-R38<br>
or<br>
T stands for C-R35 and U stands for N and V stands for N and W stands<br>
for C-R38<br>
or<br>
T stands for C-R35 and U stands for C-R36 and V stands for C-R37 and<br>
W stands for C-R38;<br>
R9 R10 p11 R12 R13 R14 R15 R16 R17 R18 R19 p20 R21 R22 R23 R24 R25<br>
R26 and R27 each independently<br>
stand for a linear or branched, saturated or unsaturated, unsubstituted<br>
or at least monosubstituted aliphatic C1-10 radical;<br>
for an unsaturated or saturated, unsubstituted or at least<br>
monosubstituted, three-membered, four-membered, five-membered,<br>
six-membered, seven-membered, eight-membered, or nine-mem be red<br>
cycloaliphatic radical optionally containing at least one heteroatom as<br><br>
ring member, which can be condensed with a saturated or unsaturated,<br>
unsubstituted or at least monosubstituted monocyclic or polycyclic ring<br>
system and/or can be bonded via a linear or branched, unsubstituted or<br>
at least monosubstituted C1-6 alkylene group or two to six-membered<br>
heteroalkylene group;<br>
or for an unsubstituted or at least monosubstituted five-membered to<br>
fourteen-membered aryl radical or heteroaryl radical, which can be<br>
condensed with a saturated or unsaturated, unsubstituted or at least<br>
monosubstituted monocyclic or polycyclic ring system and/or can be<br>
bonded via a linear or branched, unsubstituted or at least<br>
monosubstituted C1-6 alkylene group or two to six-membered<br>
heteroalkylene group;<br>
R35, R36, and R37 each independently stand for H; F; CI; Br; I; -SF5; -NO2; -CF3; -CN; -<br>
NH2; -OH; -SH; -C(= O)-NH2; -S(= O)2-NH2; -C(= O)-NH-OH; -C(= O)-<br>
OH; -C(= O)-H; -S(= O)2-OH; -NHR13; -NR14R15; -NH-C(= O)-R13; -OR16;<br>
-SR17; -C(= O)-NHR18; -C(= O)-NR19R20; -S(= O)2-NHR21; -S(= O)2-<br>
NR22R23; -C(= O)-OR24; -C(= O)-R25; -S(= O)-R26; -S(= O)2R27;<br>
for a linear or branched, saturated or unsaturated, unsubstituted or at<br>
least monosubstituted aliphatic C1-10 radical;<br>
or for an unsubstituted or at least monosubstituted five-membered to<br>
fourteen-membered aryl radical or heteroaryl radical, which can be<br>
condensed with a saturated or unsaturated, unsubstituted or at least<br><br>
monosubstituted monocyclic or polycyclic ring system and/or can be<br>
bonded via a linear or branched, unsubstituted or at least<br>
monosubstituted C1-6-alkylene group or C2-6-alkenylene group or C2_6-<br>
alkynylene group;<br>
R38 stands for F; CI; Br; I; -SF5; -NO2; -CF3; -CF2 CI; -CN; -NH2; -OH; -SH; -<br>
C(= O)-NH2; -S(= O)2-NH2; -C(= O)-NH-OH; and -C(= O)-OH; -C(= O)-<br>
H; -S(= O)2-OH; -NHR39; -NR40R41; -OR42; -SR43; -C(= O)-NHR44; -C(= <br>
O)-NR45R46; -S(= O)2-NHR47; -S(= O)2-NR48R49; -C(= O)-OR50; -C(= O)-<br>
R51; -S(= O)-R52; -S(= O)2-R53; -C(= NH)-NH2; -C(= NH)-NH-R54; -N=<br>
C(NH2)2; -N= C(NHR55)-(NHR56)<br>
for a linear or branched, saturated or unsaturated, unsubstituted or at<br>
least monosubstituted aliphatic C1-10 radical;<br>
for an unsaturated or saturated, unsubstituted or at least<br>
monosubstituted three-membered, four-membered, five-membered, six-<br>
membered, seven-membered, eight-membered, or nine-membered<br>
cycloaliphatic radical optionally exhibiting at least one heteroatom as<br>
ring member, each of which is bonded to the parent structure over a<br>
carbon atom in the ring of the cycloaliphatic radical and is condensed<br>
with a saturated or unsaturated, unsubstituted or at least<br>
monosubstituted monocyclic or polycyclic ring system and/or can be<br>
bonded via a linear or branched, unsubstituted or at least<br>
monosubstituted C1-6 alkylene group or C2-6 alkenylene group or C2-6<br>
alkynylene group;<br><br>
or for an unsubstituted or at least monosubstituted five-membered to<br>
fourteen-membered aryl radical or heteroaryl radical, which can be<br>
condensed with a saturated or unsaturated, unsubstituted or at least<br>
monosubstituted monocyclic or polycyclic ring system and/or can be<br>
bonded via a linear or branched, unsubstituted or at least<br>
monosubstituted C1-6 alkylene group or C2-6 alkenylene group or C2-6-<br>
alkynylene group;<br>
R39 R40 R41 R42 R43 R44 R45 R46 R47 R48 R49 R50 R51 R52 R53 R54 R55<br>
and R56 each independently<br>
stand for a linear or branched, saturated or unsaturated, unsubstituted<br>
or at least monosubstituted aliphatic C1-10 radical;<br>
for an unsaturated or saturated, unsubstituted or at least<br>
monosubstituted, three-membered, four-membered, five-membered,<br>
six-membered, seven-membered, eight-membered, or nine-membered<br>
cycloaliphatic radical optionally containing at least one heteroatom as<br>
ring member, which can be condensed with a saturated or unsaturated,<br>
unsubstituted or at least monosubstituted monocyclic or polycyclic ring<br>
system and/or can be bonded via a linear or branched, unsubstituted or<br>
at least monosubstituted C1-6-alkylene group or two to six-membered<br>
heteroalkylene group;<br><br>
or for an unsubstituted or at least monosubstituted five-membered to<br>
fourteen-membered aryl radical or heteroaryl radical, which can be<br>
condensed with a saturated or unsaturated, unsubstituted or at least<br>
monosubstituted monocyclic or polycyclic ring system and/or can be<br>
bonded via a linear or branched, unsubstituted or at least<br>
monosubstituted C1-6-alkylene group or two to six-membered<br>
heteroalkylene group;<br>
or<br>
R40 and R41 form, together with the interconnecting nitrogen atom as ring<br>
member, a saturated or unsaturated four-membered, five-membered,<br>
six-membered, seven-membered, eight-membered, or nine-membered<br>
heterocycloaliphatic radical, which is unsubstituted or substituted by 1,<br>
2, 3, 4, or 5 radicals R57 and optionally exhibits at least one further<br>
heteroatom as ring member, and which can be condensed with a<br>
saturated or unsaturated, unsubstituted or at least monosubstituted<br>
monocyclic or polycyclic ring system;<br>
R57 stands for -NHR58, -NR59R60, or for a linear or branched, saturated or<br>
unsaturated, unsubstituted or at least monosubstituted aliphatic C1-10<br>
radical;<br>
R58, R59, and R60 each independently stand for -C(= O)-R61; for a linear or<br>
branched, saturated or unsaturated, unsubstituted or at least<br>
monosubstituted aliphatic C1-10 radical<br><br>
or for an unsubstituted or at least monosubstituted five-membered to<br>
fourteen-membered aryl radical or heteroaryl radical, which can be<br>
condensed with a saturated or unsaturated, unsubstituted or at least<br>
monosubstituted monocyclic or polycyclic ring system and/or can be<br>
bonded via a linear or branched, unsubstituted or at least<br>
monosubstituted C1-6 alkylene group or C2-6 alkenylene group or C2-6<br>
alkynylene group;<br>
and<br>
R61 stands for a linear or branched, saturated or unsaturated, unsubstituted<br>
or at least monosubstituted aliphatic C1-10 radical;<br>
each optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers thereof, the racemates thereof or<br>
in the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or each in the form of<br>
corresponding salts, or each in the form of corresponding solvates;<br>
wherein<br>
the aforementioned aliphatic C1-10 radicals and tert-butyl radicals can each be<br>
optionally substituted by 1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents independently<br>
selected from the group consisting of F, CI, Br, I, -CN, -NO2, -OH, -NH2, -SH, -<br><br>
O(C1-5 alkyl), -S(C1-5 alkyl), -NH(C1-5 alkyl), -N(C1-5 alkyl)-(C1-5 alkyl), -C(= O)-<br>
O-(C1-5 alkyl), -O-C(= O)-(C1-5 alkyl), -O-phenyl, phenyl, -OCF3, and -SCF3;<br>
the aforementioned two to six-membered heteroalkylene groups, C1-6 alkylene<br>
groups, and C2-6 alkenylene groups and C2-6 alkynylene groups can each be<br>
optionally substituted by 1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents independently<br>
selected from the group consisting of F, CI, Br, I, -CN, -NO2, -OH, -NH2, -SH, -<br>
0(C1-5 alkyl), -S(C1-5 alkyl), -NH(C1-5 alkyl), -N(C1-5 alkyl)-(C1-5 alkyl), -OCF3,<br>
and -SCF3;<br>
the aforementioned heteroalkylene groups each optionally exhibit 1, 2, or 3<br>
heteroatom(s) independently selected from the group consisting of oxygen,<br>
sulfur, and nitrogen (NH) as link(s);<br>
the aforementioned (hetero)cycloaliphatic radicals are optionally each<br>
substituted by 1, 2, 3, 4, or 5 substituents independently selected from the<br>
group consisting of -C1-6-alkylene-OH, = CH2, -O-C1-5-alkyleneoxetanyl, -C1-5-<br>
alkylene-O-C1-5 alkylene-oxetanyl, -CH2-NH-C1-5 alkyl, -CH2-N(C1-5 alkyl)2, -<br>
N[C(= O)-C1-5 alkyl]-phenyl, -CH2-O-C1-5-alkyl, oxo (= O), thioxo (= S), F, CI,<br>
Br, I, -CN, -CF3, -SF5, -OH, -O-C1-5-alkyl, -O-C(= O)-C1-5-alkyl, -NH2, -NO2, -O-<br>
CF3, -S-CF3, -SH, -S-C1-5-alkyI), -C1-5-alkyI, -C(= O)-C1-5-alkyl), -C(= O)-OH, -<br>
C(= O)-O-C1-5-alkyl, -NH-C1-5-alkyl), -N(C1-5 alkyl)2, -NH-phenyl, -N(C1-5-alkyl)-<br>
phenyl, cyclohexyl, cyclopentyl, (4,5)-dihydroisoxazolyl, thiazolyl, (1,2,5)-<br>
thiadiazolyl, thiophenyl, phenethyl, piperidinyl, pyrrolidinyl, -(CH2)pyridinyl,<br>
pyridinyl, -O-phenyl, -O-benzyl, phenyl, and benzyl, and the cyclic moiety of<br>
the radicals oxetanyl, (4,5)-dihydroisoxazolyl, thiazolyl, (1,2,5)-thiadiazolyl,<br><br>
thiophenyl, phenethyl, -N[C(= O)-C1-5-alkyl]-phenyl, -NH-phenyl, -N(C1-5 alkyl)-<br>
phenyl, -(CH2)-pyridinyl, pyridinyl, -O-phenyl, -O-benzyl, phenyl, and benzyl<br>
can each be substituted by 1, 2, 3, 4, or 5 substituents independently selected<br>
from the group consisting of F, CI, Br, -OH, -CF3, -SF5, -CN, -NO2, -d-5-alkyl, -<br>
O-C1-5-alkyl, -O-CF3, -S-CF3, phenyl, and -O-benzyl,<br>
and, unless otherwise stated, the aforementioned (hetero)cycloaliphatic<br>
radicals can each optionally exhibit 1, 2, or 3 (further) heteroatom(s)<br>
independently selected from the group consisting of oxygen, nitrogen, and<br>
sulfur;<br>
the rings of the aforementioned monocyclic or polycyclic ring systems can<br>
each be optionally substituted by 1, 2, 3, 4, or 5 substituents independently<br>
selected from the group consisting of oxo (= O), thioxo (= S), F, CI, Br, I, -CN, -<br>
CF3, -SF5, -OH, -O-C1-5-alkyl, -NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-C1-5-alkyl, -<br>
C1-5-alkyl, -C(= O)-C1-5-alkyl, -C(= O)-OH, -C(= O)-O-C1-5-alkyl), -NH-C1-5-alkyl,<br>
-N(C1-5-alkyl)2, -O-phenyl, -O-benzyl, phenyl, and benzyl, and the cyclic moiety<br>
of the radicals -O-phenyl, -O-benzyl, phenyl, and benzyl can each be<br>
substituted by 1, 2, 3, 4, or 5 substituents independently selected from the<br>
group consisting of F, CI, Br, -OH, -CF3, -SF5, -CN, -NO2, -C1-5-alkyl, -O-C1-5-<br>
alkyl, -O-CF3, -S-CF3, phenyl, and -O-benzyl,<br>
and the rings of the aforementioned monocyclic or polycyclic ring systems are<br>
each five-membered, six-membered, or seven-membered and can each<br>
optionally exhibit 1, 2, 3, 4, or 5 heteroatom(s) as ring member(s), which are<br><br>
independently selected from the group consisting of oxygen, nitrogen, and<br>
sulfur;<br>
and the aforementioned aryl radicals or heteroaryl radicals can each be<br>
optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected<br>
from the group consisting of F, CI, Br, I, -CN, -CF3, -SF5, -OH, -O-C1-5-alkyl, -<br>
NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-C1-5-alkyI, -C1-5-alkyl, -C(= O)-OH, -C(= <br>
O)-O-C1-5-alkyl, -NH-C1-5-alkyl), -N(C1-5-alkyl)2, -NH-S(= O)2-C1-5-alkyl, -NH-<br>
C(= O)-O-C1-5-alkyl, -C(= O)-H, -C(= O)-C1-5-alkyl, -C(= O)-NH2, -C(= O)-NH-<br>
C1-5-alkyl, -C(= O)-N-(C1-5 alkyl)2, -O-phenyl, -O-benzyl, phenyl, and benzyl,<br>
and the cyclic moiety of the radicals -O-phenyl, -O-benzyl, phenyl, and benzyl<br>
can each be substituted by 1, 2, 3, 4, or 5 substituents independently selected<br>
from the group consisting of F, CI, Br, -OH, -CF3, -SF5, -CN, -NO2, -C1-5-alkyl, -<br>
O-C1-5-alkyl, -O-CF3, -S-CF3, phenyl, and -O-benzyl,<br>
and<br>
the aforementioned heteroaryl radicals can each optionally exhibit 1,2,3, 4, or<br>
5 heteroatom(s) independently selected from the group consisting of oxygen,<br>
nitrogen, and sulfur as ring member(s).<br>
The compounds according to claim 1, characterized in that<br>
n	stands for 0, 1, 2, 3, or 4;<br><br>
R1 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; and -NH2; -OH; -SH; -C(=O)-<br>
NH2; -S(=O)2-NH2; -C(=O)-NH-OH; -C(=O)-OH; -C(=O)-H; -S(=O)2-OH;<br>
-NHR13; -NR14R15; -NH-C(=O)-R13; -OR16; -SR17; -S(=O)-NR22R23; -<br>
S(=O)-R26; -S(=O)2-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CCI3, -CBr3, -CHF2, -CH2F, -CF2CI, -CCI2F,<br>
ethyl, -CF2-CH3, -CH2-CF3, -C2F5, -CH2-CCI3, -CH2-CBr3, -CHF-CF2CI, -<br>
CF2-CF2CI, -CFCI-CF2CI, n-propyl, -CF2-CF2-CF3, -CF(CF3)2, isopropyl,<br>
n-butyl, sec-butyl, isobutyl, and tert-butyl;<br>
R2 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(=O)-NH2;<br>
-S(=O)2-NH2; -C(=O)-NH-OH; -C(=O)-OH; -C(=O)-H; -S(=O)2-OH; -<br>
NHR13; -NR14R15; -NH-C(=O)-R13; -OR16; -SR17; -S(=O)-NR22R23; -<br>
S(=O)-R26; -S(=O)2-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CCI3, -CBr3, -CHF2, -CH2F, -CF2CI, -CCI2F,<br>
ethyl, -CF2-CH3, -CH2-CF3, -C2F5, -CH2-CCI3, -CH2-CBr3, -CHF-CF2CI, -<br>
CF2-CF2CI, -CFCI-CF2CI, n-propyl, -CF2-CF2-CF3, -CF(CF3)2, isopropyl,<br>
n-butyl, sec-butyl, isobutyl, and tert-butyl;<br>
R3 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(=O)-NH2;<br>
-S(=O)2-NH2; -C(=O)-NH-OH; -C(=O)-OH; -C(=O)-H; -S(=O)2-OH; -<br>
NHR13; -NR14R15; -NH-C(=O)-R13; -OR16; -SR17; -S(=O)-NR22R23; -<br>
S(=O)-R26; -S(=O)2-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CCI3, -CBr3, -CHF2, -CH2F, -CF2CI, -CCI2F,<br>
ethyl, -CF2-CH3, -CH2-CF3, -C2F5, -CH2-CCI3, -CH2-CBr3, -CHF-CF2CI, -<br>
CF2-CF2CI, -CFCI-CF2CI, n-propyl, -CF2-CF2-CF3, -CF(CF3)2, isopropyl,<br>
n-butyl, sec-butyl, isobutyl, and tert-butyl;<br><br>
R4 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(=O)-NH2;<br>
-S(=O)2-NH2; -C(=O)-NH-OH; -C(=O)-OH; -C(=O)-H; -S(=O)2-OH; -<br>
NHR13; -NR14R15; -NH-C(=O)-R13; -OR16; -SR17; -S(=O)-NR22R23; -<br>
S(=O)-R26; -S(=O)2-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CCI3, -CBr3, -CHF2, -CH2F, -CF2CI, -CCI2F,<br>
ethyl, -CF2-CH3, -CH2-CF3, -C2F5, -CH2-CCI3, -CH2-CBr3, -CHF-CF2CI, -<br>
CF2-CF2CI, -CFCI-CF2CI, n-propyl, -CF2-CF2-CF3, -CF(CF3)2, isopropyl,<br>
n-butyl, sec-butyl, isobutyl, and tert-butyl;<br>
R5 stands for H; F; CI; Br; I; -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(=O)-NH2;<br>
-S(=O)2-NH2; -C(=O)-NH-OH; -C(=O)-OH; -C(=O)-H; -S(=O)2-OH; -<br>
NHR13; -NR14R15; -NH-C(=O)-R13; -OR16; -SR17; -S(=O)-NR22R23; -<br>
S(=O)-R26; -S(=O)2-R27 or for a radical selected from the group<br>
consisting of methyl, -CF3, -CCI3, -CBr3, -CHF2, -CH2F, -CF2CI, -CCI2F,<br>
ethyl, -CF2-CH3, -CH2-CF3, -C2F5, -CH2-CCI3, -CH2-CBr3, -CHF-CF2CI, -<br>
CF2-CF2CI, -CFCI-CF2CI, n-propyl, -CF2-CF2-CF3, -CF(CF3)2, isopropyl,<br>
n-butyl, sec-butyl, isobutyl, and tert-butyl;<br>
R6 stands for hydrogen or for an alkyl radical selected from the group<br>
consisting of-CH2-OH, -CH2-CH2-OH, -CH2-CH2-CH2-OH, -CH2-CH2-<br>
CH2-CH2-OH, isopropyl, n-butyl, sec-butyl, isobutyl, methyl, ethyl, and<br>
n-propyl;<br>
R7 stands for hydrogen or-OH;<br><br>
or R6 and R7 form, together with the interconnecting carbon atom as ring<br>
member, a radical selected from the group consisting of cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl;<br>
R8 stands for -SF5; -O-CF3; -O-CFH2; -O-CF2H; -CFH2; -CF2H; -CF3; or for<br>
a tert-butyl radical, each of which can be unsubstituted or substituted by<br>
1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents independently selected from the<br>
group consisting of F, CI, Br, I, -CN, -NO2, -OH, -NH2, -SH, -O-CH3, -O-<br>
C2H5, -O-CH(CH3)2, -NH-CH3, and -NH-C2H5;<br>
T stands for C-R35 and U stands for C-R36 and V stands for N and W stands<br>
for C-R38<br>
or<br>
T stands for C-R35 and U stands for N and V stands for C-R37 and W stands<br>
for C-R38<br>
or<br>
T stands for N and U stands for C-R36 and V stands for C-R37 and W stands<br>
for C-R38<br>
or<br>
T stands for N and U stands for N and V stands for C-R37 and W stands for C-<br>
R38<br>
or<br>
T stands for N and U stands for C-R36 and V stands for N and W stands for C-<br>
R38<br>
or<br><br>
T stands for C-R35 and U stands for N and V stands for N and W stands for C-<br>
R38<br>
or<br>
T stands for C-R35 and U stands for C-R36 and V stands for C-R37 and W<br>
stands for C-R38<br>
R13, R14, R15, R16, R17, R26, and R27 each independently<br>
stand for a radical selected from the group consisting of methyl, -CF3, -<br>
CCI3, -CBr3, -CHF2, -CH2F, -CF2CI, -CCI2F, -CH2-CN, -CH2-O-CH3, -<br>
CH2-O-CF3, -CH2-SF3, ethyl, -CF2-CH3, -CH2-CF3, -C2F5, -CH2-CCI3, -<br>
CH2-CBr3, -CHF-CF2CI, -CF2-CF2CI, -CFCI-CF2CI, -CH2-CH2-CN, n-<br>
propyl, -CF2-CF2-CF3, -CF(CF3)2, isopropyl, -CH2-CH2-CH2-CN, -CH2-O-<br>
CH2-CH3, -CH2-CH2-SF3, -CH2-CH2-OCF3, -CH(CH3)-(O-CH3), -<br>
CH(CH3)-(S-CH3), n-butyl, -CF2-CF2-CF2-CF3, -CH2-CH2-CH2-CH2-CN,<br>
sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-heptyl, 4-heptyl, n-<br>
octyl, n-nonyl, 5-nonyl, (2,6)-dimethyl-hept-4-yl, 3-methyl-butyl, n-hexyl,<br>
(3,3)-dimethylbutyl, -CH2-CH2-O-CH3, -CH2-CH2-O-C2H5, -CH2-CH2-<br>
CH2-O-CH3, ethenyl, propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, and 3-<br>
pentenyl;<br>
for a radical selected from the group consisting of 2,3-dihydro-1H-<br>
indenyl, cyclopropyl, oxetanyl, cyclobutyl, cyclopentyl, cyclohexyl,<br>
imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl,<br>
piperidinyl, morpholinyl, piperazinyl, azepanyl, diazepanyl, azocanyl,<br>
and thiomorpholinyl, each of which can be bonded via a -CH2-O-, -CH2-<br><br>
CH2-O-, -CH2-CH2-O-CH2-, -CH2-CH(CH3)-O-CH2-, -(CH2)-, -(CH2)2 or -<br>
(CH2)3 group and/or can each be unsubstituted or optionally substituted<br>
by 1, 2, 3, 4, or 5 substituents independently selected from the group<br>
consisting of oxo (=O), thioxo (=S), -OH, -O-CH3, -O-C2H5, -O-<br>
CH(CH3)2, -O-C(CH3)3, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, -S-<br>
CH(CH3)2, -S-C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-<br>
butyl, isobutyl, tert-butyl, n-pentyl, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-<br>
CH(CH3)2, -C(=O)-C(CH3)3, -C(=O)-OH, -C(=O)-O-CH3, -C(=O)-O-C2H5,<br>
-C(=O)-O-CH(CH3)2, and -C(=O)-O-C(CH3)3;<br>
or for a radical selected from the group consisting of phenyl, naphthyl,<br>
thiophenyl, furanyl, pyrrolyl, pyrazolyl, pyrazinyl, pyranyl, triazolyl,<br>
pyridinyl, imidazolyl, thiazolyl, oxazolyl, and isoxazolyl, and each radical<br>
can be bonded via a -(CH2)-, -(CH2)2 or -(CH2)3 group and/or can be<br>
unsubstituted or optionally substituted by 1, 2, 3, 4, or 5 substituents<br>
independently selected from the group consisting of F, CI, Br, I, -CN, -<br>
CF3, -SF5, -OH, -O-CH3, -O-C2H5, -O-CH(CH3)2, -O-C(CH3)3, -NH2, -<br>
NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, -S-CH(CH3)2, -S-C(CH3)3,<br>
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,<br>
n-pentyl, -C(=O)-OH, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-<br>
CH(CH3)2, -C(=O)-O-C(CH3)3, -NH-CH3, -NH-C2H5, -NH-C(CH3)3, -<br>
N(CH3)2, -N(C2H5)2, -N(CH3)-(C2H5), -NH-C(=O)-O-CH3, -NH-C(=O)-O-<br>
C2H5, -NH-C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -<br>
C(=O)-CH(CH3)2, -C(=O)-C(CH3)3, -C(=O)-NH2, -C(=O)-NH-CH3, -<br>
C(=O)-NH-C2H5, -C(=O)-N(CH3)2, -C(=O)-N(C2H5)2, -O-phenyl, -O-<br>
benzyl, phenyl, and benzyl;<br><br>
R35, R36, and R37 each independently stand for H; F; CI; Br; I; -SF5; -NO2; -CN;<br>
-NH2; -OH; -SH; -C(=O)-NH2; -S(=O)2-NH2; -C(=O)-NH-OH; -C(=O)-OH;<br>
-C(=O)-H; -S(=O)2-OH; -NHR13; -NR14R15; -OR16; -SR17; -S(=O)-R25; -<br>
S(=O)2-R26; for a radical selected from the group consisting of-CH2-OH,<br>
methyl, -CF3, -CCI3, -CBr3, -CHF2, -CH2F, -CF2CI, -CCI2F, ethyl, -CF2-<br>
CH3, -CH2-CF3, -C2F5, -CH2-CCI3, -CH2-CBr3, -CHF-CF2CI, -CF2-CF2CI,<br>
-CFCI-CF2CI, n-propyl, -CF2-CF2-CF3, -CF(CF3)2, isopropyl, n-butyl,<br>
sec-butyl, isobutyl, and tert-butyl or for a phenyl radical, which are<br>
unsubstituted or can optionally be substituted by 1, 2, 3, 4, or 5<br>
substituents independently selected from the group consisting of F, CI,<br>
Br, I, -CN, -CF3, -SF5, -OH, -O-CH3, -O-C2H5, -O-CH(CH3)2, -O-C(CH3)3,<br>
-NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, -S-CH(CH3)2, -S-<br>
C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, and n-pentyl;<br>
R38 stands for -SF5; -NO2; -CN; -NH2; -OH; -SH; -C(=O)-NH2; -S(=O)2-NH2; -<br>
C(=O)-NH-OH; -C(=O)-OH; -C(=O)-H; -S(=O)2-OH; -NHR39; -NR40R41; -<br>
OR42; -SR43; -C(=O)-OR50; -S(=O)-R52; -S(=O)2-R53; -C(=NH)-NH2; -<br>
C(=NH)-NH-R54; -N=C(NH2)2; -N=C(NHR55)-(NHR56);<br>
for a radical selected from the group consisting of cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, imidazolidinyl,<br>
tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl,<br>
morpholinyl, piperazinyl, azepanyl, diazepanyl, azocanyl, and<br>
thiomorpholinyl, each of which is bonded to the basic framework via a<br><br>
carbon atom of the rings of the aforementioned radicals or via a -<br>
(CH=CH)-, -CC or -CC-CH2- group and is unsubstituted or can<br>
optionally be substituted by 1, 2, 3, 4, or 5 substituents independently<br>
selected from the group consisting of-CN, -CH2-N(CH3)2, -CH2-<br>
N(C2H5)2, -CH2-NH-CH3, -CH2-NH-C2H5, -N-[C(=O)-C2H5]phenyl, -N-<br>
[C(=O)-CH3]phenyl, oxo (=O), thioxo (=S), -OH, -O-CH3, -O-C2H5, -O-<br>
CH(CH3)2, -O-C(CH3)3, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, -S-<br>
CH(CH3)2, -S-C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-<br>
butyl, isobutyl, tert-butyl, n-pentyl, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-<br>
CH(CH3)2, -C(=O)-C(CH3)3, -C(=O)-OH, -C(=O)-O-CH3, -C(=O)-O-C2H5,<br>
-C(=O)-O-CH(CH3)2, and -C(=O)-O-C(CH3)3;<br>
or for a radical selected from the group consisting of (1,3)-<br>
benzodioxolyl, (1,4)-benzodioxanyl, tetrazolyl, (2,3)-dihydrothieno[3.4-<br>
b][1.4]dioxinyl, benzo[b]furanyl, phenyl, naphthyl, thiophenyl, furanyl,<br>
pyrrolyl, pyrazolyl, pyrazinyl, pyranyl, triazolyl, pyridinyl, imidazolyl,<br>
indolyl, isoindolyl, thiazolyl, oxazolyl, isoxazolyl, pyridazinyl, pyrazinyl,<br>
pyrimidinyl, indazolyl, quinoxalinyl, quinolinyl, and isoquinolinyl, each of<br>
which can be bonded via a -(CH=CH)-, -C=C-, -(CH2)-, -(CH2)2- or -<br>
(CH2)3 group and/or is unsubstituted or can optionally be substituted by<br>
1,2,3, 4, or 5 substituents independently selected from the group<br>
consisting of F, CI, Br, I, -CN, -CF3, -SF5, -OH, -O-CH3, -O-C2H5, -O-<br>
CH(CH3)2, -O-C(CH3)3, -NH2, -NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-<br>
C2H5, -S-CH(CH3)2, -S-C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-<br>
butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, -C(=O)-OH, -C(=O)-O-CH3,<br>
-C(=O)-O-C2H5, -C(=O)-O-CH(CH3)2, -C(=O)-O-C(CH3)3, -NH-CH3, -<br><br>
NH-C2H5, -NH-C(CH3)3, -N(CH3)2, -N(C2H5)2, -N(CH3)-(C2H5), -NH-<br>
C(=O)-O-CH3, -NH-S(=O)2-CH3, -NH-S(=O2)-C2H5, -NH-S(=O)2-<br>
CH(CH3)2, -NH-C(=O)-O-C2H5, -NH-C(=O)-O-C(CH3)3, -C(=O)-H, -<br>
C(=O)-CH3, -C(=O)-C2H5, -C(=O)-CH(CH3)2, -C(=O)-C(CH3)3, -C(=O)-<br>
NH2, -C(=O)-NH-CH3, -C(=O)-NH-C2H5, -C(=O)-N(CH3)2) -C(=O)-<br>
N(C2H5)2, -O-phenyl, -O-benzyl, phenyl, and benzyl;<br>
R39, R40, and R41, R42, R43, R50, R52, R53, R54, R55, and R56 each independently<br>
stand for a radical selected from the group consisting of methyl, -CF3, -<br>
CCI3, -CBr3, -CHF2, -CH2F, -CF2CI, -CCI2F, -CH2-CN, -CH2-O-CH3, -<br>
CH2-O-CF3, -CH2-SF3, ethyl, -CF2-CH3, -CH2-CF3, -C2F5, -CH2-CCI3, -<br>
CH2-CBr3, -CHF-CF2CI, -CF2-CF2CI, -CFCI-CF2CI, -CH2-CH2-CN, n-<br>
propyl, -CF2-CF2-CF3, -CF(CF3)2, isopropyl, -CH2-CH2-CH2-CN, -CH2-O-<br>
CH2-CH3, -CH2-CH2-SF3, -CH2-CH2-OCF3, -CH(CH3)-(O-CH3), -<br>
CH(CH3)-(S-CH3), n-butyl, -CF2-CF2-CF2-CF3, -CH2-CH2-CH2-CH2-CN,<br>
sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-heptyl, 4-heptyl, n-<br>
octyl, n-nonyl, 5-nonyl, (2,6)-dimethyl-hept-4-yl, 3-methyl-butyl, n-hexyl,<br>
(3,3)-dimethylbutyl, -CH2-CH2-O-CH3, -CH2-CH2-O-C2H5, -CH2-CH2-<br>
CH2-O-CH3, ethenyl, propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, and 3-<br>
pentenyl;<br>
for a radical selected from the group consisting of 2,3-dihydro-1H-<br>
indenyl, cyclopropyl, oxetanyl, cyclobutyl, cyclopentyl, cyclohexyl,<br>
imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl,<br>
piperidinyl, morpholinyl, piperazinyl, azepanyl, diazepanyl, azocanyl,<br><br>
and thiomorpholinyl, each of which can be bonded via a -CH2-O-, -CH2-<br>
CH2-O-, -CH2-CH2-O-CH2-, -CH2-CH(CH3)-O-CH2-, -(CH2)-, -(CH2)2- or -<br>
(CH2)3 group and/or can each be unsubstituted or optionally substituted<br>
by 1, 2, 3, 4, or 5 substituents independently selected from the group<br>
consisting of oxo (=O), thioxo (=S), -OH, -O-CH3, -O-C2H5, -O-<br>
CH(CH3)2, -O-C(CH3)3, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, -S-<br>
CH(CH3)2, -S-C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-<br>
butyl, isobutyl, tert-butyl, n-pentyl, -C(=O)-CH3, -C(=O)-C2H5, -C(=O)-<br>
CH(CH3)2, -C(=O)-C(CH3)3, -C(=O)-OH, -C(=O)-O-CH3, -C(=O)-O-C2H5,<br>
-C(=O)-O-CH(CH3)2, and -C(=O)-O-C(CH3)3;<br>
or for a radical selected from the group consisting of phenyl, naphthyl,<br>
thiophenyl, furanyl, pyrrolyl, pyrazolyl, pyrazinyl, pyranyl, triazolyl,<br>
pyridinyl, imidazolyl, thiazolyl, oxazolyl, and isoxazolyl, and each radical<br>
can be bonded via a -(CH2)-, -(CH2)2- or -(CH2)3 group and/or can each<br>
be unsubstituted or optionally substituted by 1, 2, 3, 4, or 5 substituents<br>
independently selected from the group consisting of F, CI, Br, I, -CN, -<br>
CF3, -SF5, -OH, -O-CH3, -O-C2H5, -O-CH(CH3)2, -O-C(CH3)3, -NH2, -<br>
NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, -S-CH(CH3)2, -S-C(CH3)3,<br>
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,<br>
n-pentyl, -C(=O)-OH, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-<br>
CH(CH3)2, -C(=O)-O-C(CH3)3, -NH-CH3, -NH-C2H5, -NH-C(CH3)3, -<br>
N(CH3)2, -N(C2H5)2, -N(CH3)(C2H5), -NH-C(=O)-O-CH3, -NH-C(=O)-O-<br>
C2H5, -NH-C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -<br>
C(=O)-CH(CH3)2, -C(=O)-C(CH3)3, -C(=O)-NH2, -C(=O)-NH-CH3, -<br><br>
C(=O)-NH-C2H5, -C(=O)-N(CH3)2, -C(=O)-N(C2H5)2, -O-phenyl, -O-<br>
benzyl, phenyl, and benzyl;<br>
or<br>
R40 and R41 form, together with the interconnecting nitrogen atom as ring<br>
member,<br>
a radical selected from the group consisting of 3-aza-<br>
bicyclo[3.1.1]heptyl, 6-aza-spiro[2.5]octyl, 3-aza-bicyclo[3.2.1]octyl, 6-<br>
aza-bicyclo[3.3.1]heptyl, 8-aza-bicyclo[3.2.1]octyl, 1-oxa-2,8-<br>
diazaspiro[4.5]dec-2-enyl, azocanyl, isoindolyl, indolyl, (1,2,3,6)-<br>
tetrahydropyridinyl, (4,5,6,7)-tetrahydroisoxazolo[5.4-c]pyridinyl,<br>
pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl, diazepanyl,<br>
and thiomorpholinyl, of which the heterocycloaliphatic portion can in<br>
each case be unsubstituted or substituted by 1, 2, 3, 4, or 5 radicals<br>
R57;<br>
R57 stands for -NHR58, -NR59R60, or for an alkyl radical selected from the<br>
group consisting of-CF3, -CH2-CF3, methyl, ethyl, n-propyl, isopropyl,<br>
tert-butyl, n-butyl, sec-butyl, and isobutyl;<br>
R58, R59, and R60 each independently stand for -C(=O)-R61; or for an alkyl<br>
radical selected from the group consisting of-CF3, -CH2-CF3, methyl,<br>
ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, sec-butyl, and isobutyl;<br><br>
or for a radical selected from the group consisting of phenyl, naphthyl,<br>
thiophenyl, furanyl, pyrrolyl, pyrazolyl, pyrazinyl, pyranyl, triazolyl,<br>
pyridinyl, imidazolyl, thiazolyl, oxazolyl, and isoxazolyl, and each radical<br>
can be bonded via a -(CH2)-, -(CH2)2- or -(CH2)3 group and/or can each<br>
be unsubstituted or optionally substituted by 1, 2, 3, 4, or 5 substituents<br>
independently selected from the group consisting of F, CI, Br, I, -CN, -<br>
CF3, -SF5, -OH, -O-CH3, -O-C2H5, -O-CH(CH3)2, -O-C(CH3)3, -NH2, -<br>
NO2, -O-CF3, -S-CF3, -SH, -S-CH3, -S-C2H5, -S-CH(CH3)2, -S-C(CH3)3,<br>
methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,<br>
n-pentyl, -C(=O)-OH, -C(=O)-O-CH3, -C(=O)-O-C2H5, -C(=O)-O-<br>
CH(CH3)2, -C(=O)-O-C(CH3)3, -NH-CH3, -NH-C2H5, -NH-C(CH3)3l -<br>
N(CH3)2, -N(C2H5)2, -N(CH3)-(C2H5), -NH-C(=O)-O-CH3, -NH-C(=O)-O-<br>
C2H5, -NH-C(=O)-O-C(CH3)3, -C(=O)-H, -C(=O)-CH3, -C(=O)-C2H5, -<br>
C(=O)-CH(CH3)2, -C(=O)-C(CH3)3, -C(=O)-NH2, -C(=O)-NH-CH3, -<br>
C(=O)-NH-C2H5, -C(=O)-N(CH3)2l -C(=O)-N(C2H5)2, -O-phenyl, -O-<br>
benzyl, phenyl, and benzyl;<br>
and R61	stands for an alkyl radical selected from the group consisting of -<br>
CF3, -CH2-CF3, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, sec-<br>
butyl, and isobutyl;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br><br>
3. The compounds according to claim 1 or claim 2, characterized in that<br>
n stands for 0, 1, or 2;<br>
R1 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(=O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23; -S(=O)2-R27; or for a radical selected<br>
from the group consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-<br>
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl;<br>
R2 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(=O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23; -S(=O)2-R27; or for a radical selected<br>
from the group consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-<br>
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl;<br>
R3 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(=O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23; -S(=O)2-R27; or for a radical selected<br>
from the group consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-<br>
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl;<br>
R4 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(=O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23; -S(=O)2-R27; or for a radical selected<br>
from the group consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-<br>
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl;<br><br>
R5 stands for H; F; CI; Br; I; -NO2; -CF3; -CN; -NH2; -OH; -NH-C(=O)-R13; -<br>
OR16; -SR17; -S(=O)2-NR22R23; -S(=O)2-R27; or for a radical selected<br>
from the group consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, n-<br>
propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl;<br>
R6 stands for hydrogen or for an alkyl radical selected from the group<br>
consisting of isopropyl, n-butyl, sec-butyl, isobutyl, methyl, ethyl, and n-<br>
propyl;<br>
R7 stands for hydrogen or -OH;<br>
or<br>
R6 and R7 form, together with the interconnecting carbon atom as ring<br>
member, a radical selected from the group consisting of cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl;<br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl or -C(CH3)2(CH2OH);<br>
T stands for C-R35 and U stands for C-R36 and V stands for N and W stands<br>
for C-R38<br>
or<br>
T stands for C-R35 and U stands for C-R36 and V stands for C-R37 and W<br>
stands for C-R38;<br><br>
R13 R16 R17 R22 R23 and R27 egch independ ently stand for a radical selected<br>
from the group consisting of methyl, -CF3, -CHF2, -CH2F, ethyl, -CF2-<br>
CH3, -CH2-CF3, -C2F5, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, n-pentyl, 3-pentyl, n-heptyl, 4-heptyl, n-octyl, n-nonyl, 5-nonyl,<br>
(2,6)-dimethyl-hept-4-yl, 3-methyl-butyl, n-hexyl, (3,3)-dimethylbutyl and<br>
ethenyl;<br>
R35, R36, and R37 each independently stand for H; F; CI; Br; I; -SF5; -NO2; -CN;<br>
-NH2; -OH; -SH; -OR16; -SR17; or for a radical selected from the group<br>
consisting of-CH2-OH, methyl, -CF3, -CHF2, -CH2F, ethyl, n-propyl,<br>
isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl;<br>
R38 stands for -SF5; -NO2; -CN; -NH2; -OH; -SH; -NHR39; -NR40R41; -OR42; -<br>
SR43;<br>
for a radical selected from the group consisting of cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, imidazolidinyl,<br>
tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl,<br>
morpholinyl, piperazinyl, azepanyl, diazepanyl, azocanyl, and<br>
thiomorpholinyl, each of which is bonded to the parent structure via a<br>
carbon atom of the rings of the aforementioned residues and are<br>
unsubstituted or can optionally be substituted by 1, 2, 3, 4, or 5<br>
substituents independently selected from the group consisting of -CH2-<br>
N(CH3)2, -CH2-N(C2H5)2, -CH2-NH-CH3, -CH2-NH-C2H5, -N-[C(=O)-<br>
C2H5]phenyl, -N-[C(=0)-CH3]-phenyl, methyl, ethyl, n-propyl, isopropyl,<br>
n-butyl, sec-butyl, isobutyl, and tert-butyl;<br><br>
or for a radical selected from the group consisting of phenyl, thiophenyl,<br>
furanyl, pyrrolyl, pyrazolyl, pyrazinyl, pyranyl, triazolyl, pyridinyl,<br>
imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridazinyl, pyrazinyl, and<br>
pyrimidinyl, each of which can be optionally substituted by 1, 2, 3, 4, or<br>
5 substituents independently selected from the group consisting of F,<br>
CI, Br, I, -CN, -CF3, -SF5, -OH, -O-CH3, -O-C2H5, -O-CH(CH3)2, -O-<br>
C(CH3)3, -O-CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,<br>
isobutyl, tert-butyl, and n-pentyl;<br>
R41, R42, R43, R42, and R43, each independently<br>
stand for a radical selected from the group consisting of methyl, -CH2-<br>
O-CH3, ethyl, n-propyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-<br>
pentyl, n-hexyl, (3,3)-dimethylbutyl, -CH2-CH2-O-CH3, -CH2-CH2-O-<br>
C2H5, and -CH2-CH2-CH2-O-CH3;<br>
for a radical selected from the group consisting of 2,3-dihydro-1 H-<br>
indenyl, cyclopropyl, oxetanyl, cyclobutyl, cyclopentyl, cyclohexyl,<br>
imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl,<br>
piperidinyl, morpholinyl, piperazinyl, azepanyl, diazepanyl, azocanyl,<br>
and thiomorpholinyl, each of which can be optionally substituted by 1, 2,<br>
3, 4, or 5 substituents independently selected from the group consisting<br>
of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-<br>
butyl, and n-pentyl;<br><br>
or<br>
R40 and R41 form, together with the interconnecting nitrogen atom as ring<br>
member, a radical selected from the group consisting of 3-aza-<br>
bicyclo[3.1.1]heptyl, 6-aza-spiro[2.5]octyl, 3-aza-bicyclo[3.2.1]octyl, 6-<br>
aza-bicyclo[3.3.1]heptyl, 8-aza-bicyclo[3.2.1]octyl, 1-oxa-2,8-<br>
diazaspiro[4.5]dec-2-enyl, azocanyl, isoindolyl, indolyl, (1,2,3,6)-<br>
tetrahydropyridinyl, (4,5,6,7)-tetrahydroisoxazolo[5.4-c]pyridinyl,<br>
pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl, diazepanyl,<br>
and thiomorpholinyl, of which the heterocycloaliphatic moiety can in<br>
each case be unsubstituted or substituted by 1, 2, 3, 4, or 5 radicals<br>
R57;<br>
R57 stands for -NHR58, -NR59R60, or for an alkyl radical selected from the<br>
group consisting of-CF3, -CH2-CF3, methyl, ethyl, n-propyl, isopropyl,<br>
tert-butyl, n-butyl, sec-butyl, and isobutyl;<br>
R58, R59, and R60 each independently stand for -C(=O)-R61; for an alkyl radical<br>
selected from the group consisting of -CF3, -CH2-CF3, methyl, ethyl, n-<br>
propyl, isopropyl, tert-butyl, n-butyl, sec-butyl, and isobutyl;<br>
or for a radical selected from the group consisting of phenyl and<br>
naphthyl, and the radical can each be bonded via a -(CH2)-, -(CH2)2- or<br>
-(CH2)3 group and/or can each be unsubstituted or optionally substituted<br>
by 1, 2, 3, 4, or 5 substituents independently selected from the group<br>
consisting of F, CI, Br, I, -CN, -CF3, -O-CH3, -O-C2H5, -O-CH(CH3)2, -O-<br><br>
C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,<br>
tert-butyl, and n-pentyl;<br>
and R61	stands for an alkyl radical selected from the group consisting of -<br>
CF3, -CH2-CF3, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, sec-<br>
butyl, and isobutyl;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br>
4. The compounds according to any one or more of claims 1 to 3, characterized<br>
in that<br>
n stands for 0, 1, or 2;<br>
R1 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(=O)-<br>
R13; -OR16; -SR17; -S(=O)2-NR22R23 or-S(=O)2-R27;<br>
R2 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(=O)-<br>
R13; -OR16; -SR17; -S(=O)2-NR22R23 or -S(=O)2-R27;<br>
R3 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(=O)-<br>
R13; -OR16; -SR17; -S(=O)2-NR22R23 or-S(=O)2-R27;<br><br>
R4 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(=O)-<br>
R13; -OR16; -SR17; -S(=O)2-NR22R23 or-S(=O)2-R27;<br>
R5 stands for H; F; CI; Br; I; methyl, ethyl, -NO2; -OH; -NH2; -NH-C(=O)-<br>
R13; -OR16; -SR17; -S(=O)2-NR22R23 or-S(=O)2-R27;<br>
R6 stands for hydrogen or for an alkyl radical selected from the group<br>
consisting of isopropyl, n-butyl, sec-butyl, isobutyl, methyl, ethyl, and n-<br>
propyl;<br>
R7 stands for hydrogen or -OH;<br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl; or -C(CH3)2(CH2OH);<br>
T stands for C-R35 and U stands for C-R36 and V stands for N and W stands<br>
for C-R38<br>
or<br>
T stands for C-R35 and U stands for C-R36 and V stands for C-R37 and W<br>
stands for C-R38<br>
R13, R16, R17, R22, R23 and R27 each independently stand for a radical selected<br>
from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl,<br>
sec-butyl, isobutyl, tert-butyl, n-pentyl, and ethenyl;<br>
R35, R36, and R37 each stand for H;<br><br>
R38 stands for -NHR39; -NR40R41; -OR42; -SR43;<br>
R39, R42, and R43 each independently<br>
stand for a radical selected from the group consisting of methyl, ethyl,<br>
n-propyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-<br>
hexyl, and (3,3)-dimethylbutyl;<br>
or for a radical selected from the group consisting of cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, each of which can<br>
be optionally substituted by 1, 2, 3, 4, or 5 substituents independently<br>
selected from the group consisting of methyl, ethyl, n-propyl, isopropyl,<br>
n-butyl, sec-butyl, isobutyl, tert-butyl, and n-pentyl;<br>
or<br>
R40 and R41 form, together with the interconnecting nitrogen atom as ring<br>
member, a radical selected from the group consisting of pyrrolidinyl,<br>
piperidinyl, piperazinyl, morpholinyl, and azepanyl, of which the<br>
heterocycloaliphatic moiety can in each case be unsubstituted or<br>
substituted by 1, 2, 3, 4, or 5 radicals R57;<br>
and R57	stands for an alkyl radical selected from the group consisting of<br>
methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, sec-butyl, and<br>
isobutyl;<br><br>
each optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers thereof, the racemates thereof or<br>
in the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or each in the form of<br>
corresponding salts, or each in the form of corresponding solvates.<br>
5. The compounds according to any one or more of claims 1 to 4, characterized<br>
in that<br>
n stands for 1;<br>
R1 stands for H; F; CI; Br; or I;<br>
R2 stands for H; F; CI; Br; I; -OH; -NH2 or -OR16;<br>
R3 stands for H; F; CI; Br; I; -NO2; -OH; -NH2; -NH-C(=O)-R13; -OR16; -<br>
SR17; -S(=O)-NR22R23 or -S(=O)2-R27;<br>
R4 stands for H; F; CI; Br; I; methyl, -OH; -NH2 or -OR16;<br>
R5 stands for H; F; CI; Br or I;<br>
R6 stands for hydrogen or for an alkyl radical selected from the group<br>
consisting of isopropyl, n-butyl, sec-butyl, isobutyl, methyl, ethyl, and n-<br>
PropyI;<br><br>
R7 stands for hydrogen or -OH;<br>
R8 stands for -SF5; -O-CF3; -CF3; tert-butyl or -C(CH3)2(CH2OH);<br>
T stands for C-R35 and U stands for C-R36 and V stands for N and W stands<br>
for C-R38<br>
or<br>
T stands for C-R35 and U stands for C-R36 and V stands for C-R37 and W<br>
stands for C-R38;<br>
R13 Rie R17 R22 R23 and R27 each independently stand for a radical selected<br>
from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl,<br>
sec-butyl, isobutyl, tert-butyl, n-pentyl, and ethenyl;<br>
R35, R36, and R37 each stand for H;<br>
R38 stands for -NHR39; -NR40R41; -OR42; -SR43;<br>
R39, R42, and R43 each independently<br>
stand for a radical selected from the group consisting of methyl, ethyl,<br>
n-propyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 3-pentyl, n-<br>
hexyl, and (3,3)-dimethylbutyl;<br><br>
or for a radical selected from the group consisting of cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, each of which can<br>
be optionally substituted by 1, 2, 3, 4, or 5 substituents independently<br>
selected from the group consisting of methyl, ethyl, n-propyl, isopropyl,<br>
n-butyl, sec-butyl, isobutyl, tert-butyl, and n-pentyl;<br>
or<br>
R40 and R41 form, together with the interconnecting nitrogen atom as ring<br>
member, a radical selected from the group comprising the group<br>
consisting pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and<br>
azepanyl, the heterocycloaliphatic moiety of which can each be<br>
unsubstituted or substituted by 1, 2, 3, 4, or 5 radicals R57;<br>
and R57	stands for an alkyl radical selected from the group consisting of<br>
methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, sec-butyl, and<br>
isobutyl;<br>
each optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers thereof, the racemates thereof or<br>
in the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or each in the form of<br>
corresponding salts, or each in the form of corresponding solvates.<br>
6. The compounds of the general formula la according to any one or more of<br>
claims 1 to 3,<br><br><br>
in which<br>
D stands for N or CH;<br>
and<br>
R1, R2, R3, R4, R5, R8, and R42 have the meanings stated in claim 3;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br>
7. The compounds of the general formula la according to any one or more of<br>
claims 1 to 6,<br><br><br>
la,<br>
in which<br>
D stands for N or CH;<br>
and<br>
R1, R2, R3, R4, R5, R8, and R42 have the meanings stated in claim 4;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br>
8. The compounds of the general formula la according to any one or more of<br>
claims 1 to 7,<br><br>
in which<br>
D stands for N or CH;<br><br>
and<br>
R1, R2, R3, R4, R5, R8, and R42 have the meanings stated in claim 5;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br>
9. The compounds of the general formula lb according to any one or more of<br>
claims 1 to 3,<br><br>
in which<br>
D stands for N or CH;<br>
and<br>
R1, R2, R3, R4, R5, R8, and R42 have the meanings stated in claim 3;<br><br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br>
10. The compounds of the general formula lb according to any one or more of<br>
claims 1 to 9,<br><br>
in which<br>
D stands for N or CH;<br>
and<br>
R1, R2, R3, R4, R5, R8, and R42 have the meanings stated in claim 4;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br><br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br>
11. The compounds of the general formula lb according to any one or more of<br>
claims 1 to 10,<br><br>
in which<br>
D stands for N or CH;<br>
and<br>
R1, R2, R3, R4, R5, R8, and R42 have the meanings stated in claim 5;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br><br>
12.	The compounds of the general formula Ic according to any one or more of<br>
claims 1 to 3,<br><br>
in which<br>
D stands for N or CH;<br>
and<br>
R1, R2, R3, R4, R5, R8, and R42 have the meanings stated in claim 3;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br>
13.	The compounds of the general formula Ic according to any one or more of<br>
claims 1 to 12,<br><br><br>
in which<br>
D stands for N or CH;<br>
and<br>
R1, R2, R3, R4, R5, R8, and R42 have the meanings stated in claim 4;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br>
14. The compounds of the general formula Ic according to any one or more of<br>
claims 1 to 13,<br><br><br>
Ic,<br>
in which<br>
D stands for N or CH;<br>
and<br>
R1, R2, R3, R4, R5, R8, and R42 have the meanings stated in claim 5;<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br>
15. The compounds according to any one or more of claims 1 to 14, selected from<br>
the group consisting of<br>
[1 ] 2-(4-Amino-3-fluorophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[2] 2-(3,5-Dibromophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide,<br>
[3] 2-(4-Amino-3-bromo-5-methoxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide,<br>
[4] 2-(3-Fluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide,<br><br>
[5] 2-(2,4-Difluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide,<br>
[6] 2-(2,6-Difluorophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide,<br>
[7] 2-(2,5-Difluorophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide,<br>
[8] 2-(4-Fluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide,<br>
[9] 2-(4-Hydroxy-3-methoxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[10] 2-(3,5-Difluorophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[11] 2-(3,4-Difluorophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[12] 2-(4-Fluorophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[13] 2-(3-Fluorophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[14] 2-(3,4-Diaminophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[15] N-(2-Butoxy-6-tert-butylpyridin-3-ylmethyl)-2-(3,4-diamino-phenyl)-<br>
propionamide,<br>
[16] N-((6-tert-Butyl-2-(4-methylpiperidin-1-yl)pyridin-3-yl)methyl)-2-(3,4-<br>
diaminophenyl)propanamide,<br>
[17] N-((6-tert-Butyl-2-(cyclohexylthio)pyridin-3-yl)methyl)-2-(3,4-<br>
diaminophenyl)propanamide,<br><br>
[18] 2-(4-Acetamido-3-fluorophenyl)-N-((2-(4-methylpiperidin-1 -yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[19] 2-(3,5-Dibromo-4-hydroxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[20] 2-(4-Amino-3,5-dibromophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[21] 2-(3-Bromo-4-hydroxy-5-methoxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-<br>
6-(trifluoromethyl)pyridin-3-yl)methyl)acetamide,<br>
[22] 2-(4-Amino-3,5-dibromophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide,<br>
[23] 2-(3,5-Dibromo-4-hydroxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)acetamide,<br>
[24] 2-(3-Amino-4-hydroxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[25] 2-(3,5-Dibromo-phenyl)-N-(4-methyl-6'-trifluoromethyl-3,4,5,6-<br>
tetrahydro-2H-[1,2']bipyridinyl-3'-ylmethyl)-acetamide.<br>
[26] 2-(4-Amino-3,5-difluorophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[27] 2-(3-Fluoro-5-hydroxy-4-nitrophenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[28] 2-(3-Chloro-4-(methylthio)phenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[29] 2-(3-Chloro-4-(methylsulfonyl)phenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[30] 2-(3-Fluoro-4-(methylthio)phenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br><br>
[31] 2-(3-Fluoro-4-(methylsulfonyl)phenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[32] 2-(4-(N,N-Dimethylsulfamoyl)-3-fluorophenyl)-N-((2-(4-methylpiperidin-<br>
1-yl)-6-(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[33] N-(2-Fluoro-4-(1 -((2-(4-methylpiperidin-1 -yl)-6-(trifluoromethyl)pyridin-3-<br>
yl)methylamino)-1-oxopropane-2-yl)phenyl)acrylamide,<br>
[34] N-(2-Fluoro-6-iodo-4-(1-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methylamino)-1-oxopropane-2-<br>
yl)phenyl)acrylamide,<br>
[35] 2-(4-Methoxy-3,5-dimethylphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[36] 2-(3,5-Difluoro-4-methoxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[37] 2-(4-Hydroxy-3,5-dimethylphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
[38] 2-(3,5-Difluoro-4-hydroxyphenyl)-N-((2-(4-methylpiperidin-1-yl)-6-<br>
(trifluoromethyl)pyridin-3-yl)methyl)propanamide,<br>
in each case optionally in the form of one of the pure stereoisomers thereof,<br>
particularly enantiomers or diastereoisomers, or the racemates thereof or in<br>
the form of a mixture of stereoisomers, particularly the enantiomers and/or<br>
diastereoisomers, in an arbitrary mixing ratio, or in each case in the form of<br>
corresponding salts, or in each case in the form of corresponding solvates.<br>
16. The compounds according to any one or more of claims 1 to 15, characterized<br>
in that, in the FLIPR assay using CHO-K1 cells, which have been transfected<br><br>
with the human VR1 gene in a concentration below 2000 nM, preferably below<br>
1000 nM, more preferably below 300 nM, even more preferably below 100 nM,<br>
still more preferably below 75 nM, very preferably below 50 nM and most<br>
preferably below 10 nM, they cause a 50 percent displacement of capsaicin<br>
present in a concentration of 100 nM.<br>
17. A process for the production of a compound according to any one or more of<br>
claims 1 to 16, characterized in that at least one compound of the general<br>
formula II,<br><br>
in which R8, U, T, V, and W have the meanings stated in any one or more of<br>
claims 1 to 16, m stands for 0, 1, 2, or 3, and R stands for hydrogen or for a<br>
linear or branched C1-6 alkyl radical, in a reaction medium, in the presence of<br>
at least one reducing agent, preferably in the presence of at least one<br>
reducing agent selected from the group consisting of sodium hydride, sodium,<br>
potassium hydride, lithium aluminum hydride, sodium tetrahydridoborate, and<br>
di(isobutyl)aluminum hydride<br>
is converted to at least one compound of the general formula III,<br><br><br>
in which R8, U, T, V, and W have the meanings stated in any one or more of<br>
claims 1 to 16 and m stands for 0, 1, 2, or 3, and this is optionally purified<br>
and/or isolated,<br>
and at least one compound of the general formula III is converted, in a<br>
reaction medium in the presence of diphenylphosphorylazide or in the<br>
presence of HN3, to at least one compound of the general formula IV,<br><br>
in which R8, U, T, V, and W have the meanings stated in any one or more of<br>
claims 1 to 16 and m stands for 0, 1, 2, or 3, and this is optionally purified<br>
and/or isolated,<br>
and at least one compound of the general formula IV is converted, in a<br>
reaction medium in the presence of at least one reducing agent, preferably in<br>
the presence of at least one reducing agent selected from the group consisting<br><br>
of sodium hydride, potassium hydride, lithium aluminum hydride, sodium<br>
tetrahydridoborate, and di(isobutyl)aluminum hydride,<br>
or in a reaction medium in the presence of a catalyst, preferably in the<br>
presence of a catalyst based on platinum or palladium, more preferably in the<br>
presence of palladium-on-charcoal, and in the presence of hydrogen or in the<br>
presence of hydrazine,<br>
or in a reaction medium in the presence of triphenylphosphine<br>
to at least one compound of the general formula V,<br><br>
in which R8, U, T, V, and W have the meanings stated in any one or more of<br>
claims 1 to 16 and m stands for 0, 1, 2, or 3, and this is optionally purified<br>
and/or isolated,<br>
or at least one compound of the general formula VI<br><br><br>
VI,<br>
in which R8, U, T, V, and W have the meanings stated in any one or more of<br>
claims 1 to 16 and m stands for 0, 1,2, or 3, in a reaction medium is<br>
converted,<br>
in the presence of at least one catalyst, preferably in the presence of at least<br>
one catalyst based on palladium or platinum, more preferably in the presence<br>
of palladium-on-charcoal, under a blanket of hydrogen, optionally in the<br>
presence of at least one acid, preferably in the presence of hydrochloric acid,<br>
or in the presence of at least one reducing agent selected from the group<br>
consisting of BH3.S(CH3)2, lithium aluminum hydride, and sodium<br>
tetrahydridoborate, optionally in the presence of NiCI2,<br>
to form at least one compound of the general formula V, optionally in the form<br>
of a corresponding salt, preferably in the form of a corresponding<br>
hydrochloride, and this is optionally purified and/or isolated,<br>
and at least one compound of the general formula V is caused to react with at<br>
least one compound of the general formula VII,<br><br><br>
VII,<br>
in which R1, R2, R3, R4, R5, R6, and R7 have the meanings stated in any one or<br>
more of claims 1 to 16, in a reaction medium, optionally in the presence of at<br>
least one suitable coupling agent, optionally in the presence of at least one<br>
base,<br>
or with at least one compound of the general formula VIII,<br><br>
in which R1, R2, R3, R4, R5, R6, and R7 have the meanings stated in any one or<br>
more of claims 1 to 16 and LG stands for a leaving group, preferably for a<br>
chlorine or bromine atom, in a reaction medium, optionally in the presence of<br>
at least one base, to form at least one compound of the general formula I,<br><br><br>
in which T, U, V, W, R1, R2, R3, R4, R5, R6, R7, and R8, have the meanings<br>
stated in any one or more of claims 1 to 16 and n stands for 1, 2, 3, or 4, and<br>
this is optionally purified and/or isolated.<br>
18. A process for the production of at least one compound according to any one or<br>
more of claims 1 to 16, characterized in that at least one compound of the<br>
general formula X,<br><br>
in which R8, U, T, V, and W have the meanings stated in any one or more of<br>
claims 1 to 16, is caused to react with at least one compound of the general<br>
formula VII,<br><br>
in which R1, R2, R3, R4, R5, R6, and R7, have the meanings stated in any one<br>
or more of claims 1 to 16, in a reaction medium, optionally in the presence of<br>
at least one suitable coupling agent, optionally in the presence of at least one<br>
base,<br><br>
or with at least one compound of the general formula VIII,<br><br>
in which R1, R2, R3, R4, R5, R6, and R7 have the meanings stated in any one or<br>
more of claims 1 to 16 and LG stands for a leaving group, preferably for a<br>
chlorine or bromine atom, in a reaction medium, optionally in the presence of<br>
at least one base, to form at least one compound of the general formula Im,<br><br>
in which T, U, V, W, R1, R2, R3, R4, R5, R6, R7, and R8 have the meanings<br>
stated in any one or more of claims 1 to 16, and this is optionally purified<br>
and/or isolated.<br>
19. A pharmaceutical comprising at least one compound according to any one or<br>
more of claims 1 to 16 and optionally one or more physiologically compatible<br>
adjuvants.<br><br>
20.	The pharmaceutical according to claim 19 for the treatment and/or prophylaxis<br>
of any one or more of the disorders selected from the group consisting of pain,<br>
preferably pain selected from the group consisting of acute pain, chronic pain,<br>
neuropathic pain and visceral pain; arthralgia; hyperalgesia; allodynia;<br>
causalgia; and migraine.<br>
21.	The pharmaceutical according to claim 19 for the treatment and/or prophylaxis<br>
of any one or more of the disorders selected from the group consisting of<br>
states of depression; nervous disorders; neurotraumas; neurodegenerative<br>
disorders, preferably selected from the group consisting of multiple sclerosis,<br>
Morbus Alzheimer, Morbus Parkinson, and Morbus Huntington; cognitive<br>
dysfunctions, preferably cognitive deficiency states, more preferably memory<br>
defects; and epilepsy.<br>
22.	The pharmaceutical according to claim 19 for the treatment and/or prophylaxis<br>
of any one or more of the disorders selected from the group consisting of<br>
respiratory tract diseases, preferably selected from the group consisting of<br>
asthma, bronchitis and pneumonia; coughing; urinary incontinence; an<br>
overactive bladder (OAB); disorders and/or injuries of the gastrointestinal tract;<br>
duodenal ulcers; gastric ulcers; colitis syndrome; apoplectic strokes; eye<br>
irritations; cutaneous irritations; neurotic skin conditions; allergic skin diseases;<br>
psoriasis; vitiligo; Herpes simplex; inflammations, preferably inflammation of<br>
the intestine, the eyes, the bladder, the skin, or the nasal mucosa; diarrhea;<br>
pruritus; osteoporosis; arthritis; osteoarthritis; rheumatic disorders; food intake<br><br>
disorders, preferably selected from the group consisting of bulimia, cachexia,<br>
anorexia, and obesity; medicine addiction; medicine abuse; withdrawal<br>
phenomena following medicine addiction; tolerance development to<br>
medicines, particularly to natural or synthetic opioids; drug addiction; drug<br>
abuse; withdrawal phenomena following drug addiction; alcohol addiction;<br>
alcohol abuse and withdrawal phenomena following alcohol addiction; for<br>
diuresis; for antinatriuresis; for affection of the cardiovascular system; for<br>
vigilance enhancement; for treatment of wounds and/or burning; for treatment<br>
of severed nerves; for libido enhancement; for modulation of movement<br>
activity; for anxiolysis; for local anesthesia and/or for inhibition of undesirable<br>
side effects, preferably selected from the group consisting of hyperthermia,<br>
hypertension, and bronchial constriction, as caused by administration of<br>
vanilloid receptor 1 (VR1/TRPV1 receptor) agonists, preferably selected from<br>
the group consisting of capsaicin, resiniferatoxin, olvanil, arvanil, SDZ-249665,<br>
SDZ-249482, nuvanil, and capsavanil.<br>
23.	The use of at least one compound according to any one or more of claims 1 to<br>
16 for the production of a pharmaceutical for the treatment and/or prophylaxis<br>
of any one or more of the disorders selected from the group consisting of pain,<br>
preferably pain selected from the group consisting of acute pain, chronic pain,<br>
neuropathic pain, and visceral pain; arthralgia; hyperalgesia; allodynia;<br>
causalgia and migraine.<br>
24.	The use of at least one compound according to any one or more of claims 1 to<br>
16 for the production of a pharmaceutical for the treatment and/or prophylaxis<br><br>
of any one or more of the disorders selected from the group consisting of<br>
states of depression; nervous disorders; neurotraumas; neurodegenerative<br>
disorders, preferably selected from the group consisting of multiple sclerosis,<br>
Morbus Alzheimer, Morbus Parkinson, and Morbus Huntington; cognitive<br>
dysfunctions, preferably cognitive deficiency states, more preferably memory<br>
defects; and epilepsy.<br>
25. The use of at least one compound according to any one or more of claims 1 to<br>
10 for the production of a pharmaceutical for the treatment and/or prophylaxis<br>
of any one or more of the disorders selected from the group consisting of.<br>
respiratory tract diseases, preferably selected from the group consisting of<br>
asthma, bronchitis and pneumonia; coughing; urinary incontinence; an<br>
overactive bladder (OAB); disorders and/or injuries of the gastrointestinal tract;<br>
duodenal ulcers; gastric ulcers; colitis syndrome; apoplectic strokes; eye<br>
irritations; cutaneous irritations; neurotic skin conditions; allergic skin diseases;<br>
psoriasis; vitiligo; Herpes simplex; inflammation, preferably inflammation of the<br>
intestine, the eyes, the bladder, the skin, or the nasal mucosa; diarrhea;<br>
pruritus; osteoporosis; arthritis; osteoarthritis; rheumatic disorders; food intake<br>
disorders, preferably selected from the group consisting of bulimia, cachexia,<br>
anorexia, and obesity; medicine addiction; medicine abuse; withdrawal<br>
phenomena following medicine addiction; tolerance development to<br>
pharmaceuticals, particularly to natural or synthetic opioids; drug addiction;<br>
drug abuse; withdrawal phenomena following drug addiction; alcohol<br>
addiction; alcohol abuse and withdrawal phenomena following alcohol<br>
addiction; for diuresis; for antinatriuresis; for affection of the cardiovascular<br>
system; for vigilance enhancement; for treatment of wounds and/or burning;<br><br>
for treatment of severed nerves; for libido enhancement; for modulation of<br>
movement activity; for anxiolysis; for local anesthesia and/or for inhibition of<br>
undesirable side effects, preferably selected from the group consisting of<br>
hyperthermia, hypertension, and bronchial constriction, as caused by<br>
administration of vanilloid receptor 1 (VR1/TRPV1 receptor) agonists,<br>
preferably selected from the group consisting of capsaicin, resiniferatoxin,<br>
olvanil, arvanil, SDZ-249665, SDZ-249482, nuvanil, and capsavanil.<br><br><br>
The present invention relates to novel vanilloid receptor ligands, to processes for the<br>
production thereof, to pharmaceuticals containing said compounds and to the use of<br>
said compounds for the production of pharmaceuticals.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LSgwNS0wMi0yMDE0KS1BTk5FWFVSRSBUTyBGT1JNIDMucGRm" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-(05-02-2014)-ANNEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LSgwNS0wMi0yMDE0KS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-(05-02-2014)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LSgxMy0wOC0yMDE0KUFCU1RSQUNULnBkZg==" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-(13-08-2014)ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LSgxMy0wOC0yMDE0KUFOTkVYVVJFIFRPIEZPUk0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-(13-08-2014)ANNEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LSgxMy0wOC0yMDE0KUNMQUlNUy5wZGY=" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-(13-08-2014)CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LSgxMy0wOC0yMDE0KUNPUlJFU1BPTkRFTkNFLi5wZGY=" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-(13-08-2014)CORRESPONDENCE..pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LSgxMy0wOC0yMDE0KUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-(13-08-2014)CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LSgxMy0wOC0yMDE0KU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-(13-08-2014)OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LSgxMy0wOC0yMDE0KVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnBkZg==" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-(13-08-2014)PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LUNPUlJFU1BPTkRFTkNFIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-CORRESPONDENCE 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LUNPUlJFU1BPTkRFTkNFIDEuMi5wZGY=" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-CORRESPONDENCE 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LWNvcnJlc3BvbmRlbmNlLnBkZg==" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LWZvcm0gMS5wZGY=" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LUZPUk0gMTgucGRm" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-FORM 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LWZvcm0gMi5wZGY=" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LUZPUk0gMy4xLjEucGRm" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-FORM 3.1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LWZvcm0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LWZvcm0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LWludGVybmF0aW9uYWwgcHJlbGltaW5hcnkgZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-international preliminary examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LWludGVybmF0aW9uYWwgcHVibGljYXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LWludGVybmF0aW9uYWwgc2VhcmNoIHJlcG9ydC5wZGY=" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1LT0xOUC0yMDA5LVBBLnBkZg==" target="_blank" style="word-wrap:break-word;">3972-KOLNP-2009-PA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LXBjdCBwcmlvcml0eSBkb2N1bWVudCBub3RpZmljYXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-pct priority document notification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LXBjdCByZXF1ZXN0IGZvcm0ucGRm" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-pct request form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LXNwZWNpZmljYXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-specification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzk3Mi1rb2xucC0yMDA5LXRyYW5zbGF0ZWQgY29weSBvZiBwcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">3972-kolnp-2009-translated copy of priority document.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="263973-method-and-apparatus-for-reporting-reception-ratio-of-streaming-service-by-terminal-in-a-mobile-broadcasting-system-and-system-thereof.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="263975-method-and-ringback-tone-generator-system-for-providing-customized-ring-back-tone.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>263974</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>3972/KOLNP/2009</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>49/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>05-Dec-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>28-Nov-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>16-Nov-2009</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>GRNENTHAL GMBH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>ZIEGLERSTRASSE 6, 52078 AACHEN, GERMANY</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>BAHRENBERG, GREGOR</td>
											<td>KLEINBAHNSTR. 7A, D-52078 AACHEN, GERMANY</td>
										</tr>
										<tr>
											<td>2</td>
											<td>SUNDERMANN, BERND</td>
											<td>TANNENMHLENWEG 8, D-61381 FRIEDRICHSDORF, GERMANY</td>
										</tr>
										<tr>
											<td>3</td>
											<td>DE VRY, JEAN</td>
											<td>MHLENROTSCHEN 40, D-52223 STOLBERG, GERMANY</td>
										</tr>
										<tr>
											<td>4</td>
											<td>SAUNDERS, DEREK</td>
											<td>FRSTERSTRASSE 19, D-52072 AACHEN, GERMANY</td>
										</tr>
										<tr>
											<td>5</td>
											<td>PRZEWOSNY, MICHAEL</td>
											<td>BORNGASSE 43, D-52062 AACHEN, GERMANY</td>
										</tr>
										<tr>
											<td>6</td>
											<td>FRANK, ROBERT</td>
											<td>LUISENSTRASSE 28, D-52070 AACHEN, GERMANY</td>
										</tr>
										<tr>
											<td>7</td>
											<td>CHRISTOPH, THOMAS</td>
											<td>SCHILDERSTRASSE 42, D-52080 AACHEN, GERMANY</td>
										</tr>
										<tr>
											<td>8</td>
											<td>SCHIENE, KLAUS</td>
											<td>SCHAAN 51, D-41363 JCHEN, GERMANY</td>
										</tr>
										<tr>
											<td>9</td>
											<td>LEE, JEEWOO</td>
											<td>DIGITALBIOTECH CO., LTD. 1227 SHINGIL-DONG, ANSAN-SI, GYENGGI-DO 425-838, KOREA</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D213/64; A61K31/44; A61K31/4545</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2008/002994</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2008-04-15</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>10 2007 018 151.7</td>
									<td>2007-04-16</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/263974-novel-vanilloid-receptor-ligands-and-the-use-thereof-for-the-production-of-pharmaceuticals by HTTrack Website Copier/3.x [XR&CO'2014], Thu, 04 Apr 2024 23:02:14 GMT -->
</html>
